Cardiac Anaesthesia Podcast

Reference library

Review in progress.

HOLD: independent review is not a full clinical sign-off. Fully verified posts: 0. Fully verified posts: 0. Partial: 45. Correction needed: 30. Proposals: 16 confirmed errors, 20 missing qualifiers, 4 version differences, 8 rejected proposals, 3 awaiting validation.

Newest recorded publish time first. No tied timestamps. Recorded Postiz publishDate (scheduled publishing time), newest first. Not a verified native Instagram feed order. 25 October 2026, 20:17 IST through 8 November 2026, 00:32 IST.

For clinician education and exam study. Not patient-specific advice.

Posts

Tricyclic Overdose: ECG Signs and Sodium Bicarbonate Partial Sgarbossa Criteria: MI in LBBB or Paced Rhythm Partial Anaphylaxis: Adrenaline Doses That Matter Correction needed ARDS: Berlin Definition and Lung-Protective Ventilation Partial Vasopressors and Inotropes at a Glance (infographic) Correction needed CVP Waveforms at a Glance (infographic) Partial Etomidate for Induction in Cardiac Patients Partial Digoxin Toxicity: ECG Clues and Treatment Correction needed Pulsus Paradoxus: Mechanism and Causes Correction needed CABG Conduits: LIMA, Radial and Vein Partial Electrolytes on the ECG (infographic) Partial The LV Pressure–Volume Loop (infographic) Partial Pre-op Anaemia Before Cardiac Surgery Correction needed Heart Murmurs and Bedside Manoeuvres Partial Jones Criteria for Acute Rheumatic Fever (AHA 2015) Partial Cell Salvage in Cardiac Surgery Partial AV Block: Every Degree (infographic) Correction needed Echo Probability of Pulmonary Hypertension (infographic) Partial Mitral Stenosis 5/5: Intra-op TEE and Bypass Pearls Correction needed Mitral Stenosis 4/5: Anaesthetic Goals and Haemodynamics Partial Mitral Stenosis 3/5: Intervention Criteria (ESC 2021 + ACC/AHA 2020) Partial Mitral Stenosis 2/5: Grading Severity on Echo Correction needed Mitral Stenosis 1/5: Aetiology and Pathophysiology Partial Perioperative Beta-Blockers: Continue, Don’t Start Partial Endocarditis Prophylaxis: Who Needs It? Correction needed Prostaglandin E1 for Duct-Dependent Lesions Partial CHA2DS2-VASc and HAS-BLED Scores Partial The Bypass Circuit: Every Component (infographic) Correction needed Cardiac Action Potential: Every Phase (infographic) Partial Reversing Anticoagulants Before Urgent Surgery Correction needed NYHA Class vs ACC/AHA Heart Failure Stage Correction needed Humour: Muscle relaxants ranked by how long they stay at the party Correction needed Shock Types: Haemodynamic Profiles Partial PA Catheter Normal Values Partial RV Systolic Function on Echo: Every Method (infographic) Partial LV Normals: Men vs Women (infographic) Partial Aortic Regurgitation 5/5: Intra-op TEE and Bypass Pearls Partial Aortic Regurgitation 4/5: Anaesthetic Goals and Haemodynamics Partial Aortic Regurgitation 3/5: Intervention Criteria (ESC 2021 + ACC/AHA 2020) Correction needed Aortic Regurgitation 2/5: Grading Severity on Echo Correction needed Aortic Regurgitation 1/5: Aetiology and Pathophysiology Partial Coronary Anatomy: Dominance and Territories Partial LAST After Chest Wall Blocks Partial Oxyhaemoglobin Dissociation Curve Shifts Partial Wiggers Diagram: Key Cardiac Cycle Events Partial Stopping DOACs Before Cardiac Surgery Partial Oxygen content and delivery on one page Correction needed 9 arterial line waveforms to read at a glance Partial Aortic Dissection: Stanford vs DeBakey Correction needed Modified Duke Criteria for Endocarditis Correction needed Type 5 MI After CABG: Fourth Universal Definition Correction needed Heart Failure by Ejection Fraction Correction needed Which ECG leads should be on your screen? Partial A1 to P3 on one page Partial Magnesium in Cardiac Surgery Correction needed Adenosine: Doses and Cautions Correction needed Amiodarone in Cardiac Surgery Partial Vasoactive Drugs: Receptor Table Partial Why inhaled NO drops PVR without dropping SVR Correction needed Four CCS classes, exact wording — the pre-op and viva staple Correction needed Aortic Stenosis 5/5: Intra-op TEE and Post-bypass Pearls Partial Aortic Stenosis 4/5: Anaesthetic Goals and Haemodynamics Correction needed Aortic Stenosis 3/5: Intervention Criteria (ESC 2021 + ACC/AHA 2020) Correction needed Aortic Stenosis 2/5: Grading Severity on Echo Partial Aortic Stenosis 1/5: Aetiology and Pathophysiology Partial SVR and PVR: Formulas and Normal Values Correction needed Ventricular Interdependence Partial Fluid Responsiveness: PPV and SVV Cut-offs Partial Myocardial O2 Supply vs Demand Partial Coronary Blood Flow: LV vs RV Timing Partial The β-blocker that wears off in minutes. Here's all of it on one page: mechanism, RBC esterase metabolism, kinetics, lab Correction needed Aortic Root Anatomy Partial Pulmonary Hypertension: Definition, WHO Groups and Haemodynamic Cut-offs Partial Fick Principle: Calculating Cardiac Output Correction needed Severe Chronic AR: Anaesthetic Goals and Bypass Pitfalls Correction needed

No release in this tracked set is fully verified.

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Tricyclic Overdose: ECG Signs and Sodium Bicarbonate

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

ECG markers of risk in tricyclic antidepressant toxicity. Two recorded study references checked; treatment recommendations remain under review.

Review scope

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Original TOXBASE dose/ventilation/drug-exclusion protocol and full original ECG-risk study texts.

Still unreviewed

  • Obtain the actual recorded TOXBASE/UK protocol and verify bicarbonate dose/bolus cap, ventilation, sodium/pH limits and all drug exclusions.
  • Read both original study full texts for boundary definitions, ECG technique and cohort applicability; current source records rely on indexed publisher material.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — Bicarbonate target and major toxicity mechanisms

Actual CHOP specialist sheet supports pH 7.45–7.55 and QRS/electrolyte monitoring. It gives 1 mEq/kg boluses (max 50 mEq), not the entire recorded 1–2 mmol/kg regimen; protocols differ. TOXBASE itself remains inaccessible/unreviewed.

Qualifications on the reviewed points

  • ECG thresholds indicate risk, not guaranteed seizures or arrhythmias.
  • Published study boundaries include 100 ms, 160 ms and 3 mm (≥), not strictly greater than.
  • pH 7.45–7.55 and response/electrolyte monitoring are supported by the additional CHOP sheet; exact recorded TOXBASE regimen, ventilation instruction and all drug exclusions remain unresolved. Do not combine protocols silently.

References recorded with the episode

Recorded with the episode

Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants

Boehnert MT, Lovejoy FH Jr

1985

DOI 10.1056/NEJM198508223130804

Open source at doi.org

Link check recorded

Recorded as supporting
  • In the 49-patient cohort, seizures occurred with QRS ≥100 ms; ventricular arrhythmias were observed only with QRS ≥160 ms.
Limits and what this source leaves unreviewed
  • Observational cohort, not deterministic thresholds. Does not itself validate bicarbonate dosing or all drug-avoidance advice.

Recorded with the episode

ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity

Liebelt EL, Francis PD, Woolf AD

1995

DOI 10.1016/S0196-0644(95)70151-6

Open source at annemergmed.com

Link check recorded

Recorded as supporting
  • Terminal R in aVR ≥3 mm was associated with seizures/arrhythmias in a 79-patient cohort.
Limits and what this source leaves unreviewed
  • Risk marker, not certainty; published threshold is ≥3 mm, whereas caption says over 3 mm. TOXBASE recommendations not accessed.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Cyclic Antidepressant (TCA) Poisoning — Quick Tox Treatment Tips QT3, updated 16 June 2025

The Poison Control Center at Children's Hospital of Philadelphia

2025

DOI not recorded

Open source at chop.edu

Link check recorded

Recorded as supporting
  • Fast sodium-channel blockade, GABA-A antagonism and alpha-1 blockade are described.
  • Sodium bicarbonate with QRS and blood-pH response monitoring; target pH 7.45–7.55; monitor Ca, K and Mg.
  • Institutional sheet gives 1 mEq/kg boluses, maximum 50 mEq per bolus; norepinephrine, refractory rescue and individualized toxicology advice are discussed.
Limits and what this source leaves unreviewed
  • Institutional expert tip sheet explicitly does not establish a standard of care; not the recorded TOXBASE source.
  • Its 1 mEq/kg, maximum-50-mEq bolus does not independently validate the entire recorded 1–2 mmol/kg regimen or all drug exclusions.
  • Website file path contains 2026, but the document itself states last updated 16 June 2025.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Boehnert and Lovejoy, NEJM 1985; Liebelt, Ann Emerg Med 1995; TOXBASE/UK poisons guidance.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Tricyclic Overdose: ECG Signs and Sodium Bicarbonate

Tricyclic overdose kills through sodium channel blockade. A QRS over 100 ms predicts seizures, over 160 ms predicts ventricular arrhythmias, and a terminal R wave over 3 mm in aVR predicts both. Treat with 8.4% sodium bicarbonate 1–2 mmol/kg IV, repeated to narrow the QRS, aiming for arterial pH 7.45–7.55. Use benzodiazepines for seizures and avoid flumazenil, physostigmine and class IA/IC antiarrhythmics. Sources: Boehnert and Lovejoy, NEJM 1985; Liebelt, Ann Emerg Med 1995; TOXBASE/UK poisons guidance.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #Toxicology #Overdose #ECG #EmergencyMedicine #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CriticalCare

Sequence 1 in this tracked set.

Postiz publish time (8 November 2026, 00:32 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Sgarbossa Criteria: MI in LBBB or Paced Rhythm

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Original Sgarbossa criteria and their limitations in LBBB. The paced-rhythm application and remaining references are still being checked.

Review scope

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Original Smith 2012 modified criteria, paced-rhythm validation, exact score/measurement rules and current ACS pathway.

Still unreviewed

  • Original Smith 2012 modified criteria, paced-rhythm validation, exact score/measurement rules and current ACS pathway.

Qualifications on the reviewed points

  • A low score does not exclude acute coronary occlusion or MI.
  • The cited 20% sensitivity and 98% specificity derive from an LBBB meta-analysis, not a blanket estimate for paced rhythms.

References recorded with the episode

Recorded with the episode

Electrocardiographic Diagnosis of Evolving Acute Myocardial Infarction in the Presence of Left Bundle-Branch Block

Sgarbossa EB et al.

1996

DOI 10.1056/NEJM199602223340801

Open source at nejm.org

Link check recorded

Recorded as supporting
  • Original Sgarbossa criteria in LBBB.
Limits and what this source leaves unreviewed
  • Original LBBB study; should not alone validate diagnostic accuracy in paced rhythms.

Recorded with the episode

Electrocardiographic Criteria for Detecting Acute Myocardial Infarction in Patients With Left Bundle Branch Block: A Meta-analysis

Tabas JA et al.

2008

DOI 10.1016/j.annemergmed.2007.12.006

Open source at doi.org

Link check recorded

Recorded as supporting
  • Score ≥3: pooled sensitivity approximately 20%, specificity approximately 98% in LBBB.
Limits and what this source leaves unreviewed
  • Not a rule-out test; these pooled values should not be asserted for all paced rhythms. Smith 2012 modified criteria and ESC 2023 source not yet fully reviewed.

Supporting literature checked separately

None recorded in this review.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Sgarbossa, NEJM 1996; Tabas, Ann Emerg Med 2008; Smith, Ann Emerg Med 2012; ESC ACS guidelines 2023.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Sgarbossa Criteria: MI in LBBB or Paced Rhythm

In LBBB and right ventricular pacing the ST segment normally runs opposite to the QRS. Sgarbossa scores the exceptions: concordant ST elevation of 1 mm or more (5 points), concordant ST depression of 1 mm or more in V1–V3 (3 points), and discordant ST elevation of 5 mm or more (2 points). A score of 3 or more is about 98% specific but only about 20% sensitive, so a low score never excludes MI. Sources: Sgarbossa, NEJM 1996; Tabas, Ann Emerg Med 2008; Smith, Ann Emerg Med 2012; ESC ACS guidelines 2023.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #ECG #Sgarbossa #LBBB #EmergencyMedicine #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CriticalCare

Sequence 2 in this tracked set.

Postiz publish time (7 November 2026, 20:22 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Anaphylaxis: Adrenaline Doses That Matter

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Anaphylaxis: Adrenaline Doses That Matter. Safety/accuracy corrections are required; see the correction and qualifications.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Confirmed error

The independent review confirmed an error against the checked source.

Reviewed wording

Under anaesthesia (AAGBI 2021) ... Harper, Anaesthesia 2021.

First-pass proposal

The specific Harper/AAGBI title resolves to a 2009 publication, not 2021. Cite the exact source actually used; label the 2024 RCUK perioperative algorithm as additional guidance, not an original source.

Independent review wording

Citation corrected: Harper et al., Anaesthesia 2009 (AAGBI); current perioperative algorithm RCUK 2024.

Missing qualifier

The point needs a qualifier. The independent wording is below.

Reviewed wording

If two IM doses fail, start a low-dose IV infusion.

First-pass proposal

If ABC compromise persists despite two appropriate IM doses, obtain urgent critical-care expertise. IV infusion requires a skilled, monitored setting; continue appropriate IM treatment if an infusion cannot safely be delivered.

Independent review wording

Low-dose IV adrenaline infusion is for refractory anaphylaxis after two IM doses, with expert support.

Review scope

Original caption plus three decoded rendered frames and exact recorded body where recoverable. No full-frame-sequence/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Native upload identity verified: no

Remaining priority: NAP6 bibliographic identity/statistics, full tryptase/fluid/glucagon details and perioperative versus general-anaphylaxis protocol.

Still unreviewed

  • Full NAP6 source identity and trigger/first-feature statistics.
  • All tryptase timing, glucagon and fluid details across unsampled panels; full contemporary general-anaphylaxis guideline comparison.

Checks recorded in this pass

These checks do not clear the post.

  • IM age-band dose/concentration calculations checked.
  • General versus specialist perioperative routes distinguished.
  • Citation-year inconsistency confirmed.

Qualifications on the reviewed points

  • Keep IM 1 mg/mL and IV 0.1 mg/mL concentrations clearly separate.
  • 500 µg/1 mg per mL = 0.5 mL IM; 50 µg/0.1 mg per mL = 0.5 mL IV. Same volume does not mean same concentration.
  • Only experienced clinicians in monitored specialist settings should administer IV adrenaline.
  • Do not delay resuscitation for tryptase sampling; follow local/current algorithm.

References recorded with the episode

Recorded with the episode

Emergency treatment of anaphylaxis: Guidelines for healthcare providers

Resuscitation Council UK

2021

DOI not recorded

Open source at resus.org.uk

Link check recorded

Recorded as supporting
  • IM adrenaline 1 mg/mL: adult/child >12 y 500 µg; age 6–12 y 300 µg; 6 months–6 y 150 µg; <6 months 100–150 µg.
  • Repeat at 5 minutes if ABC problems persist; refractory after two appropriate IM doses requires expert support and low-dose IV infusion.
  • Antihistamines are not for initial ABC compromise; routine emergency corticosteroids are not advised.
Limits and what this source leaves unreviewed
  • A small/prepubertal child >12 years may receive 300 µg; IV adrenaline only in skilled specialist monitored settings.
  • Historical 2021 document, not a claim of latest 2026 general guideline.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Emergency treatment of peri-operative anaphylaxis: Resuscitation Council UK algorithm for anaesthetists

Dodd A et al.

2024

DOI 10.1111/anae.16206

Open source at associationofanaesthetists-publications.onlinelibrary.wiley.com

Link check recorded

Recorded as supporting
  • Initial adult/child >12 y IV adrenaline 50 µg (0.5 mL of 1 mg/10 mL), titrated by anaesthetists.
  • Poor response to boluses: start infusion; adults initial crystalloid 500–1000 mL, titrated; glucagon may be considered in beta-blocked refractory cases.
Limits and what this source leaves unreviewed
  • Supporting source identified now, not the recorded original.
  • Perioperative specialist algorithm differs from general/community IM algorithm.

Supporting literature checked separately. Not the episode’s recorded source.

Suspected Anaphylactic Reactions Associated with Anaesthesia

Harper NJN et al.

2009

DOI 10.1111/j.1365-2044.2008.05733.x

Open source at doi.org

Link check recorded

Recorded as supporting
  • The identifiable Harper/AAGBI guideline with this title was published in Anaesthesia 2009;64:199–211.
Limits and what this source leaves unreviewed
  • Recorded attribution says Harper/AAGBI 2021; that exact citation is unresolved and must not be presented as validated.
  • Archived historical guideline, not contemporary treatment authority.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Resuscitation Council UK 2021; AAGBI suspected perioperative anaphylaxis guideline (Harper, Anaesthesia 2021); NAP6 (BJA 2018).

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Anaphylaxis: Adrenaline Doses That Matter

Adrenaline is the only first-line drug in anaphylaxis. IM 1 mg/mL into the anterolateral thigh: 500 micrograms for adults and children over 12, 300 micrograms for 6–12 years, 150 micrograms for 6 months to 6 years, repeated after 5 minutes. If two IM doses fail, start a low-dose IV infusion. Under anaesthesia give 50 microgram IV boluses in adults. Antihistamines and steroids are not first-line. Sources: Resuscitation Council UK 2021; AAGBI suspected perioperative anaphylaxis guideline (Harper, Anaesthesia 2021); NAP6 (BJA 2018).

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #Anaphylaxis #EmergencyMedicine #Adrenaline #Resuscitation #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CriticalCare

Sequence 3 in this tracked set.

Postiz publish time (7 November 2026, 17:23 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

ARDS: Berlin Definition and Lung-Protective Ventilation

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Historical Berlin definition and major lung-protective ventilation/proning trials. Three recorded references checked; full current-definition and visual review remains pending.

Review scope

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Complete Berlin PEEP/CPAP and imaging exclusions, exact PROSEVA eligibility, and recorded 2024 global-definition source.

Still unreviewed

  • Complete Berlin PEEP/CPAP and imaging exclusions, exact PROSEVA eligibility, and recorded 2024 global-definition source.

Qualifications on the reviewed points

  • Use predicted, not actual, body weight.
  • Berlin categories have continuous boundaries (>200 and >100), not integer-only 201 and 101 cutoffs.
  • Mortality percentages refer to Berlin validation cohorts.
  • Proning evidence is from a selected, early mechanically ventilated population; the caption abbreviates PROSEVA inclusion criteria.
  • 2024 global-definition citation and complete rendered video are not yet reviewed.

References recorded with the episode

Recorded with the episode

Acute Respiratory Distress Syndrome: The Berlin Definition

ARDS Definition Task Force

2012

DOI 10.1001/jama.2012.5669

Open source at doi.org

Link check recorded

Recorded as supporting
  • Berlin oxygenation bands: mild 200<P/F≤300, moderate 100<P/F≤200, severe P/F≤100.
  • Mortality 27%, 32%, 45% in the validation cohorts.
Limits and what this source leaves unreviewed
  • Mortality figures are cohort estimates, not individual predictions. Berlin is the historical definition; the cited 2024 global definition remains to be checked.

Recorded with the episode

Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome Network

2000

DOI 10.1056/NEJM200005043421801

Open source at nejm.org

Link check recorded

Recorded as supporting
  • Low tidal volume arm initially used 6 mL/kg predicted body weight with plateau pressure ≤30 cmH2O and reduced mortality.
Limits and what this source leaves unreviewed
  • Trial allowed protocol adjustments; 6 mL/kg is not a universally fixed setting.

Recorded with the episode

Prone Positioning in Severe Acute Respiratory Distress Syndrome

Guérin C et al.

2013

DOI 10.1056/NEJMoa1214103

Open source at doi.org

Link check recorded

Recorded as supporting
  • Prone sessions at least 16 hours reduced mortality in the selected severe-ARDS study population.
Limits and what this source leaves unreviewed
  • Eligibility included P/F<150, FiO2≥0.6, PEEP≥5, early mechanical ventilation and low tidal volumes; P/F<150 alone is an incomplete description of trial eligibility.

Supporting literature checked separately

None recorded in this review.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • ARDS Definition Task Force, JAMA 2012; ARDSNet, NEJM 2000; Guérin, NEJM 2013; Matthay, AJRCCM 2024.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

ARDS: Berlin Definition and Lung-Protective Ventilation

Berlin 2012 defines ARDS by timing (within 1 week), bilateral opacities, a cause not fully explained by cardiac failure or fluid overload, and PaO2/FiO2 on PEEP or CPAP of at least 5: mild 201–300, moderate 101–200, severe 100 or less (mortality 27%, 32%, 45%). Ventilate at 6 mL/kg predicted body weight with plateau pressure 30 cmH2O or less (ARDSNet 2000), and prone for 16 h a day when PaO2/FiO2 is under 150 (PROSEVA 2013). Sources: ARDS Definition Task Force, JAMA 2012; ARDSNet, NEJM 2000; Guérin, NEJM 2013; Matthay, AJRCCM 2024.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #ARDS #CriticalCare #MechanicalVentilation #ICU #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed

Sequence 4 in this tracked set.

Postiz publish time (7 November 2026, 13:29 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Vasopressors and Inotropes at a Glance (infographic)

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Vasopressors and Inotropes at a Glance (infographic) — Correction required; claim-level review remains incomplete; see checks and limitations.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Confirmed error

The independent review confirmed an error against the checked source.

Reviewed wording

Epinephrine if cardiac dysfunction; 2nd agent in sepsis

First-pass proposal

Distinguish persistent hypotension despite norepinephrine plus vasopressin from persistent hypoperfusion with cardiac dysfunction despite adequate fluids/BP. For the latter, SSC 2021 suggests dobutamine added to norepinephrine or epinephrine alone; see separate current SSC 2026 recommendations.

Independent review wording

Surviving Sepsis 2021: vasopressin is the suggested second vasopressor; adrenaline is suggested third, or with cardiac dysfunction.

Missing qualifier

The point needs a qualifier. The independent wording is below.

Reviewed wording

Vasopressin … not titrated

First-pass proposal

Fixed low-dose vasopressin is a sepsis-guideline practice; product-labeled titration and post-cardiotomy regimens differ. Use a named local protocol, not a universal no-titration rule.

Independent review wording

Vasopressin is often run at a fixed 0.03 U/min in septic shock; the label permits titration.

Review scope

Exact full script/spec plus original caption and dense decoded sampling; every identified main teaching panel compared, not a claim of exhaustive media review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Audio reviewed: no
  • Native upload identity verified: no

Remaining priority: Five remaining drug-card doses/routes/pitfalls and every receptor/HR/SVR/PVR arrow; recorded original paper/label versions.

Still unreviewed

  • Complete individual dose/route/pitfall checks for five remaining drug cards and all receptor/effect arrows.
  • Resolve exact recorded product-label identities and full original paper tables.

Checks recorded in this pass

These checks do not clear the post.

  • Septic-shock sequence and cardiac-dysfunction epinephrine shortcut: correction-needed
  • Hydrocortisone 200 mg/day at norepinephrine ≥0.25 for ≥4 h: qualified
  • Vasopressin 0.01–0.04 U/min, not titrated: correction-needed
  • Angiotensin-II 20 ng/kg/min; first-3-hour 80 and later 40 limits; VTE prophylaxis: supported
  • Milrinone maintenance 0.375–0.75 µg/kg/min and renal reduction: supported
  • Levosimendan 0.05–0.2 µg/kg/min/24 h and prolonged effect: qualified
  • Norepinephrine, epinephrine, dopamine, dobutamine, phenylephrine cards and all nine receptor/HR/SVR/PVR arrows: unresolved

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

correction-needed — Septic-shock sequence and cardiac-dysfunction epinephrine shortcut

Recorded 2021 source requires inadequate MAP despite norepinephrine/vasopressin OR persistent hypoperfusion with cardiac dysfunction despite adequate fluid/BP; these are distinct pathways.

qualified — Hydrocortisone 200 mg/day at norepinephrine ≥0.25 for ≥4 h

Dose/remark matches 2021 but ongoing vasopressor requirement and clinical context are required; not an automatic trigger.

correction-needed — Vasopressin 0.01–0.04 U/min, not titrated

Fixed low-dose sepsis practice is not a universal rule; actual label explicitly permits titration and distinguishes septic/post-cardiotomy doses.

supported — Angiotensin-II 20 ng/kg/min; first-3-hour 80 and later 40 limits; VTE prophylaxis

Exact units, timing and limits match named live label.

supported — Milrinone maintenance 0.375–0.75 µg/kg/min and renal reduction

Matches named label; 50 µg/kg loading is an infusion over 10 minutes, not rapid push.

qualified — Levosimendan 0.05–0.2 µg/kg/min/24 h and prolonged effect

SmPC supports ranges; 6–12 µg/kg loading over 10 min, effects 7–9 days versus metabolite half-life 75–80 h; important contraindications absent from card.

unresolved — Norepinephrine, epinephrine, dopamine, dobutamine, phenylephrine cards and all nine receptor/HR/SVR/PVR arrows

Exact original Overgaard/SOAP-II/ATHOS-3 papers and remaining named labels have not been read in full for every card.

Qualifications on the reviewed points

  • Adult ICU infusion ranges are not bolus resuscitation/anaphylaxis protocols. Effects vary with dose, physiology, co-therapy and pulmonary vascular disease.
  • SSC 2026 is available and must not be silently represented as the recorded 2021 source. Levosimendan is not recommended for the cited septic subgroup.

References recorded with the episode

Recorded with the episode

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021

Laura Evans, Andrew Rhodes, Waleed Alhazzani

2021

DOI 10.1097/CCM.0000000000005337

Open source at sccm.org

Link check recorded

Recorded as supporting
  • Norepinephrine first-line; add vasopressin for inadequate MAP on norepinephrine, with 0.25–0.5 µg/kg/min described as practice, not an obligatory threshold.
  • Add epinephrine when MAP remains inadequate despite norepinephrine and vasopressin. For cardiac dysfunction with persistent hypoperfusion despite adequate fluid/BP, add dobutamine to norepinephrine or use epinephrine alone.
  • Hydrocortisone 200 mg/day with ongoing vasopressor requirement; ≥0.25 µg/kg/min norepinephrine/epinephrine and ≥4 hours is an initiation remark, not an unconditional prescription.
Limits and what this source leaves unreviewed
  • Recorded exact document. Official recommendation page read; not validation of every drug-card dose/receptor arrow.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026

Society of Critical Care Medicine, European Society of Intensive Care Medicine

2026

DOI not recorded

Open source at sccm.org

Link check recorded

Recorded as supporting
  • Norepinephrine generally first-line; norepinephrine or epinephrine suggested first-line with concomitant cardiac dysfunction, with heart-rate context.
  • In persistent hypoperfusion with cardiac dysfunction despite adequate fluid/BP, add dobutamine to norepinephrine or use epinephrine alone; insufficient evidence to choose dobutamine versus milrinone, and levosimendan discouraged for this septic subgroup.
  • Initial MAP 65 mmHg generally; 60–65 mmHg suggested for septic-shock patients aged ≥65.
Limits and what this source leaves unreviewed
  • Current comparison only; not an original recorded citation. Do not relabel a 2021 algorithm as a complete 2026 algorithm.

Supporting literature checked separately. Not the episode’s recorded source.

GIAPREZA (angiotensin II) prescribing information

DailyMed / US prescribing information

Year not recorded

DOI not recorded

Open source at dailymed.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Start 20 ng/kg/min; maximum 80 ng/kg/min in first 3 hours, then maintenance ≤40 ng/kg/min. Concurrent VTE prophylaxis is advised.
Limits and what this source leaves unreviewed
  • The original footer says only product labels; exact product/version not recorded. This label is supporting evidence, not proven original provenance.

Supporting literature checked separately. Not the episode’s recorded source.

Milrinone lactate injection prescribing information

DailyMed / US prescribing information

Year not recorded

DOI not recorded

Open source at dailymed.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Loading 50 µg/kg over 10 minutes; maintenance 0.375–0.75 µg/kg/min. Renal impairment prolongs elimination and requires infusion reduction. Hypotension and arrhythmias require monitoring.
Limits and what this source leaves unreviewed
  • Omitting loading is a clinical practice modification, not the label regimen; does not establish superiority for every RV-failure/PH/post-CPB case. Exact original product unidentified.

Supporting literature checked separately. Not the episode’s recorded source.

Vasopressin injection prescribing information

DailyMed / US prescribing information

Year not recorded

DOI not recorded

Open source at dailymed.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Septic-shock start 0.01 U/min; titrate by 0.005 U/min every 10–15 minutes. Limited data above 0.07 U/min septic shock and 0.1 U/min post-cardiotomy shock.
Limits and what this source leaves unreviewed
  • Fixed low-dose SSC practice differs from labeled titration. Exact original label/version unidentified.

Supporting literature checked separately. Not the episode’s recorded source.

Simdax 2.5 mg/mL: Summary of Product Characteristics, revised 18 August 2025

Swedish Medical Products Agency / Simdax SmPC

2025

DOI not recorded

Open source at docetp.mpa.se

Link check recorded

Recorded as supporting
  • Load 6–12 µg/kg over 10 minutes then 0.1 µg/kg/min, adjustable 0.05–0.2 µg/kg/min for 24 hours. Effects may persist 7–9 days; metabolite half-lives are approximately 75–80 hours, not 7–9 days.
  • Contraindications include severe hypotension/tachycardia, significant mechanical filling/outflow obstruction, CrCl <30 mL/min, severe hepatic impairment and prior torsades.
Limits and what this source leaves unreviewed
  • Supporting named label, not proven original. Regional indication/availability and local protocols differ.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Recorded visual footer: Sources: Surviving Sepsis Campaign 2021 (Evans, Crit Care Med 2021); Overgaard & Džavík, Circulation 2008; De Backer (SOAP II), NEJM 2010; Khanna (ATHOS-3), NEJM 2017; product labels. ↔ minimal change. Attribution only; not complete claim verification.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

All 9 vasoactive drugs on one page 👇 norepinephrine, epinephrine, vasopressin, phenylephrine, dopamine, dobutamine, milrinone, levosimendan and angiotensin II, each with its receptor, what it does to HR, contractility, SVR and PVR, the usual ICU dose, its key use and the pitfall that catches people out. Plus the Surviving Sepsis 2021 targets.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #Vasopressors #Inotropes #CriticalCare #SepticShock #ICU #Pharmacology #DMCardiacAnaesthesia #Anaesthesiology #ExamPrep #MedEd #FOAMed #Viva

Sequence 5 in this tracked set.

Postiz publish time (7 November 2026, 10:08 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

CVP Waveforms at a Glance (infographic)

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

CVP Waveforms at a Glance (infographic) — claim-level review remains incomplete; see checks and limitations.

Review scope

Exact full script/spec plus original caption and dense decoded sampling; every identified main teaching panel compared, not a claim of exhaustive media review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Audio reviewed: no
  • Native upload identity verified: no

Remaining priority: Every waveform/source-page match; CVP measurement/normal-range conditions, RVEDP equivalence and positive-pressure limitations.

Still unreviewed

  • Waveform-by-waveform source/page verification; normal 2–6 mmHg population/measurement conditions.
  • CVP versus RVEDP equivalence under valve disease, positive pressure and transmural pressure limitations.

Checks recorded in this pass

These checks do not clear the post.

  • CVP fluid-responsiveness AUC about 0.56: supported
  • 10 cm H₂O ≈7.4 mmHg: supported
  • Normal a/c/x/v/y and abnormal cannon-a/TR/AF/tamponade/constriction patterns; zero/end-expiratory measurement: unresolved

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — CVP fluid-responsiveness AUC about 0.56

Original meta-analysis indexed result 0.56, 95% CI 0.54–0.58.

supported — 10 cm H₂O ≈7.4 mmHg

Independent calculation: 10 ×0.73556 =7.3556 mmHg; rounding is correct.

unresolved — Normal a/c/x/v/y and abnormal cannon-a/TR/AF/tamponade/constriction patterns; zero/end-expiratory measurement

Recorded Miller/Kaplan lack edition/page mapping; clinical caveats and every waveform need exact authority.

Qualifications on the reviewed points

  • CVP is not a standalone fluid-responsiveness or fluid-need test.
  • End-expiratory CVP approximating RVEDP assumes appropriate timing, no important tricuspid obstruction and relevant intrathoracic/pericardial-pressure context.

References recorded with the episode

Recorded with the episode

Does the central venous pressure predict fluid responsiveness? An updated meta-analysis and a plea for some common sense

Paul E. Marik, Rodrigo Cavallazzi

2013

DOI 10.1097/CCM.0b013e31828a25fd

Open source at doi.org

Link check recorded

Recorded as supporting
  • Pooled AUC 0.56 (95% CI 0.54–0.58), supporting poor discrimination of fluid responsiveness by CVP.
Limits and what this source leaves unreviewed
  • Recorded original citation. Numeric result checked against indexed original article; this study does not validate every waveform diagnosis or catheter-zeroing instruction.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Prediction of fluid responsiveness: an update

Xavier Monnet, Paul E. Marik, Jean-Louis Teboul

2016

DOI 10.1186/s13613-016-0216-7

Open source at link.springer.com

Link check recorded

Recorded as supporting
  • Static CVP does not reliably predict fluid responsiveness. PPV/SVV are dynamic preload-responsiveness tests only under suitable ventilatory/rhythm conditions. A positive test is not by itself an indication to administer fluid.
Limits and what this source leaves unreviewed
  • Retrospective supporting review, not an original citation for these posts. Not a tamponade diagnostic algorithm.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Recorded visual footer: Schematic waveforms. Sources: Miller’s Anesthesia (CVP monitoring); Kaplan’s Cardiac Anesthesia; Marik & Cavallazzi, Crit Care Med 2013;41:1774. 3D render is illustrative. Attribution only; not complete claim verification.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Every CVP shape on one page 👇 the normal a, c, x, v and y, then the 6 abnormal traces examiners love: cannon a waves, absent a in AF, large a waves, the giant c-v wave of tricuspid regurgitation, the lost y descent of tamponade and the steep M/W pattern of constriction. Plus where to read it, how to zero it, and why one CVP number won't tell you about fluid responsiveness.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #CVP #Haemodynamics #CriticalCare #Monitoring #Tamponade #DMCardiacAnaesthesia #Anaesthesiology #ICU #ExamPrep #MedEd #FOAMed #Viva

Sequence 6 in this tracked set.

Postiz publish time (7 November 2026, 08:03 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Etomidate for Induction in Cardiac Patients

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Etomidate for Induction in Cardiac Patients. Selected claim-source mappings checked; remaining claims and full media review are unresolved.

Review scope

Original caption plus three decoded rendered frames and exact recorded body where recoverable. No full-frame-sequence/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Native upload identity verified: no

Remaining priority: Exact critically-ill adrenal-suppression duration, historical infusion mortality, induction selection, awakening/myoclonus and injection-site claims.

Still unreviewed

  • Suppression up to 24 hours or more needs an exact critically-ill patient study.
  • Historical ICU infusion mortality attribution.
  • Specific AS/tamponade/shock selection, 5–15-minute awakening, >50% unpremedicated myoclonus frequency, and thrombophlebitis wording.

Checks recorded in this pass

These checks do not clear the post.

  • Dose 0.3 mg/kg and no-analgesia claim checked against live label.
  • Label adverse-effect rates vary; exact frequency wording not signed off.

Qualifications on the reviewed points

  • Relative haemodynamic stability is not a guarantee: titrate dose to patient and monitor; elderly and hypovolaemic patients need particular caution.
  • The label describes anaesthesia usually 3–5 minutes at 0.3 mg/kg; the reel says awake in 5–15 minutes, which requires a separate endpoint-specific source.
  • Do not infer single-dose mortality harm from historical prolonged-infusion observations.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

AMIDATE (etomidate injection) US prescribing information

Hospira, Inc.

2026

DOI not recorded

Open source at dailymed.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Usual induction dose 0.3 mg/kg IV over 30–60 seconds; label range 0.2–0.6 mg/kg, individualised; elderly may need less.
  • No analgesia; myoclonus and injection pain occur.
  • 11-beta-hydroxylation inhibition; label describes cortisol/aldosterone suppression for ~6–8 hours after induction and warns against prolonged infusion.
  • Haemodynamic effects are usually small but elderly hypertensive patients may have cardiac depression.
Limits and what this source leaves unreviewed
  • Supporting label, no original reference was recorded in the inspected caption/script.
  • Label alone does not establish the caption claim of ≥24-hour suppression, mortality causation during historical ICU infusions, or suitability for all shock/tamponade patients.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Etomidate for Induction in Cardiac Patients

Etomidate 0.2–0.3 mg/kg keeps heart rate, SVR and contractility steady, which is why it suits poor LV function, severe AS, tamponade and shock. The trade-off is adrenal suppression: it inhibits 11β-hydroxylase and lowers cortisol for up to 24 hours or more after a single dose, and infusions were abandoned after higher ICU mortality. It gives no analgesia, so add an opioid, and expect myoclonus and pain on injection.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #Etomidate #Induction #Pharmacology #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 7 in this tracked set.

Postiz publish time (7 November 2026, 00:11 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Digoxin Toxicity: ECG Clues and Treatment

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Digoxin Toxicity: ECG Clues and Treatment. Safety/accuracy corrections are required; see the correction and qualifications.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Confirmed error

The independent review confirmed an error against the checked source.

Reviewed wording

Fab for life-threatening arrhythmia or K above 5.0 in acute overdose.

First-pass proposal

Treat life-threatening digoxin toxicity urgently with Fab under toxicology/local guidance. Potassium criteria are protocol-specific: the US label uses >5.5 mEq/L in adults with rapidly progressive toxicity, while the 2023 consensus uses >6.5 mmol/L for immediate treatment. Do not wait for either threshold when other life-threatening signs exist.

Independent review wording

Digoxin Fab: for life-threatening arrhythmia; adult label (DigiFab) — serum K+ >5.5 mEq/L with rapidly progressive toxicity (children >6); 2023 clinical toxicology consensus — K+ >6.5 mmol/L warrants immediate Fab. Neither supports >5.0.

Confirmed error

The independent review confirmed an error against the checked source.

Reviewed wording

Correct K+ and Mg2+ first.

First-pass proposal

Correct relevant electrolyte abnormalities with monitoring, but do not delay urgent Fab in life-threatening digoxin toxicity.

Independent review wording

Give Fab without delay when indicated; correct hypokalaemia/hypomagnesaemia, but don't delay Fab to treat hyperkalaemia.

Review scope

Original caption plus three decoded rendered frames and exact recorded body where recoverable. No full-frame-sequence/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Native upload identity verified: no

Remaining priority: Original potassium threshold, all ECG/interaction/electrolyte/cardioversion claims, level timing and post-Fab assay interpretation.

Still unreviewed

  • Exact source for the reel K >5.0 threshold.
  • All ECG morphology, calcium/magnesium risk-factor, interaction and low-energy-cardioversion advice.
  • Interpretation of digoxin levels ≥6 hours after ingestion and post-Fab assay interference.

Checks recorded in this pass

These checks do not clear the post.

  • Antidote threshold is not universal; label/consensus difference documented.
  • Dialysis removal claim checked; independent indications for renal replacement are not excluded.

Qualifications on the reviewed points

  • Fab indications depend on clinical severity, age, acute/chronic context and the cited protocol; do not present K >5.0 as a universal threshold.
  • Do not postpone life-saving Fab until potassium/magnesium correction is complete.
  • Carefully monitor potassium after Fab; low potassium can emerge rapidly.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

DIGIFAB (digoxin immune Fab [ovine]) prescribing information

US Food and Drug Administration

Year not recorded

DOI not recorded

Open source at dailymed.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Life-threatening ventricular arrhythmia, progressive bradycardia/atropine-resistant heart block and rapidly progressive toxicity with K >5.5 mEq/L in adults or >6 in children are label indications.
  • Fab may cause a rapid fall in potassium, requiring monitoring.
Limits and what this source leaves unreviewed
  • Supporting source checked now, not a recorded original.
  • Clinical guidance differs in potassium thresholds; never use a potassium number alone to delay antidote in life-threatening toxicity.

Supporting literature checked separately. Not the episode’s recorded source.

Diagnosis and practical management of digoxin toxicity: a narrative review and consensus

Andrews P et al.

2023

DOI 10.1097/MEJ.0000000000001065

Open source at journals.lww.com

Link check recorded

Recorded as supporting
  • Consensus identifies K >6.5 mmol/L as a sign of life-threatening toxicity requiring immediate Fab.
  • Dialysis/haemoperfusion generally not recommended for digoxin removal because of large volume of distribution.
Limits and what this source leaves unreviewed
  • Supporting consensus, not original provenance.
  • Only selected statements retrieved; full ECG, interaction, cardioversion and electrolyte sections still need direct full-text review.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Digoxin Toxicity: ECG Clues and Treatment

Know the difference: the scooped 'reverse tick' ST segment and short QT are digoxin effect, not toxicity. Toxicity can cause almost any arrhythmia, classically ventricular bigeminy, atrial tachycardia with block and bidirectional VT. Low K⁺, low Mg²⁺, high Ca²⁺, renal impairment, amiodarone and verapamil all raise the risk. Treat life-threatening arrhythmia, or K⁺ above 5.0 after acute overdose, with digoxin-specific antibody fragments; dialysis does not remove it.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #Digoxin #ECG #Arrhythmia #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 8 in this tracked set.

Postiz publish time (6 November 2026, 19:31 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Pulsus Paradoxus: Mechanism and Causes

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Pulsus Paradoxus: Mechanism and Causes — Correction required; claim-level review remains incomplete; see checks and limitations.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Missing qualifier

The point needs a qualifier. The independent wording is below.

Reviewed wording

Under positive-pressure ventilation the swing reflects volume status

First-pass proposal

Under controlled positive-pressure ventilation, respiratory arterial-pressure variation may predict preload responsiveness only under appropriate conditions; it is not a direct volume-status measure and neither confirms nor excludes tamponade.

Independent review wording

Respiratory variation predicts fluid responsiveness, not volume status, under specific conditions.

Review scope

Exact full script/spec plus original caption and dense decoded sampling; every identified main teaching panel compared, not a claim of exhaustive media review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Audio reviewed: no
  • Native upload identity verified: no

Remaining priority: All Doppler thresholds with breathing/rhythm context; rare/loculated postoperative tamponade and full escalation pathway.

Still unreviewed

  • Every transmitral/tricuspid Doppler cutoff with spontaneous versus positive-pressure breathing and arrhythmia limits.
  • Rare causes, loculated postoperative findings and complete escalation pathway.

Checks recorded in this pass

These checks do not clear the post.

  • Definition, cuff/arterial-line detection and ventricular interdependence: supported
  • Absent pulsus despite tamponade with AR/ASD/high LV filling pressure/PPV: supported
  • PPV swing reflects volume status: correction-needed
  • Mitral E >25%, tricuspid >40%; rare causes/RV infarct; Kussmaul/constriction; loculated postop TEE: unresolved

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — Definition, cuff/arterial-line detection and ventricular interdependence

Publisher review describes >10-mmHg fall, measurement and septal interaction.

supported — Absent pulsus despite tamponade with AR/ASD/high LV filling pressure/PPV

Listed exceptions supported by review; absence cannot exclude tamponade.

correction-needed — PPV swing reflects volume status

Dynamic arterial-pressure variation is not direct blood-volume measurement; ventilatory/rhythm conditions and competing RV/afterload pathology matter.

unresolved — Mitral E >25%, tricuspid >40%; rare causes/RV infarct; Kussmaul/constriction; loculated postop TEE

Exact recorded original absent; additional authoritative echo/pericardial source required.

Qualifications on the reviewed points

  • Postoperative shock requires urgent clinical/surgical assessment; do not delay treatment awaiting a textbook sign.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Cardiac tamponade: 12 pearls in diagnosis and management

William A. Schiavone

2013

DOI 10.3949/ccjm.80a.12052

Open source at ccjm.org

Link check recorded

Recorded as supporting
  • Pulsus paradoxus is an inspiratory systolic-BP fall >10 mmHg; cuff measurement compares expiratory-only with throughout-respiration Korotkoff sounds.
  • Pulsus can occur without tamponade and may be absent with tamponade, including positive-pressure ventilation, severe AR, ASD, severe LVH/dysfunction or low-pressure states.
Limits and what this source leaves unreviewed
  • Supporting review only; no original source recorded. Does not independently validate every listed rare cause or Doppler threshold.

Supporting literature checked separately. Not the episode’s recorded source.

Prediction of fluid responsiveness: an update

Xavier Monnet, Paul E. Marik, Jean-Louis Teboul

2016

DOI 10.1186/s13613-016-0216-7

Open source at link.springer.com

Link check recorded

Recorded as supporting
  • Static CVP does not reliably predict fluid responsiveness. PPV/SVV are dynamic preload-responsiveness tests only under suitable ventilatory/rhythm conditions. A positive test is not by itself an indication to administer fluid.
Limits and what this source leaves unreviewed
  • Retrospective supporting review, not an original citation for these posts. Not a tamponade diagnostic algorithm.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Pulsus Paradoxus: Mechanism and Causes

Pulsus paradoxus is an inspiratory fall in systolic BP of more than 10 mmHg. In tamponade the full pericardium means extra RV filling on inspiration pushes the septum left, so LV filling and stroke volume fall. It also occurs in severe asthma/COPD, massive PE, tension pneumothorax and hypovolaemia, and it can be absent despite tamponade with severe AR, ASD, high LVEDP, positive-pressure ventilation or a loculated effusion.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #PulsusParadoxus #CardiacTamponade #Haemodynamics #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 9 in this tracked set.

Postiz publish time (6 November 2026, 16:56 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

CABG Conduits: LIMA, Radial and Vein

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

CABG Conduits: LIMA, Radial and Vein. Selected claim-source mappings checked; remaining claims and full media review are unresolved.

Review scope

Original caption plus three decoded rendered frames and exact recorded body where recoverable. No full-frame-sequence/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Native upload identity verified: no

Remaining priority: Conduit selection/harvest collateral tests, antispasm treatment, bilateral-IMA risk, vein-failure sequence, TTFM and new-ST/RWMA differential.

Still unreviewed

  • Original authorities for harvest collateral assessment, antispasm treatment, bilateral IMA sternal infection risk, vein-graft failure sequence, transit-time flowmetry and new ST/RWMA differential.
  • One intermediate panel was not captured in the three samples; exact script available but whole media remains unreviewed.

Checks recorded in this pass

These checks do not clear the post.

  • Goldman numeric results checked against publisher abstract.
  • RADIAL composite endpoint and angiographic outcome distinguished from mortality.

Qualifications on the reviewed points

  • Patency percentages are study estimates, influenced by target vessel and cohort; do not promise those outcomes to all patients.
  • Radial-artery superiority statement concerns selected trial populations and composite outcomes, not all patients or mortality.

References recorded with the episode

Recorded with the episode

Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study

Goldman S et al.

2004

DOI 10.1016/j.jacc.2004.08.064

Open source at jacc.org

Link check recorded

Recorded as supporting
  • Study 10-year patency: SVG 61%, IMA 85%.
Limits and what this source leaves unreviewed
  • Historical VA cohort; IMA overall result must not be represented as a universal contemporary individual LIMA-to-LAD prediction.

Recorded with the episode

Radial-Artery or Saphenous-Vein Grafts in Coronary-Artery Bypass Surgery

Gaudino M et al.

2018

DOI 10.1056/NEJMoa1716026

Open source at nejm.org

Link check recorded

Recorded as supporting
  • Individual-patient pooled trial data: radial grafts associated with fewer adverse cardiac events at mean 60±30 months (HR 0.67) and less occlusion at angiographic mean 50±30 months (HR 0.44).
Limits and what this source leaves unreviewed
  • Not a demonstrated mortality benefit at five years; non-LAD conduit comparison in selected trial patients.

Supporting literature checked separately

None recorded in this review.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

CABG Conduits: LIMA, Radial and Vein

Conduit choice decides how long a CABG lasts. LIMA to LAD is about 85% patent at 10 years, versus about 61% for saphenous vein grafts (Goldman 2004). The radial artery outperforms vein (RADIAL meta-analysis, NEJM 2018), but check ulnar collateral flow before harvest and treat spasm with nitrates or calcium channel blockers. Bilateral IMA raises sternal wound infection risk in diabetic and obese patients.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #CABG #CoronaryBypass #CardiacSurgery #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed

Sequence 10 in this tracked set.

Postiz publish time (6 November 2026, 14:24 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Electrolytes on the ECG (infographic)

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Electrolytes on the ECG (infographic) — claim-level review remains incomplete; see checks and limitations.

Review scope

Exact full script/spec plus original caption and dense decoded sampling; every identified main teaching panel compared, not a claim of exhaustive media review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Audio reviewed: no
  • Native upload identity verified: no

Remaining priority: Exact RCUK/UKKA editions, full post-insulin monitoring, every ECG schematic and all calcium/magnesium dose/renal contexts.

Still unreviewed

  • Resolve original RCUK 2021 and UKKA 2020 version; check updated UKKA 2023 full monitoring schedule.
  • Every ECG schematic including separation of hypocalcaemia from hypomagnesaemia; all Mg/Ca doses and renal adjustments.

Checks recorded in this pass

These checks do not clear the post.

  • Hyperkalaemia rescue calcium/insulin/glucose/salbutamol quantities: qualified
  • Non-arrest KCl rate versus hypokalaemic arrest: qualified
  • Seven ECG patterns, Mg/Ca shared long-ST depiction, MgSO₄ 2g/10min, CPB causes and haemofiltration: unresolved

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — Hyperkalaemia rescue calcium/insulin/glucose/salbutamol quantities

Quantities match current official guidance; calcium administration times and glucose prevention/monitoring are missing from the compact card.

qualified — Non-arrest KCl rate versus hypokalaemic arrest

Routine ≤20 mmol/h language is not an arrest regimen; current RCUK has separate rapid IV/IO arrest dosing.

unresolved — Seven ECG patterns, Mg/Ca shared long-ST depiction, MgSO₄ 2g/10min, CPB causes and haemofiltration

Recorded RCUK 2021/UKKA 2020 originals not fully retrieved. Do not certify all morphology or bypass-treatment claims from current potassium guidance alone.

Qualifications on the reviewed points

  • Calcium chloride and gluconate are not interchangeable volume-for-volume. Include actual calcium infusion time, route/extravasation precautions and reassessment.
  • Insulin requires glucose and serial glucose/K monitoring; hypoglycaemia risk persists after dosing.
  • Torsades with haemodynamic instability or cardiac arrest needs the appropriate immediate electrical/resuscitation pathway, not a ten-minute magnesium delay.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Special circumstances Guidelines 2025: hyperkalaemia and hypokalaemia

Resuscitation Council UK

2025

DOI not recorded

Open source at resus.org.uk

Link check recorded

Recorded as supporting
  • Moderate/severe hyperkalaemia: insulin 10 units with glucose 25 g IV; salbutamol 10–20 mg nebulised as adjunct. If pretreatment glucose <7 mmol/L, follow with 10% glucose 50 mL/hour for 5 hours.
  • Severe hyperkalaemia with ECG changes: calcium chloride 10 mL of 10% IV over 5 minutes; if unavailable, calcium gluconate 30 mL of 10% over 10 minutes.
  • Hypokalaemic cardiac arrest uses a separate rapid IV/IO KCl regimen with monitoring; routine non-arrest infusion-rate guidance must not be transplanted into arrest.
Limits and what this source leaves unreviewed
  • Supporting current guideline, not the recorded RCUK 2021 original. Full glucose-monitoring schedule and local infusion safeguards must be checked separately.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Recorded visual footer: Schematic ECGs. Sources: Resuscitation Council UK ALS Guidelines 2021 (special circumstances: hyperkalaemia; peri-arrest arrhythmias); UK Kidney Association, Treatment of Acute Hyperkalaemia in Adults, 2020. Attribution only; not complete claim verification.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Seven strips, every classic electrolyte pattern 👇 hyperkalaemia from peaked T waves to the sine wave, hypokalaemia with U waves, short QT in hypercalcaemia, long QT in hypocalcaemia and hypomagnesaemia, plus the RC UK 2021 doses: calcium, insulin–glucose, salbutamol and magnesium for torsades.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #ECG #Hyperkalaemia #Hypokalaemia #Electrolytes #Torsades #DMCardiacAnaesthesia #Anaesthesiology #Cardiology #ExamPrep #MedEd #FOAMed #Viva

Sequence 11 in this tracked set.

Postiz publish time (6 November 2026, 11:27 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

The LV Pressure–Volume Loop (infographic)

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

The LV Pressure–Volume Loop (infographic) — claim-level review remains incomplete; see checks and limitations.

Review scope

Exact full script/spec plus original caption and dense decoded sampling; every identified main teaching panel compared, not a claim of exhaustive media review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Audio reviewed: no
  • Native upload identity verified: no

Remaining priority: All pressure-volume and valve-loop arrows, load/contractility/diastolic changes and PVA/oxygen assertions against exact original pages.

Still unreviewed

  • Full original-source mapping of every static panel and physiological arrow, PVA/SW/oxygen statement and valve-loop schematic.

Checks recorded in this pass

These checks do not clear the post.

  • SV=120−50=70 mL, EF≈58%, Ea≈100/70=1.43 mmHg/mL: supported
  • ESPVR/EDPVR, PVA versus stroke work/oxygen consumption, loading/contractility perturbations and valve-loop diagrams: unresolved

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — SV=120−50=70 mL, EF≈58%, Ea≈100/70=1.43 mmHg/mL

Independent arithmetic checked. Example values are illustrations, not universal normal values.

unresolved — ESPVR/EDPVR, PVA versus stroke work/oxygen consumption, loading/contractility perturbations and valve-loop diagrams

Original paper bibliographic identity resolved, but full relevant passages and exact Guyton/Hall pages unavailable.

Qualifications on the reviewed points

  • End-systolic elastance is a relatively load-insensitive chamber contractility index within model assumptions, not absolutely load-independent in every state.
  • EDPVR is a nonlinear passive chamber pressure-volume relationship, not a single context-free compliance number; Ea is a lumped approximation.

References recorded with the episode

Recorded with the episode

Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers

Daniel Burkhoff, Israel Mirsky, Hiroyuki Suga

2005

DOI 10.1152/ajpheart.00138.2005

Open source at doi.org

Link check recorded

Recorded as supporting

No supported claim was recorded for this source.

Limits and what this source leaves unreviewed
  • Exact original paper identity resolved. Full text not obtained, so not used to certify all ESPVR/EDPVR/PVA/oxygen-consumption or perturbation-panel claims. Guyton and Hall edition named but exact pages absent.

Supporting literature checked separately

None recorded in this review.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Recorded visual footer: Schematic, typical adult values. Sources: Burkhoff D, Mirsky I, Suga H. Am J Physiol Heart Circ Physiol 2005;289:H501–12; Hall JE, Guyton and Hall Textbook of Medical Physiology, 14th ed. Attribution only; not complete claim verification.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Read any pressure–volume loop in seconds 👇 the four valve events (A to D), the four phases, and the three lines that matter: ESPVR for contractility, EDPVR for compliance and Ea for afterload, with typical adult volumes and how preload, afterload, contractility and a stiff LV change the loop.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #PVLoop #CardiacPhysiology #FrankStarling #Contractility #Afterload #DMCardiacAnaesthesia #Anaesthesiology #Cardiology #ExamPrep #MedEd #FOAMed #Viva

Sequence 12 in this tracked set.

Postiz publish time (6 November 2026, 07:38 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Pre-op Anaemia Before Cardiac Surgery

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Preoperative anaemia assessment and iron treatment. Recorded 2017 consensus identified; important qualifications and correction wording are provided.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Awaiting validation

Validation is unfinished. This is not a confirmed error.

Reviewed wording

Ferritin below 100 µg/L and/or TSAT below 20% means iron deficiency peri-operatively.

First-pass proposal

Ferritin <30 µg/L supports absolute iron deficiency; in the presence of inflammation (CRP >5 mg/L) and/or TSAT <20%, ferritin <100 µg/L supports iron deficiency. Interpret results in clinical context.

Independent review wording

Awaiting validation against full text of Muñoz et al., Anaesthesia 2017;72:233-247. No change to the inflammation qualifier or transfusion wording until then.

Awaiting validation

Validation is unfinished. This is not a confirmed error.

Reviewed wording

Don't transfuse to fix anaemia before elective surgery.

First-pass proposal

Do not routinely transfuse asymptomatic anaemia merely to normalise Hb before elective surgery; investigate and treat the cause, and individualise transfusion when clinically indicated.

Independent review wording

Awaiting validation against full text of Muñoz et al., Anaesthesia 2017;72:233-247. No change to the inflammation qualifier or transfusion wording until then.

Awaiting validation

Validation is unfinished. This is not a confirmed error.

Reviewed wording

Treat Hb below 13 g/dL in both sexes.

First-pass proposal

Investigate Hb <13 g/dL and treat the underlying cause; iron is indicated for iron deficiency, not automatically for every low Hb.

Independent review wording

Awaiting validation against full text of Muñoz et al., Anaesthesia 2017;72:233-247. No change to the inflammation qualifier or transfusion wording until then.

Review scope

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Prevalence/outcome associations, oral-versus-IV iron timing and response-time claims; exact full primary passages and actual rendered text.

Still unreviewed

  • Prevalence/outcome associations, oral-versus-IV iron timing and response-time claims; exact full primary passages and actual rendered text.

Qualifications on the reviewed points

  • Interpret ferritin with inflammation/CRP and TSAT; ferritin <100 alone is not a universal diagnostic rule.
  • Hb <13 g/dL should trigger assessment of anaemia and its cause, not automatic iron treatment.
  • Do not routinely transfuse asymptomatic anaemia solely to normalise Hb; individual transfusion indications still apply.

References recorded with the episode

Recorded with the episode

International consensus statement on the peri-operative management of anaemia and iron deficiency

Muñoz M et al.

2017

DOI 10.1111/anae.13773

Open source at associationofanaesthetists-publications.onlinelibrary.wiley.com

Link check recorded

Recorded as supporting
  • Ferritin <30 µg/L identifies absolute iron deficiency.
  • With inflammation (CRP>5 mg/L) and/or TSAT<20%, ferritin <100 µg/L supports iron deficiency.
  • Investigate and treat anaemia before major non-urgent surgery; target Hb ≥130 g/L in both sexes when treating.
  • Oral iron when 6–8 weeks are available; IV iron for intolerance, nonresponse or surgery within <6 weeks.
Limits and what this source leaves unreviewed
  • Recorded script names the 2017 consensus; full bibliographic identity resolved and checked now.
  • A low Hb alone does not diagnose iron deficiency or justify automatic iron treatment.
  • Not all prevalence/outcome and response-time claims have been individually traced.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management

Tibi P, McClure RS, Huang J, et al.

2021

DOI 10.1016/j.athoracsur.2021.03.033

Open source at annalsthoracicsurgery.org

Link check recorded

Recorded as supporting
  • Assess anaemia and determine its cause in cardiac surgery.
  • Preoperative transfusion for asymptomatic anaemia is of uncertain benefit (Class III: No Benefit, B-NR).
Limits and what this source leaves unreviewed
  • Additional supporting guideline checked now, NOT recorded as the Reel original source.
  • Does not create an absolute prohibition on clinically indicated transfusion.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Pre-op Anaemia Before Cardiac Surgery

Pre-op anaemia affects about 1 in 3 cardiac surgical patients and is linked to more transfusion, AKI, stroke and death. The 2017 international consensus treats Hb below 13 g/dL in both sexes before major surgery. Check ferritin, TSAT, CRP, B12, folate and renal function. Ferritin below 100 µg/L and/or TSAT below 20% means iron deficiency peri-operatively. Use oral iron if there are 6–8 weeks or more, otherwise IV iron; Hb rises over 2–4 weeks. Don't transfuse to fix anaemia before elective surgery.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #PatientBloodManagement #Anaemia #IVIron #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 13 in this tracked set.

Postiz publish time (6 November 2026, 00:41 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Heart Murmurs and Bedside Manoeuvres

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Heart Murmurs and Bedside Manoeuvres — claim-level review remains incomplete; see checks and limitations.

Review scope

Exact full script/spec plus original caption and dense decoded sampling; every identified main teaching panel compared, not a claim of exhaustive media review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Audio reviewed: no
  • Native upload identity verified: no

Remaining priority: Original source for each murmur/manoeuvre response, especially VSD handgrip, location/radiation and exceptions.

Still unreviewed

  • Original source identity; VSD handgrip response and all site/radiation exceptions.

Checks recorded in this pass

These checks do not clear the post.

  • Seven murmur timing/site patterns and most manoeuvres: qualified
  • Opening snap with MS: qualified
  • Absolute no-carotid-radiation HOCM, all radiation/site variants, VSD handgrip and leg-raise equivalence: unresolved

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — Seven murmur timing/site patterns and most manoeuvres

Live clinical reference supports timing classes, PDA location and principal inspiration/Valsalva/squat/handgrip responses.

qualified — Opening snap with MS

Can soften/disappear with calcification/fibrosis; not required for diagnosis.

unresolved — Absolute no-carotid-radiation HOCM, all radiation/site variants, VSD handgrip and leg-raise equivalence

Exact original absent; supporting reference does not establish every rendered categorical phrase.

Qualifications on the reviewed points

  • These are typical examination clues, not rule-in/rule-out tests; flow state, coexisting lesions and anatomy change findings.
  • Valsalva strain and release differ. Squatting changes both preload and afterload; passive leg raising is not physiologically identical.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Cardiac Auscultation — MSD Manual Professional Edition

Jessica I. Gupta, Michael J. Shea

2026

DOI not recorded

Open source at msdmanuals.com

Link check recorded

Recorded as supporting
  • AS/HOCM ejection-systolic; MR/VSD holosystolic; AR early-diastolic; MS mid-diastolic; PDA continuous.
  • Inspiration usually augments right-sided murmurs; Valsalva strain reduces filling, augmenting HOCM/MVP; squatting usually has the reverse effect. Handgrip augments MR/AR and reduces AS/HOCM.
  • An MS opening snap may soften or disappear with fibrosis/calcification. PDA murmurs may disappear as pulmonary/systemic resistance equalise.
Limits and what this source leaves unreviewed
  • Supporting clinical reference reviewed/updated in 2026, not recorded original provenance. Does not verify every location/radiation exception or VSD handgrip statement.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Heart Murmurs and Bedside Manoeuvres

Murmurs at a glance: AS is ejection systolic at the right 2nd interspace radiating to the carotids; MR is pansystolic at the apex radiating to the axilla; VSD is pansystolic at the left lower sternal edge; HOCM is ejection systolic at the left sternal edge without carotid radiation; AR is early diastolic, heard best sitting forward in expiration; MS is a mid-diastolic rumble with an opening snap. Manoeuvres: inspiration louder on the right; Valsalva and standing soften most murmurs but make HOCM louder; squatting does the opposite; handgrip increases MR, AR and VSD.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #HeartMurmurs #ClinicalExam #HOCM #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 14 in this tracked set.

Postiz publish time (5 November 2026, 20:14 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Jones Criteria for Acute Rheumatic Fever (AHA 2015)

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Jones Criteria for Acute Rheumatic Fever (AHA 2015). Selected claim-source mappings checked; remaining claims and full media review are unresolved.

Review scope

Original caption plus three decoded rendered frames and exact recorded body where recoverable. No full-frame-sequence/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Native upload identity verified: no

Remaining priority: Every Jones minor threshold, double-counting exclusion/corrigendum and exact secondary-prophylaxis regimen/duration.

Still unreviewed

  • All minor-criteria CRP/ESR/PR thresholds, excluded double-counting rules and 2020 correction.
  • Secondary prophylaxis regimen/interval and duration by residual disease and age; these are not validated by merely citing the diagnostic statement.

Checks recorded in this pass

These checks do not clear the post.

  • Risk-specific joint criteria and non-double-counting qualification checked.

Qualifications on the reviewed points

  • Risk category is based on epidemiology, not nationality alone.
  • Exclude alternative causes of joint symptoms; do not double-count arthritis/arthralgia.
  • Isolated chorea requires differential assessment; it is not a blanket instruction to diagnose every chorea as ARF.

References recorded with the episode

Recorded with the episode

Revision of the Jones Criteria for the Diagnosis of Acute Rheumatic Fever in the Era of Doppler Echocardiography: A Scientific Statement From the American Heart Association

Gewitz MH et al.

2015

DOI 10.1161/CIR.0000000000000205

Open source at ahajournals.org

Link check recorded

Recorded as supporting
  • Risk-stratified Jones criteria include subclinical carditis; monoarthritis/polyarthritis/polyarthralgia can be major in moderate/high-risk populations.
  • Polyarthralgia is only considered major after other causes have been excluded; joint manifestations cannot count simultaneously as major and minor.
Limits and what this source leaves unreviewed
  • Exact 2015 statement recorded by title/caption; 2020 correction exists (10.1161/CIR.0000000000000889), not yet fully reviewed.
  • Complete diagnostic table, recurrence/chorea exceptions and secondary-prophylaxis schedules still require verification against full source/current local guidance.

Supporting literature checked separately

None recorded in this review.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Jones Criteria for Acute Rheumatic Fever (AHA 2015)

Jones criteria (AHA 2015 revision). Major: carditis (clinical or echo), arthritis, chorea, erythema marginatum and subcutaneous nodules. In moderate/high-risk populations such as India, monoarthritis and polyarthralgia count as major arthritis, and the minor thresholds are lower (fever 38.0 °C, ESR 30). Initial ARF needs 2 major, or 1 major plus 2 minor, with evidence of preceding group A strep infection; a recurrence can also be 3 minor. Chorea alone can be enough. Secondary prophylaxis is benzathine penicillin every 3–4 weeks for 5 to 10+ years depending on carditis.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #RheumaticFever #JonesCriteria #RheumaticHeartDisease #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 15 in this tracked set.

Postiz publish time (5 November 2026, 17:21 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Cell Salvage in Cardiac Surgery

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Cell Salvage in Cardiac Surgery — claim-level review remains incomplete; see checks and limitations.

Review scope

Exact full script/spec plus original caption and dense decoded sampling; every identified main teaching panel compared, not a claim of exhaustive media review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Audio reviewed: no
  • Native upload identity verified: no

Remaining priority: Manufacturer/process evidence for haematocrit/component removal, contraindications and complete coagulation-replacement implications.

Still unreviewed

  • Manufacturer/process validation of Hct 50–70% and component removal; full coagulation replacement algorithm.

Checks recorded in this pass

These checks do not clear the post.

  • Collection/anticoagulation, centrifugation and 0.9% saline washing: supported
  • Factor/platelet depletion and avoid incompatible topical solutions: supported
  • Jehovah’s Witness acceptance with continuous circuit: qualified
  • Hct 50–70%; removal of most heparin/free Hb/fat/activated factors; replacement thresholds: unresolved

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — Collection/anticoagulation, centrifugation and 0.9% saline washing

Primary guideline describes both anticoagulants and washed red cells suspended in saline.

supported — Factor/platelet depletion and avoid incompatible topical solutions

Primary guideline explicitly discusses clotting-factor/platelet depletion and topical agents.

qualified — Jehovah’s Witness acceptance with continuous circuit

Must discuss/document each patient; continuity is not universally necessary or sufficient.

unresolved — Hct 50–70%; removal of most heparin/free Hb/fat/activated factors; replacement thresholds

Guideline does not establish a universal Hct band or every clearance percentage; device/process-specific evidence needed.

Qualifications on the reviewed points

  • Never infer consent from religious identity; document individual acceptance of collection, processing, storage and continuity.
  • Washed red cells are not whole blood. Assess haemostasis after large volumes; replacement is guided by bleeding and appropriate tests, not volume alone.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Association of Anaesthetists guidelines: cell salvage for peri-operative blood conservation 2018

A. A. Klein

2018

DOI 10.1111/anae.14331

Open source at associationofanaesthetists-publications.onlinelibrary.wiley.com

Link check recorded

Recorded as supporting
  • Heparinised saline or acid-citrate dextrose anticoagulation, centrifugation and washing with IV 0.9% saline produce red cells suspended in saline.
  • Platelets/clotting factors are depleted; avoid collecting incompatible solutions/topical clotting agents.
  • Jehovah’s Witness patients require individual discussion/documentation; a continuous connection is not universally required or sufficient for consent.
Limits and what this source leaves unreviewed
  • Supporting guideline, not an original source in this script. Does not establish a universal returned Hct 50–70% or uniform removal percentages for fat/free Hb/heparin. Full text read from publicly mirrored publisher PDF.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Cell Salvage in Cardiac Surgery

Cell salvage collects shed blood with heparin or citrate, then centrifuges and washes it in 0.9% saline and returns packed red cells (haematocrit about 50–70%). Washing clears most heparin, free haemoglobin, fat and activated factors, but also removes platelets and clotting factors, so after large volumes check coagulation and replace fibrinogen, FFP or platelets as guided. Keep topical haemostats and non-IV antiseptics out of the suction. Pump suckers return blood unwashed; the cell saver washes it.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #CellSalvage #PatientBloodManagement #Transfusion #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 16 in this tracked set.

Postiz publish time (5 November 2026, 13:37 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

AV Block: Every Degree (infographic)

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

AV Block: Every Degree (infographic) — Correction required; claim-level review remains incomplete; see checks and limitations.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Confirmed error

The independent review confirmed an error against the checked source.

Reviewed wording

High-degree or complete AV block after surgery: observe up to 5 days before a permanent pacemaker (I-C)

First-pass proposal

For high-degree or complete AV block after cardiac surgery, ESC 2021 indicates observation for AT LEAST 5 days to assess recovery (I C); this may be shortened for complete block with low/no escape when resolution is unlikely.

Independent review wording

Observe at least 5 days (ESC 2021, I-C); TAVI 24-48 h is correct as stated.

Missing qualifier

The point needs a qualifier. The independent wording is below.

Reviewed wording

Atropine often fails below the AV node (Mobitz II,wide-QRSCHB)

First-pass proposal

RCUK 2025: do not give atropine in high-degree AV block with a wide QRS; it is ineffective and may worsen the block. Seek expert help and timely pacing/appropriate interim measures. Do not give atropine after heart transplantation either.

Independent review wording

Add: do not use atropine after heart transplantation.

Review scope

Exact full script/spec plus original caption and dense decoded sampling; every identified main teaching panel compared, not a claim of exhaustive media review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Audio reviewed: no
  • Native upload identity verified: no

Remaining priority: All ECG definitions/strip timings, congenital/reflex/reversible-cause exceptions, AV dissociation and complete pacing/epicardial-wire pathway.

Still unreviewed

  • CompleteformalECGdefinition/escape-rate/stripinterpretationmapping,congenital/reflexexceptionsandreversiblecauses;notallAVdissociationimpliescompleteblock.
  • Entirecurrentpacing/resuscitationalgorithmandspecifictemporaryepicardialwiremanagementarenotfullyaudited.

Checks recorded in this pass

These checks do not clear the post.

  • Post-cardiac-surgery observe up to five days (I C): correction-needed
  • Post-TAVI persistent high-grade/complete block 24–48 h (I B): supported
  • Atropine 500 µg/max3mg; isoprenaline5µg/min; adrenaline2–10µg/min; asystole risk: supported
  • All seven PR/QRS schematics, first-degree benign, permanent/temporary pacing selection and transplant atropine warning: unresolved

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

correction-needed — Post-cardiac-surgery observe up to five days (I C)

Original ESC primary table says AT LEAST five days, with specified early-shortening exception.

supported — Post-TAVI persistent high-grade/complete block 24–48 h (I B)

Exact class, LOE and interval match primary table.

supported — Atropine 500 µg/max3mg; isoprenaline5µg/min; adrenaline2–10µg/min; asystole risk

Current official algorithm matches listed doses/risk markers.

unresolved — All seven PR/QRS schematics, first-degree benign, permanent/temporary pacing selection and transplant atropine warning

Schematic source-code timing compared, but every clinical definition/exception and transplant warning need exact relevant primary sections.

supported — Original2021bradycardiadrugdoses/asystolemarkers

Exact originalone-page2021primaryalgorithmnowread;matchesdoses/unitsand4markers.

supported — Atropineafterhearttransplant

Current official2025ALS explicitlydoNOTgive; potentialhighdegreeblock/sinusarrest.

correction-needed — AtropineoftenfailsbelowAVnode

Current2025specificinstructionisdoNOTgiveinHIGH-DEGREEAVblockwithWIDEQRS,notmerelyatrialofpossiblyineffectiveatropine.

qualified — Firstdegreebenign/highgradepacingbadges/2:1

FullESC2021§5.2.1.1–3:goodprognosiswithoutstructuraldisease;markedPR≥300msmaycausesymptoms.PacemakerforMobitzII/highgrade/completeinabsenceofreversiblecause;incidental2:1case-by-casewithleveldetermination.

Qualifications on the reviewed points

  • A wide QRS is a clue, not proof of the AV-block site; first-degree block is not uniformly benign.
  • Unstable bradycardia needs cause treatment and timely pacing/expert help; an ineffective atropine trial must not delay definitive support.
  • ESC2021first-degreeAVblock prognosis is usuallygoodwithoutstructuraldisease,notuniversallybenign.MarkedPR≥300mscanbesymptomatic;pacingrequirestheappropriatesymptomcorrelation.
  • MobitzII/highgrade/completeAVblockpacingrecommendationsassumenoreversiblecause.Incidental2:1blockneedscase-by-caselevelassessment;wideQRSisnotproofofblocksite.

References recorded with the episode

Recorded with the episode

2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy

Michael Glikson, Jens Cosedis Nielsen

2021

DOI 10.1093/eurheartj/ehab364

Open source at doi.org

Link check recorded

Recorded as supporting
  • High-degree/complete AV block after cardiac surgery: clinical observation of at least 5 days; may shorten if complete block with low/no escape and resolution unlikely (I C).
  • After TAVI, complete/high-degree AV block persisting 24–48 hours warrants permanent pacing (I B).
Limits and what this source leaves unreviewed
  • Recorded original document. Complete primary PDF read at postoperative recommendation table (PDF page 69); not a universal five-day deadline.

Recorded with the episode

Adult bradycardia algorithm2021

Resuscitation Council UK

2021

DOI not recorded

Open source at resus.org.uk

Link check recorded

Recorded as supporting
  • Atropine500µgIV,max3mg;isoprenaline5µg/minIV;adrenaline2–10µg/minIV;transcutaneous/transvenouspacing pathways andfourasystoleriskmarkers.
Limits and what this source leaves unreviewed
  • Exactoriginalone-pagealgorithmretrieved/read. DoesnotcontainthetransplantwarningorvalidateeveryECG/pacingindication.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Adult bradyarrhythmia algorithm 2025

Resuscitation Council UK

2025

DOI not recorded

Open source at resus.org.uk

Link check recorded

Recorded as supporting
  • Atropine 500 µg IV, repeat maximum 3 mg; interim isoprenaline 5 µg/min or adrenaline 2–10 µg/min or pacing.
  • Asystole risk includes recent asystole, Mobitz II, complete block with broad QRS and ventricular pause >3 seconds; address reversible causes and seek expert help.
Limits and what this source leaves unreviewed
  • Current comparison, not recorded RCUK 2021 original. This one-page algorithm does not itself contain the transplant-specific atropine exclusion.

Supporting literature checked separately. Not the episode’s recorded source.

Adult advanced life support Guidelines2025 — bradycardia

Jasmeet Soar, Joyce Yeung, Keith Couper

2025

DOI not recorded

Open source at resus.org.uk

Link check recorded

Recorded as supporting
  • Do not give atropine to heart-transplant patients; it may cause high-degreeAVblock/sinusarrest.
  • Do not give atropine in high-degreeAVblockwithwideQRS:ineffectiveandmayworsenblock.
  • Consider earlytransvenouspacing inunstablesymptomaticbradycardia;transcutaneousbridgeasappropriate.
Limits and what this source leaves unreviewed
  • Current supporting update,notoriginal2021 attribution. Specialist resuscitation setting; not a replacement forcompletealgorithm.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Recorded visual footer: Schematic ECGs. Sources: ESC 2021 Guidelines on cardiac pacing (Glikson M et al., Eur Heart J 2021;42:3427); Resuscitation Council UK ALS Guidelines 2021, adult bradycardia algorithm. Attribution only; not complete claim verification.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Seven ECG strips, one question: where is the block? 👇 normal, first degree, Mobitz I, Mobitz II, 2:1, advanced and complete heart block, with the PR intervals marked, which ones need pacing, the bradycardia drug doses and when to pace after cardiac surgery or TAVI.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #HeartBlock #ECG #Mobitz #Pacing #Bradycardia #DMCardiacAnaesthesia #Anaesthesiology #Cardiology #ExamPrep #MedEd #FOAMed #Viva

Sequence 17 in this tracked set.

Postiz publish time (5 November 2026, 10:44 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Echo Probability of Pulmonary Hypertension (infographic)

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Echo Probability of Pulmonary Hypertension (infographic) — claim-level review remains incomplete; see checks and limitations.

Review scope

Exact full script/spec plus original caption and dense decoded sampling; every identified main teaching panel compared, not a claim of exhaustive media review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Audio reviewed: no
  • Native upload identity verified: no

Remaining priority: Complete Doppler exception mapping, severe TR/poor envelope, RHC classification and actual diagram labels.

Still unreviewed

  • Complete Doppler exception mapping for severeTR/poor envelope and full haemodynamic classification including PAWP/PVR; complete media/audio review remains outstanding.

Checks recorded in this pass

These checks do not clear the post.

  • All nine Table-10 measurements and three sign categories: supported
  • Five TRV probability rows including unmeasurable and >3.4 independent of other signs: supported
  • 4×2.8²≈31;4×3.4²≈46 mmHg gradient: supported
  • sPAP estimation and universal RHC sentence: qualified

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — All rendered Table10 measurements and three sign categories

Each numeric threshold/unit/comparator checked against full primary Table10; ≥2 DIFFERENT categories required.

supported — Five TRV probability rows including unmeasurable and >3.4 independent of other signs

Matches primary Figure5, including footnotes.

supported — 4×2.8²≈31;4×3.4²≈46 mmHg gradient

Independent calculations:31.36 and46.24. These are RV–RA gradients, not sPAP without RAP.

qualified — sPAP estimation and universal RHC sentence

RAP/velocity measurement errors and RVOT/PS context matter; RHC decisions use clinical consequence/risk, not every mild echo elevation.

supported — Additional exact ASE2023 section mapping

Relevant primary sections IV.A, V.B–D read; support limited to reference supportedClaims.

Qualifications on the reviewed points

  • RHC when useful information or a therapeutic consequence is expected; it may not be indicated for mild PH with predominant left-heart/lung disease and no PAH/CTEPH risks.
  • mPAP >20 mmHg defines PH haemodynamically, but PAWP and PVR are needed to classify pre-/post-capillary disease.
  • No absolute echo-based PAH diagnosis, severity or treatment decision from TRV alone.

References recorded with the episode

Recorded with the episode

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Marc Humbert, Gabor Kovacs, Marius M. Hoeper

2022

DOI 10.1093/eurheartj/ehac237

Open source at doi.org

Link check recorded

Recorded as supporting
  • Table 10 thresholds: RV/LV >1; LVEI >1.1; TAPSE/sPAP <0.55 mm/mmHg; RVOT AT <105 ms/notching; PR >2.2 m/s; PA >aortic-root diameter or >25 mm; IVC >21 mm with reduced collapse; RA area >18 cm².
  • Figure 5 probability uses TRV ≤2.8/unmeasurable, 2.9–3.4, >3.4 m/s and signs from at least TWO DIFFERENT categories; not two signs within one category.
  • RHC is performed when useful information/therapeutic consequence is expected; may not be indicated in mild PH with predominant left-heart/lung disease and no PAH/CTEPH risk factors.
Limits and what this source leaves unreviewed
  • Recorded original guideline. Figure 4 contains measurement diagrams; probability algorithm is Figure 5. Echo alone cannot classify PH haemodynamics.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Recommendations for the Use of Echocardiography in the Evaluation of Rheumatic Heart Disease: A Report from the American Society of Echocardiography

Natesa G. Pandian, Jin Kyung Kim

2023

DOI 10.1016/j.echo.2022.10.009

Open source at asecho.org

Link check recorded

Recorded as supporting
  • PASP approximates RVSP only without RVOT/pulmonic obstruction; subtract an obstruction gradient if present. Obtain a dense, well-defined TR envelope, exclude noise and avoid post-extrasystolic measurements.
Limits and what this source leaves unreviewed
  • Supporting primary update, not a recorded original series citation.
  • Use only the explicitly mapped sections: this document contains the older mPAP ≥25 mmHg definition; do NOT use that threshold instead of current ESC/ERS >20 mmHg.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Recorded visual footer: Source: 2022 ESC/ERS Guidelines for PH (Humbert et al., Eur Heart J 2022;43:3618), Fig. 4 & Table 10. LVEI = LV eccentricity index; AT = acceleration time. Attribution only; not complete claim verification.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

One question, every echo sign 👇 how likely is pulmonary hypertension? Peak TR velocity first, then the extra signs from the ventricles, the pulmonary artery and the IVC/RA, and the ESC/ERS 2022 table that turns them into low, intermediate or high probability.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #PulmonaryHypertension #Echocardiography #TEE #TRVelocity #RightVentricle #DMCardiacAnaesthesia #Anaesthesiology #Cardiology #ExamPrep #MedEd #FOAMed #Viva

Sequence 18 in this tracked set.

Postiz publish time (5 November 2026, 08:01 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Mitral Stenosis 5/5: Intra-op TEE and Bypass Pearls

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Mitral Stenosis 5/5: Intra-op TEE and Bypass Pearls — Correction required; claim-level review remains incomplete; see checks and limitations.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Guideline version difference

The cited edition and a later or other edition differ.

Reviewed wording

Tricuspid annulus ≥40 mm (or >21 mm/m²): consider concomitant tricuspid repair

First-pass proposal

In patients undergoing left-sided valve surgery, integrate TR severity and mechanism. ESC/EACTS2025: concomitant surgery for severe TR (I B); consider repair for moderate TR (IIa B); selected mild secondary TR with annular dilatation ≥40mm or >21mm/m² may be considered for repair (IIb B). Annular size alone is not the indication.

Independent review wording

Name ESC 2021 (IIa); ESC 2025 lists this as IIb.

Review scope

Exact full script/spec plus original caption and dense decoded sampling; every identified main teaching panel compared, not a claim of exhaustive media review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Audio reviewed: no
  • Native upload identity verified: no

Remaining priority: Exact historical prosthetic-valve source and every specific post-bypass complication/TEE/treatment claim.

Still unreviewed

  • Original ASE2009 prosthetic source identity/full table and every specific peri-bypass complication/treatment claim.

Checks recorded in this pass

These checks do not clear the post.

  • Tricuspid annulus ≥40mm or >21mm/m² as isolated repair trigger: correction-needed
  • Mechanical MV screening E<1.9,MG≤5,EOA≥2,PHT<130: qualified
  • LA/LAA/valve/RV TEE; circumflex injury/new AR/AV-groove rupture; inhaledNO/milrinone; PA-catheter rupture: unresolved

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

correction-needed — Tricuspid annulus ≥40mm or >21mm/m² as isolated repair trigger

Missing TR severity and left-sided surgery context; 2025 distinguishes severe, moderate and selected mild secondary TR.

qualified — Mechanical MV screening E<1.9,MG≤5,EOA≥2,PHT<130

All four values match current ASE2024Table11, with HR/flow/type/size and multiple-parameter interpretation.

unresolved — LA/LAA/valve/RV TEE; circumflex injury/new AR/AV-groove rupture; inhaledNO/milrinone; PA-catheter rupture

Recorded sources not mapped to every anaesthetic/surgical complication and treatment; named ASE2009 prosthetic document not yet obtained.

supported — Additional exact ASE2023 section mapping

Relevant primary sections IV.A, V.B–D read; support limited to reference supportedClaims.

Qualifications on the reviewed points

  • The four normal-screen numbers cannot universally certify every prosthesis. Report HR, flow, valve model/size and postoperative baseline.
  • Inhaled NO or milrinone is not automatic for all postoperative PH/RV failure; assess physiology, systemic pressure and contraindications.

References recorded with the episode

Recorded with the episode

2021 ESC/EACTS Guidelines for the management of valvular heart disease

Alec Vahanian, Friedhelm Beyersdorf

2021

DOI 10.1093/eurheartj/ehab395

Open source at doi.org

Link check recorded

Recorded as supporting
  • Clinically significant rheumatic MS uses MVA ≤1.5 cm²; 2D planimetry is reference and gradient/PA pressure reflect consequences.
  • The five rendered ESC 2021 commissurotomy/surgery recommendation rows and classes/LOE match the primary recommendation table.
  • Concomitant tricuspid repair annular thresholds apply in valve-surgery/TR context, not as an isolated-annulus indication.
Limits and what this source leaves unreviewed
  • Recorded source across the series, not proof that every anaesthetic/peri-bypass claim comes from this guideline. 2025 update must be distinguished.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

2025 ESC/EACTS Guidelines for the management of valvular heart disease

ESC/EACTS Task Force

2025

DOI 10.1093/eurheartj/ehaf194

Open source at doi.org

Link check recorded

Recorded as supporting
  • Current MS recommendation Table 8 retains principal rheumatic PMC rows with class/LOE; favourable anatomy/clinical selection and contraindications remain essential.
  • With left-sided valve surgery: severe TR concomitant surgery I B; moderate TR repair IIa B; selected mild secondary TR with annulus ≥40 mm or >21 mm/m² repair IIb B.
Limits and what this source leaves unreviewed
  • Current supporting comparison only, not original 2026 post citation. Exact individual patient selection and entire guideline not signed off.

Supporting literature checked separately. Not the episode’s recorded source.

Guidelines for the Evaluation of Prosthetic Valve Function With Cardiovascular Imaging

William A. Zoghbi

2024

DOI not recorded

Open source at asecho.org

Link check recorded

Recorded as supporting
  • Table 11 normal mitral-prosthesis screen: peak velocity <1.9 m/s, mean gradient ≤5 mmHg, EOA ≥2 cm², PHT <130 ms. Integrate multiple findings, HR, flow, valve type/size, regurgitation and patient-prosthesis mismatch.
Limits and what this source leaves unreviewed
  • Supporting update, not recorded ASE 2009 prosthetic guideline. A threshold table is not a universal normal value for every valve or proof of absent dysfunction.

Supporting literature checked separately. Not the episode’s recorded source.

Recommendations for the Use of Echocardiography in the Evaluation of Rheumatic Heart Disease: A Report from the American Society of Echocardiography

Natesa G. Pandian, Jin Kyung Kim

2023

DOI 10.1016/j.echo.2022.10.009

Open source at asecho.org

Link check recorded

Recorded as supporting
  • LA/LAA thrombus assessment, MVA/MR/multivalve/right-heart evaluation before intervention and post-procedural gradient/regurgitation/complication assessment are recommended.
Limits and what this source leaves unreviewed
  • Supporting primary update, not a recorded original series citation.
  • Use only the explicitly mapped sections: this document contains the older mPAP ≥25 mmHg definition; do NOT use that threshold instead of current ESC/ERS >20 mmHg.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Recorded series-wide source header: ESC/EACTS2021VHD;ACC/AHA2020VHD;EAE/ASE2009stenosis(Baumgartner);ASE2009prostheticvalves. Global header is not proof that each claim originated in each document.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Mitral Stenosis 5/5: Intra-op TEE and Bypass Pearls

MS part 5, the last MS part: intra-op pearls. Before bypass, check the LA and LAA for thrombus and dense spontaneous contrast, confirm the MVA, MR and TR, and measure the tricuspid annulus (40 mm or more, or over 21 mm/m², supports a concomitant tricuspid repair). After MVR, check leaflet motion, gradient and paravalvular leak, look for circumflex injury (new lateral RWMA) and new AR, and avoid hypertension that can rupture the AV groove. Expect RV failure and pulmonary hypertension after bypass.

Save this for your exam 📌

Next: Mitral Regurgitation series, Part 1/5. Starts this Sunday.

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #MitralStenosis #TEE #MitralValveReplacement #CardiopulmonaryBypass #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 19 in this tracked set.

Postiz publish time (4 November 2026, 21:34 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Mitral Stenosis 4/5: Anaesthetic Goals and Haemodynamics

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Mitral Stenosis 4/5: Anaesthetic Goals and Haemodynamics — claim-level review remains incomplete; see checks and limitations.

Review scope

Exact full script/spec plus original caption and dense decoded sampling; every identified main teaching panel compared, not a claim of exhaustive media review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Audio reviewed: no
  • Native upload identity verified: no

Remaining priority: All mitral-stenosis rate/preload/SVR/RV/drug/neuraxial targets with severity, rhythm and procedure context.

Still unreviewed

  • Each anaesthetic target/drug/neuraxial recommendation with severity/rhythm/RV/perioperative context.

Checks recorded in this pass

These checks do not clear the post.

  • Avoid tachycardia/overload; gradient/PA pressure reflect MS consequences: qualified
  • Rate60–70, sinus/AF/cardioversion, SVR/PVR, N₂O, vasopressor selection, beta-blocker continuation, PAWP–LVEDP and neuraxial preference: unresolved

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — Avoid tachycardia/overload; gradient/PA pressure reflect MS consequences

Primary stenosis/valve texts support flow/heart-rate dependence; no universal60–70target or fixed-output guarantee.

unresolved — Rate60–70, sinus/AF/cardioversion, SVR/PVR, N₂O, vasopressor selection, beta-blocker continuation, PAWP–LVEDP and neuraxial preference

Exact original anaesthesia authority/page not recorded or retrieved; valve guideline alone does not validate whole management card.

supported — Additional exact ASE2023 section mapping

Relevant primary sections IV.A, V.B–D read; support limited to reference supportedClaims.

Qualifications on the reviewed points

  • Individualise HR and preload to perfusion, rhythm, RV function and stenosis severity; “slow, full, tight” is not a complete protocol.
  • Neuraxial choice depends on lesion severity, anticoagulation, procedure and monitoring; a blanket technique preference is not universal.
  • PAWP reflects LA pressure and may exceed LVEDP across a stenotic valve; measurement timing and ventilation still matter.

References recorded with the episode

Recorded with the episode

2021 ESC/EACTS Guidelines for the management of valvular heart disease

Alec Vahanian, Friedhelm Beyersdorf

2021

DOI 10.1093/eurheartj/ehab395

Open source at doi.org

Link check recorded

Recorded as supporting
  • Clinically significant rheumatic MS uses MVA ≤1.5 cm²; 2D planimetry is reference and gradient/PA pressure reflect consequences.
  • The five rendered ESC 2021 commissurotomy/surgery recommendation rows and classes/LOE match the primary recommendation table.
  • Concomitant tricuspid repair annular thresholds apply in valve-surgery/TR context, not as an isolated-annulus indication.
Limits and what this source leaves unreviewed
  • Recorded source across the series, not proof that every anaesthetic/peri-bypass claim comes from this guideline. 2025 update must be distinguished.

Recorded with the episode

Echocardiographic Assessment of Valve Stenosis: EAE/ASE Recommendations for Clinical Practice

Helmut Baumgartner, Judy Hung, Javier Bermejo

2009

DOI 10.1016/j.echo.2008.11.029

Open source at asecho.org

Link check recorded

Recorded as supporting
  • Rheumatic commissural fusion/chordal shortening differ from degenerative annular calcification; other inflammatory/carcinoid/drug causes are described.
  • PHT depends on gradient, combined LA/LV compliance and relaxation; severe AR, immediate post-commissurotomy and calcific MS can undermine accuracy. Continuity equation is limited by AF and significant MR/AR.
  • Mean gradient and PA pressure are supportive, not substitutes for valve area.
Limits and what this source leaves unreviewed
  • Recorded original. Official ASE page directs CURRENT MS staging to 2023 RHD and 2020 ACC/AHA, not the historical 2009 grading table. Corrigenda exist in 2009 and 2023; contents must be checked before certifying all formulas/tables.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Recommendations for the Use of Echocardiography in the Evaluation of Rheumatic Heart Disease: A Report from the American Society of Echocardiography

Natesa G. Pandian, Jin Kyung Kim

2023

DOI 10.1016/j.echo.2022.10.009

Open source at asecho.org

Link check recorded

Recorded as supporting
  • Transmitral gradients depend on flow/HR; high-output states, MR and atrial tachyarrhythmia can aggravate gradients. This does not validate every anaesthetic target.
Limits and what this source leaves unreviewed
  • Supporting primary update, not a recorded original series citation.
  • Use only the explicitly mapped sections: this document contains the older mPAP ≥25 mmHg definition; do NOT use that threshold instead of current ESC/ERS >20 mmHg.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Recorded series-wide source header: ESC/EACTS2021VHD;ACC/AHA2020VHD;EAE/ASE2009stenosis(Baumgartner);ASE2009prostheticvalves. Global header is not proof that each claim originated in each document.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Mitral Stenosis 4/5: Anaesthetic Goals and Haemodynamics

MS part 4: anaesthetic goals. Think slow, full and tight: keep the heart rate low-normal (about 60–70) so the LA has time to empty, stay in sinus or control the AF rate, maintain preload without overloading, keep SVR up because output is fixed, and avoid anything that raises PVR (hypoxia, hypercapnia, acidosis, pain, nitrous oxide). Treat hypotension with phenylephrine or noradrenaline, not drugs that cause tachycardia. Remember that PAWP overestimates LVEDP in MS.

Save this for your exam 📌

Next, Part 5/5: Intra-op TEE and Bypass Pearls (coming up in the next post).

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #MitralStenosis #Haemodynamics #AnaestheticGoals #PulmonaryHypertension #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 20 in this tracked set.

Postiz publish time (4 November 2026, 18:19 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Mitral Stenosis 3/5: Intervention Criteria (ESC 2021 + ACC/AHA 2020)

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Mitral Stenosis 3/5: Intervention Criteria (ESC 2021 + ACC/AHA 2020) — claim-level review remains incomplete; see checks and limitations.

Review scope

Exact full script/spec plus original caption and dense decoded sampling; every identified main teaching panel compared, not a claim of exhaustive media review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Audio reviewed: no
  • Native upload identity verified: no

Remaining priority: Complete contraindications/unfavourable-anatomy list and omitted calcific-MAC/high-risk intervention pathways.

Still unreviewed

  • Confirm complete contraindication/unfavourable-characteristic list and avoid presenting an abbreviated table as exhaustive.
  • Full continuous video/audio, native-upload identity, complete contraindications/unfavourable anatomy and omitted high-risk/calcific-MAC pathways not signed off.

Checks recorded in this pass

These checks do not clear the post.

  • Five rendered ESC2021 rows/classes/LOE: supported
  • ESC2025 current comparison: qualified
  • Five ACC2020 rows/classes/LOE/thresholds: supported

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — Five rendered ESC2021 rows/classes/LOE

Primary 2021 table compared to all two rendered ESC panels; matches I B/I C/I C/IIa C/IIa C with selection conditions.

qualified — ESC2025 current comparison

Principal rheumatic PMC rows retained; current table adds degenerative-MAC intervention context and still requires anatomy/contraindication/Heart-Team assessment.

supported — Five ACC2020 rows/classes/LOE/thresholds

Newly accessible official AHA2020 slide set compared with all three rendered ACC panels: all five displayed rows/classes/LOE/conditions match. This is an abbreviated rheumatic-MS table, not exhaustive guideline.

Qualifications on the reviewed points

  • The caption is a shortened historical comparison, not all current indications. Rheumatic commissural fusion differs from calcific MS.
  • LA thrombus and more-than-mild MR require careful assessment; high surgical risk does not erase procedural contraindications.

References recorded with the episode

Recorded with the episode

2021 ESC/EACTS Guidelines for the management of valvular heart disease

Alec Vahanian, Friedhelm Beyersdorf

2021

DOI 10.1093/eurheartj/ehab395

Open source at doi.org

Link check recorded

Recorded as supporting
  • Clinically significant rheumatic MS uses MVA ≤1.5 cm²; 2D planimetry is reference and gradient/PA pressure reflect consequences.
  • The five rendered ESC 2021 commissurotomy/surgery recommendation rows and classes/LOE match the primary recommendation table.
  • Concomitant tricuspid repair annular thresholds apply in valve-surgery/TR context, not as an isolated-annulus indication.
Limits and what this source leaves unreviewed
  • Recorded source across the series, not proof that every anaesthetic/peri-bypass claim comes from this guideline. 2025 update must be distinguished.

Recorded with the episode

2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease — official slide set

Catherine M. Otto, Rick A. Nishimura

2020

DOI 10.1016/j.jacc.2020.11.018

Open source at professional.heart.org

Link check recorded

Recorded as supporting
  • Five rendered rheumatic-MS PMBC/surgery rows match official2020 recommendations: symptomatic severe favourable PMBC IA; severely symptomatic surgery IB-NR; asymptomatic PASP>50 PMBC IIaB-NR; newAF IIbC-LD; exercise PAWP>25mmHg or mean MVgradient>15mmHg with MVA>1.5cm² IIbC-LD.
Limits and what this source leaves unreviewed
  • Exact recorded guideline; official issuing-society recommendation slide rows read. This is not exhaustive full-guideline, literature or corrigenda review. Local binary request403, WebFetch full readable source succeeded.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

2025 ESC/EACTS Guidelines for the management of valvular heart disease

ESC/EACTS Task Force

2025

DOI 10.1093/eurheartj/ehaf194

Open source at doi.org

Link check recorded

Recorded as supporting
  • Current MS recommendation Table 8 retains principal rheumatic PMC rows with class/LOE; favourable anatomy/clinical selection and contraindications remain essential.
  • With left-sided valve surgery: severe TR concomitant surgery I B; moderate TR repair IIa B; selected mild secondary TR with annulus ≥40 mm or >21 mm/m² repair IIb B.
Limits and what this source leaves unreviewed
  • Current supporting comparison only, not original 2026 post citation. Exact individual patient selection and entire guideline not signed off.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Recorded series-wide source header: ESC/EACTS2021VHD;ACC/AHA2020VHD;EAE/ASE2009stenosis(Baumgartner);ASE2009prostheticvalves. Global header is not proof that each claim originated in each document.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Mitral Stenosis 3/5: Intervention Criteria (ESC 2021 + ACC/AHA 2020)

MS part 3: when to intervene, with class of recommendation and level of evidence. ESC/EACTS 2021 (MVA 1.5 cm² or less): percutaneous commissurotomy for symptomatic patients without unfavourable characteristics (I B) or with a contraindication or high risk for surgery (I C); surgery for symptomatic patients unsuitable for PCC (I C); PCC as initial treatment with suboptimal anatomy but favourable clinical features (IIa C), and in asymptomatic patients at high thromboembolic or haemodynamic risk (IIa C). ACC/AHA 2020: PMBC for symptomatic severe MS with favourable morphology, less than 2+ MR and no LA thrombus (I A); surgery for NYHA III–IV patients who can't have PMBC (I B-NR); PMBC is reasonable in asymptomatic severe MS with PASP over 50 mmHg (IIa B-NR) and may be considered with new AF or exercise-induced haemodynamic significance (IIb C-LD).

Save this for your exam 📌

Next, Part 4/5: Anaesthetic Goals and Haemodynamics (coming up in the next post).

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #MitralStenosis #ESCGuidelines #PTMC #ValvularHeartDisease #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 21 in this tracked set.

Postiz publish time (4 November 2026, 15:26 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Mitral Stenosis 2/5: Grading Severity on Echo

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Mitral Stenosis 2/5: Grading Severity on Echo — Correction required; claim-level review remains incomplete; see checks and limitations.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Missing qualifier

The point needs a qualifier. The independent wording is below.

Reviewed wording

Pressure half-time … invalid … with AR … or a stiff LV

First-pass proposal

PHT can be unreliable after commissurotomy and when LA/LV compliance or relaxation is abnormal; severe AR can shorten PHT and overestimate area. Do not treat any degree of AR or all diastolic dysfunction as one absolute invalidity rule. Use integrated assessment, particularly in calcific MS.

Independent review wording

PHT is unreliable with significant AR, abnormal LV compliance, and early after valvotomy.

Review scope

Exact full script/spec plus original caption and dense decoded sampling; every identified main teaching panel compared, not a claim of exhaustive media review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Audio reviewed: no
  • Native upload identity verified: no

Remaining priority: Official 2009/2023 valve-stenosis corrigenda before certifying PISA; ASD-specific PHT and exact intraoperative TEE views.

Still unreviewed

  • Retrieve/read both official2009/2023corrigenda before certifying PISA formula from the uncorrected source; originalPDF printsπ while post uses2π.
  • ASD-specific PHT limitations and exact intraoperativeTEE views still need direct source mapping.

Checks recorded in this pass

These checks do not clear the post.

  • Historical2009 grading versus later clinically-significant MVA≤1.5: qualified
  • PHT220/PHT and invalid with any AR/stiffLV: correction-needed
  • Continuity equation and significant MR/AR limitation: supported
  • PISA2πr²×Valias/Vmax×α/180 and historical severity numbers: unresolved
  • Mid-diastolic leaflet-tip planimetry and TEE views: qualified

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — Historical2009 grading versus later clinically-significant MVA≤1.5

Old and later frameworks intentionally separated. Official ASE now directs current staging to2023RHD/2020ACC, not the old table.

correction-needed — PHT220/PHT and invalid with any AR/stiffLV

Primary2009text describes severe AR and compliance/relaxation interaction; the blanket any-AR/stiff-LV wording is too broad.

supported — Continuity equation and significant MR/AR limitation

Matches original2009text, which additionally notes AF limitation.

unresolved — PISA2πr²×Valias/Vmax×α/180

Uncorrected primary PDF printsπ; officialASE lists2009/2023corrigenda. Historical Table9 separately checked directly from renderedPDFpage17; formula remains unresolved.

qualified — Mid-diastolic leaflet-tip planimetry and TEE views

Reference method relates particularly to rheumatic anatomy; calcificMAC and Doppler alignment limit applicability.

supported — Additional exact ASE2023 section mapping

Relevant primary sections IV.A, V.B–D read; support limited to reference supportedClaims.

supported — Historical2009 Table9 MVA/gradient/PA-pressure cells and HR footnote

PrimaryPDFpage17 rendered image read. All displayed historical cells match; footnote applies at HR60–80 in sinus rhythm. This is historical grading, not current staging.

Qualifications on the reviewed points

  • Use consistent velocity units in PISA, r in cm and PHT in milliseconds; do not mix cm/s and m/s.
  • Plan beamed Doppler alignment; a named TEE view without adequate alignment does not guarantee a reliable gradient.

References recorded with the episode

Recorded with the episode

Echocardiographic Assessment of Valve Stenosis: EAE/ASE Recommendations for Clinical Practice

Helmut Baumgartner, Judy Hung, Javier Bermejo

2009

DOI 10.1016/j.echo.2008.11.029

Open source at asecho.org

Link check recorded

Recorded as supporting
  • Rheumatic commissural fusion/chordal shortening differ from degenerative annular calcification; other inflammatory/carcinoid/drug causes are described.
  • PHT depends on gradient, combined LA/LV compliance and relaxation; severe AR, immediate post-commissurotomy and calcific MS can undermine accuracy. Continuity equation is limited by AF and significant MR/AR.
  • Mean gradient and PA pressure are supportive, not substitutes for valve area.
Limits and what this source leaves unreviewed
  • Recorded original. Official ASE page directs CURRENT MS staging to 2023 RHD and 2020 ACC/AHA, not the historical 2009 grading table. Corrigenda exist in 2009 and 2023; contents must be checked before certifying all formulas/tables.

Recorded with the episode

2021 ESC/EACTS Guidelines for the management of valvular heart disease

Alec Vahanian, Friedhelm Beyersdorf

2021

DOI 10.1093/eurheartj/ehab395

Open source at doi.org

Link check recorded

Recorded as supporting
  • Clinically significant rheumatic MS uses MVA ≤1.5 cm²; 2D planimetry is reference and gradient/PA pressure reflect consequences.
  • The five rendered ESC 2021 commissurotomy/surgery recommendation rows and classes/LOE match the primary recommendation table.
  • Concomitant tricuspid repair annular thresholds apply in valve-surgery/TR context, not as an isolated-annulus indication.
Limits and what this source leaves unreviewed
  • Recorded source across the series, not proof that every anaesthetic/peri-bypass claim comes from this guideline. 2025 update must be distinguished.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

2025 ESC/EACTS Guidelines for the management of valvular heart disease

ESC/EACTS Task Force

2025

DOI 10.1093/eurheartj/ehaf194

Open source at doi.org

Link check recorded

Recorded as supporting
  • Current MS recommendation Table 8 retains principal rheumatic PMC rows with class/LOE; favourable anatomy/clinical selection and contraindications remain essential.
  • With left-sided valve surgery: severe TR concomitant surgery I B; moderate TR repair IIa B; selected mild secondary TR with annulus ≥40 mm or >21 mm/m² repair IIb B.
Limits and what this source leaves unreviewed
  • Current supporting comparison only, not original 2026 post citation. Exact individual patient selection and entire guideline not signed off.

Supporting literature checked separately. Not the episode’s recorded source.

Recommendations for the Use of Echocardiography in the Evaluation of Rheumatic Heart Disease: A Report from the American Society of Echocardiography

Natesa G. Pandian, Jin Kyung Kim

2023

DOI 10.1016/j.echo.2022.10.009

Open source at asecho.org

Link check recorded

Recorded as supporting
  • Current Table1 severe rheumatic MS uses MVA≤1.5cm²; planimetry at leaflet tips preferred, with 3D multiplanar guidance improving accuracy/reproducibility.
  • PHT can be distorted by compliance/relaxation, AR, MR or immediate post-PBMV state; significant MR/AR limit the LVOT continuity method. PISA/continuity are not recommended routinely due to complexity/errors.
Limits and what this source leaves unreviewed
  • Supporting primary update, not a recorded original series citation.
  • Use only the explicitly mapped sections: this document contains the older mPAP ≥25 mmHg definition; do NOT use that threshold instead of current ESC/ERS >20 mmHg.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Recorded series-wide source header: ESC/EACTS2021VHD;ACC/AHA2020VHD;EAE/ASE2009stenosis(Baumgartner);ASE2009prostheticvalves. Global header is not proof that each claim originated in each document.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Mitral Stenosis 2/5: Grading Severity on Echo

MS part 2: grading on echo. By EAE/ASE 2009, severe MS has an MVA below 1.0 cm², a mean gradient over 10 mmHg and PA systolic pressure over 50 mmHg, but the gradient is only supportive because it rises with heart rate and flow. ESC 2021 and ACC/AHA 2020 treat an MVA of 1.5 cm² or less as clinically significant. Planimetry at the leaflet tips is the reference method; pressure half-time (220/PHT) fails after PTMC and with AR, ASD or a stiff LV, and the continuity equation fails with significant MR or AR.

Save this for your exam 📌

Next, Part 3/5: Intervention Criteria (ESC 2021 + ACC/AHA 2020) (coming up in the next post).

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #MitralStenosis #Echocardiography #TEE #ValvularHeartDisease #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 22 in this tracked set.

Postiz publish time (4 November 2026, 11:47 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Mitral Stenosis 1/5: Aetiology and Pathophysiology

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Mitral Stenosis 1/5: Aetiology and Pathophysiology — claim-level review remains incomplete; see checks and limitations.

Review scope

Exact full script/spec plus original caption and dense decoded sampling; every identified main teaching panel compared, not a claim of exhaustive media review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Audio reviewed: no
  • Native upload identity verified: no

Remaining priority: Original rare-cause/physiology provenance and fixed-orifice/flow assumptions for the square-of-flow relation.

Still unreviewed

  • Square-of-flow statement requires its fixed-orifice/haemodynamic assumptions and exact source.
  • Exact original provenance for every rare-cause/physiology sentence remains unestablished.

Checks recorded in this pass

These checks do not clear the post.

  • Rheumatic versus calcific anatomy and rare inflammatory/carcinoid/drug causes: supported
  • MVA≤1.5 clinically important; LA/AF/PH/RV consequences: qualified
  • NormalMVA4–6; preservedLV/underfilling; all precipitant mechanisms and square-of-flow statement: unresolved

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — Rheumatic versus calcific anatomy and rare inflammatory/carcinoid/drug causes

Primary2009MSanatomy section explicitly describes these mechanisms and rare causes.

qualified — MVA≤1.5 clinically important; LA/AF/PH/RV consequences

Primary2021/2025MSsections support area/severity/consequence relationship; not every patient follows an inevitable sequence.

qualified — NormalMVA4–6; preservedLV; precipitant physiology and square-of-flow statement

ASE2023 explicitly supports adult4–6cm², generally normalLV with exceptions, and listed high-flow/HR precipitants. Square-of-flow relation and complete original attribution remain unresolved.

supported — Additional exact ASE2023 section mapping

Relevant primary sections IV.A, V.B–D read; support limited to reference supportedClaims.

Qualifications on the reviewed points

  • A normal LV is not guaranteed: coexisting myocardial/valvular/coronary disease and altered loading may cause dysfunction.
  • Gradient roughly follows flow² only with relevant fixed effective area and haemodynamic assumptions; HR/diastolic filling time also matter.

References recorded with the episode

Recorded with the episode

Echocardiographic Assessment of Valve Stenosis: EAE/ASE Recommendations for Clinical Practice

Helmut Baumgartner, Judy Hung, Javier Bermejo

2009

DOI 10.1016/j.echo.2008.11.029

Open source at asecho.org

Link check recorded

Recorded as supporting
  • Rheumatic commissural fusion/chordal shortening differ from degenerative annular calcification; other inflammatory/carcinoid/drug causes are described.
  • PHT depends on gradient, combined LA/LV compliance and relaxation; severe AR, immediate post-commissurotomy and calcific MS can undermine accuracy. Continuity equation is limited by AF and significant MR/AR.
  • Mean gradient and PA pressure are supportive, not substitutes for valve area.
Limits and what this source leaves unreviewed
  • Recorded original. Official ASE page directs CURRENT MS staging to 2023 RHD and 2020 ACC/AHA, not the historical 2009 grading table. Corrigenda exist in 2009 and 2023; contents must be checked before certifying all formulas/tables.

Recorded with the episode

2021 ESC/EACTS Guidelines for the management of valvular heart disease

Alec Vahanian, Friedhelm Beyersdorf

2021

DOI 10.1093/eurheartj/ehab395

Open source at doi.org

Link check recorded

Recorded as supporting
  • Clinically significant rheumatic MS uses MVA ≤1.5 cm²; 2D planimetry is reference and gradient/PA pressure reflect consequences.
  • The five rendered ESC 2021 commissurotomy/surgery recommendation rows and classes/LOE match the primary recommendation table.
  • Concomitant tricuspid repair annular thresholds apply in valve-surgery/TR context, not as an isolated-annulus indication.
Limits and what this source leaves unreviewed
  • Recorded source across the series, not proof that every anaesthetic/peri-bypass claim comes from this guideline. 2025 update must be distinguished.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

2025 ESC/EACTS Guidelines for the management of valvular heart disease

ESC/EACTS Task Force

2025

DOI 10.1093/eurheartj/ehaf194

Open source at doi.org

Link check recorded

Recorded as supporting
  • Current MS recommendation Table 8 retains principal rheumatic PMC rows with class/LOE; favourable anatomy/clinical selection and contraindications remain essential.
  • With left-sided valve surgery: severe TR concomitant surgery I B; moderate TR repair IIa B; selected mild secondary TR with annulus ≥40 mm or >21 mm/m² repair IIb B.
Limits and what this source leaves unreviewed
  • Current supporting comparison only, not original 2026 post citation. Exact individual patient selection and entire guideline not signed off.

Supporting literature checked separately. Not the episode’s recorded source.

Recommendations for the Use of Echocardiography in the Evaluation of Rheumatic Heart Disease: A Report from the American Society of Echocardiography

Natesa G. Pandian, Jin Kyung Kim

2023

DOI 10.1016/j.echo.2022.10.009

Open source at asecho.org

Link check recorded

Recorded as supporting
  • Normal adult MVA4–6cm² is explicitly stated. Rheumatic disease is the most common global MS cause.
  • Exercise, fever, pregnancy, hyperthyroidism, anaemia and atrial tachyarrhythmia raise transmitral flow/pressure; significant PH can cause RV/RA enlargement/dysfunction and functional TR. LV systolic/diastolic function generally normal but myocardial/coexistent disease can impair it.
Limits and what this source leaves unreviewed
  • Supporting primary update, not a recorded original series citation.
  • Use only the explicitly mapped sections: this document contains the older mPAP ≥25 mmHg definition; do NOT use that threshold instead of current ESC/ERS >20 mmHg.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Recorded series-wide source header: ESC/EACTS2021VHD;ACC/AHA2020VHD;EAE/ASE2009stenosis(Baumgartner);ASE2009prostheticvalves. Global header is not proof that each claim originated in each document.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Mitral Stenosis 1/5: Aetiology and Pathophysiology

New valve series: Mitral Stenosis, part 1. Rheumatic disease is the commonest cause worldwide (commissural fusion, thickened leaflets, fused chords); mitral annular calcification causes degenerative MS in the elderly. Normal MVA is 4–6 cm², and MS becomes clinically significant at 1.5 cm² or less. The fixed obstruction raises LA pressure, leading to LA dilatation, AF, LAA thrombus, pulmonary hypertension and finally RV failure, while the LV itself is usually normal and just underfilled. Tachycardia, fast AF, pregnancy, fever and exercise all raise the gradient and can tip a patient into pulmonary oedema.

Save this for your exam 📌

Next, Part 2/5: Grading MS Severity on Echo (coming up in the next post).

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #MitralStenosis #RheumaticHeartDisease #ValvularHeartDisease #Cardiology #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 23 in this tracked set.

Postiz publish time (4 November 2026, 07:38 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Perioperative Beta-Blockers: Continue, Don’t Start

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Perioperative Beta-Blockers: Continue, Don’t Start. Selected claim-source mappings checked; remaining claims and full media review are unresolved.

Review scope

Original caption plus three decoded rendered frames and exact recorded body where recoverable. No full-frame-sequence/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Native upload identity verified: no

Remaining priority: Abrupt-withdrawal evidence, hold/reduce thresholds, causal mediation and full later AF/cardiac-surgery update comparison.

Still unreviewed

  • Exact evidence for abrupt-withdrawal wording, hold/reduce thresholds and causal mediation claim.
  • Complete update comparison with later AF and cardiac-surgery guidelines.

Checks recorded in this pass

These checks do not clear the post.

  • Trial outcome direction and guideline scope checked.

Qualifications on the reviewed points

  • The headline “Don’t Start” must be read as “do not start routinely immediately before surgery”; selected planned initiation differs.
  • Continuation is conditional on haemodynamic tolerance; hypotension/bradycardia/shock need individualisation.

References recorded with the episode

Recorded with the episode

2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery

Halvorsen S et al.

2022

DOI 10.1093/eurheartj/ehac270

Open source at academic.oup.com

Link check recorded

Recorded as supporting
  • Continue established beta-blocker treatment perioperatively; routine perioperative initiation is not recommended.
  • Initiation can be considered for selected patients with CAD/ischaemia; not a ban on every planned preoperative initiation.
Limits and what this source leaves unreviewed
  • Non-cardiac surgery scope; not automatic dosing advice for unstable cardiac-surgery patients.

Recorded with the episode

Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial

POISE Study Group

2008

DOI 10.1016/S0140-6736(08)60601-7

Open source at thelancet.com

Link check recorded

Recorded as supporting
  • Trial found fewer MIs but more deaths and strokes with its perioperative extended-release metoprolol regimen.
Limits and what this source leaves unreviewed
  • Specific high-dose regimen; does not establish that all beta-blocker initiation causes those outcomes. Exact mediation analysis for hypotension/bradycardia not independently reviewed.

Recorded with the episode

2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with EACTS

Hindricks G et al.

2021

DOI 10.1093/eurheartj/ehaa612

Open source at doi.org

Link check recorded

Recorded as supporting
  • Perioperative amiodarone or beta-blocker therapy for prevention of postoperative AF after cardiac surgery has Class I, Level A recommendation in this edition.
Limits and what this source leaves unreviewed
  • Guideline named 2020, journal publication 2021; historical edition, not a check of all subsequent AF guidelines.

Supporting literature checked separately

None recorded in this review.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Perioperative Beta-Blockers: Continue, Don’t Start

Perioperative beta-blockers: continue them in patients already taking them (ESC 2022, Class I), but don't start them routinely just before surgery (Class III). POISE showed that metoprolol started on the day of non-cardiac surgery cut MIs but increased strokes and deaths, driven by hypotension and bradycardia. After cardiac surgery, peri-operative beta-blockers reduce post-op AF (ESC 2020, Class I).

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #BetaBlockers #POISE #PerioperativeMedicine #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 24 in this tracked set.

Postiz publish time (4 November 2026, 00:09 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Endocarditis Prophylaxis: Who Needs It?

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Endocarditis Prophylaxis: Who Needs It?. Safety/accuracy corrections are required; see the correction and qualifications.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Guideline version difference

The cited edition and a later or other edition differ.

Reviewed wording

Not needed for TEE, bronchoscopy, GI or GU procedures without infection.

First-pass proposal

For AHA guidance, IE prophylaxis is not routinely recommended for non-dental procedures without active infection. ESC 2023 permits considering systemic prophylaxis for selected invasive non-dental procedures in high-risk patients (Class IIb). Name the guideline and individualise; do not state a universal prohibition.

Independent review wording

High-risk patients: non-dental prophylaxis may be considered (ESC 2023, IIb C).

Review scope

Original caption plus three decoded rendered frames and exact recorded body where recoverable. No full-frame-sequence/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Native upload identity verified: no

Remaining priority: All high-risk categories, repaired CHD/LVAD/transplant context, severe allergy choices and pediatric dose maxima.

Still unreviewed

  • Complete high-risk category comparison (including CHD repaired with material, LVAD and transplant valvulopathy).
  • Full allergy/severe-penicillin-reaction choices and exact pediatric maximum doses.

Checks recorded in this pass

These checks do not clear the post.

  • Amoxicillin adult/pediatric dose and timing checked.
  • Direct society-guideline conflict identified in rendered wording.

Qualifications on the reviewed points

  • Identify the society/edition and procedure; ESC 2023 and AHA differ for selected non-dental procedures.
  • Alternative antibiotic doses in this reel are adult doses; children need weight-based dosing and limits.
  • Transplant valvulopathy and precise residual-defect definitions must not be omitted from a purported exhaustive AHA list.

References recorded with the episode

Recorded with the episode

2023 ESC Guidelines for the management of endocarditis

Delgado V et al.

2023

DOI 10.1093/eurheartj/ehad193

Open source at academic.oup.com

Link check recorded

Recorded as supporting
  • High-risk patients: systemic prophylaxis may be considered for selected invasive respiratory, GI, GU, skin or musculoskeletal procedures (Class IIb).
Limits and what this source leaves unreviewed
  • Recorded ESC 2023 attribution exists in rendered text; full high-risk category and dosing tables still need direct review.
  • This differs from the AHA non-dental recommendation; do not collapse them into a universal rule.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Prevention of Infective Endocarditis wallet card

American Heart Association

Year not recorded

DOI not recorded

Open source at heart.org

Link check recorded

Recorded as supporting
  • Dental prophylaxis: amoxicillin adult 2 g, child 50 mg/kg; single dose 30–60 min before.
  • Adult azithromycin/clarithromycin 500 mg or doxycycline 100 mg are alternatives; pediatric alternatives have separate weight-based doses.
  • AHA does not recommend prophylaxis solely to prevent IE for routine non-dental procedures absent active infection.
Limits and what this source leaves unreviewed
  • Official Spanish wallet-card indexed text checked; no original AHA edition recorded, so supporting-only provenance.
  • Do not substitute outdated wallet cards still listing clindamycin.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Endocarditis Prophylaxis: Who Needs It?

Endocarditis prophylaxis is limited to high-risk patients (prosthetic valves or repair material, TAVI, previous IE, cyanotic congenital disease and the first 6 months after repair with material; ESC 2023 adds LVADs and pulmonary valve implants) having dental work that manipulates the gingiva or root apex. Give amoxicillin 2 g 30-60 minutes before. It is not needed for TEE or routine GI and GU procedures.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #Endocarditis #Antibiotics #ESCGuidelines #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 25 in this tracked set.

Postiz publish time (3 November 2026, 20:08 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Prostaglandin E1 for Duct-Dependent Lesions

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Prostaglandin E1 for Duct-Dependent Lesions: claim-level review remains incomplete; see qualifications, source limitations and unresolved claims.

Review scope

Video decoded at 2-second intervals; contact sheet and each distinct sampled teaching panel read against recovered source. No full continuous video/audio review; transient overlays or unsampled material may remain.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Lesion-by-lesion duct dependence, TGA/atrial-septostomy caveats, dose selection and full neonatal titration/monitoring exceptions.

Still unreviewed

  • Authoritative lesion-by-lesion anatomy/duct-dependence and TGA atrial-septostomy caveats.
  • Exact original source not recorded; full dose-selection/titration/monitoring algorithm and all neonatal exceptions.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — PGE1 start0.05–0.1µg/kg/min thenlowest effective

Actual Pfizer2026 dosage and units match.

qualified — Apnoea about1in10; other short/long-infusion toxicities

Label supports10–12% and adverse effects; highest risk<2kg and firsthour, with immediate ventilation capability and prolonged monitoring.

unresolved — Every duct-dependent lesion, TGA mixing and continue-until-intervention

Label is a bridge indication, not full congenital lesion classification or unconditional continuation algorithm.

Qualifications on the reviewed points

  • Specialist neonatal/cardiology bridge therapy, with continuous monitoring and immediately available ventilation.
  • Duct dependence varies with anatomy; PGE1 does not replace urgent definitive assessment/intervention. Continuation is specialist-directed, not unconditional.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

PROSTIN VR PEDIATRIC (alprostadil): prescribing information, revised April 2026

Pfizer

2026

DOI not recorded

Open source at labeling.pfizer.com

Link check recorded

Recorded as supporting
  • Initial continuous IV infusion 0.05–0.1 µg/kg/min, then lowest effective response-based dose.
  • Apnoea about 10–12%, especially infants <2 kg and usually first hour: continuously monitor and have ventilatory assistance immediately available.
  • Fever, flushing, hypotension, bradycardia, seizures, cortical proliferation and prolonged-infusion gastric obstruction are described.
Limits and what this source leaves unreviewed
  • No exact original citation recorded. Label supports palliation until corrective surgery, not a universal lesion list or unconditional continue-until-surgery instruction. Monitor prolonged therapy, particularly beyond 120 hours.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Prostaglandin E1 for Duct-Dependent Lesions

Prostaglandin E1 (alprostadil) keeps the ductus arteriosus open in duct-dependent lesions: systemic (HLHS, critical AS, critical coarctation, interrupted arch), pulmonary (pulmonary atresia, critical PS, tricuspid atresia, severe TOF) and mixing (TGA with intact septum). Start 0.05–0.1 mcg/kg/min if the duct is closing, then titrate to the lowest effective dose. Apnoea occurs in about 1 in 10 neonates, so be ready to ventilate.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #CongenitalHeartDisease #PaediatricCardiac #Prostaglandin #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 26 in this tracked set.

Postiz publish time (3 November 2026, 16:49 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

CHA2DS2-VASc and HAS-BLED Scores

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

CHA2DS2-VASc and HAS-BLED Scores: claim-level review remains incomplete; see qualifications, source limitations and unresolved claims.

Review scope

Video decoded at 2-second intervals; contact sheet and each distinct sampled teaching panel read against recovered source. No full continuous video/audio review; transient overlays or unsampled material may remain.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Every score component/sex-age boundary, stroke/bleeding interpretation, guideline version and anticoagulation-decision exclusions.

Still unreviewed

  • Full exact original score provenance, version-specific HAS-BLED definitions and full ESC2024 primary table.
  • AF population exclusions, mechanical valve/rheumatic MS and perioperative drug/bleeding context.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — CHA2DS2VASc component points

Full primary Table8 compared; ≥75 and65–74 are mutually exclusive age bands.

qualified — Anticoagulate≥2men/≥3women; consider1/2

Primary recommendations frame these as examples of annual-risk thresholds; shared decision-making and context remain necessary.

supported — HAS-BLED≥3 not standalone denial

Primary guideline cautions against isolated bleeding-score withholding.

unresolved — All HAS-BLED subdefinitions including age>65, renal/liver cutoffs and alcohol; ESC2024VA substitution

2023US guideline says≥65, recorded post>65; must resolve named score/version, not manufacture universal error. Full ESC2024 source not read.

Qualifications on the reviewed points

  • These scores guide assessment, not automatic perioperative anticoagulant dosing. Female sex is a modifier in CHA2DS2VASc; ESC2024 uses a different sex-free framework.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation

José A. Joglar, Mina K. Chung

2024

DOI 10.1016/j.jacc.2023.08.017

Open source at pmc.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Table 8 supports CHA2DS2-VASc component points; ages 65–74 and ≥75 are alternative age bands, not additive.
  • Anticoagulation recommended at estimated annual thromboembolic risk ≥2% (e.g. score ≥2 men/≥3 women); reasonable at 1–2% (e.g. 1 men/2 women).
  • Bleeding scores must not be used in isolation to deny anticoagulation; assess/modify risk.
Limits and what this source leaves unreviewed
  • Supporting source: not explicitly recorded. The 2023 guideline was published in 2024. Its HAS-BLED description uses age ≥65; recorded post uses >65, which requires version-specific reconciliation rather than an invented universal correction. ESC2024 full primary recommendations have not been checked here.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

CHA2DS2-VASc and HAS-BLED Scores

CHA2DS2-VASc scores stroke risk in AF: CHF 1, hypertension 1, age 75 or over 2, diabetes 1, stroke/TIA/thromboembolism 2, vascular disease 1, age 65–74 1, female sex 1. Anticoagulate at 2 or more in men and 3 or more in women (consider at 1 and 2). ESC 2024 drops the sex point (CHA2DS2-VA). HAS-BLED 3 or more flags high bleeding risk: fix the modifiable factors and review more often, but don't withhold anticoagulation on the score alone.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #AtrialFibrillation #Anticoagulation #CHA2DS2VASc #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 27 in this tracked set.

Postiz publish time (3 November 2026, 14:13 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

The Bypass Circuit: Every Component (infographic)

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

The Bypass Circuit: Every Component (infographic): claim-level review remains incomplete; see qualifications, source limitations and unresolved claims.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Missing qualifier

The point needs a qualifier. The independent wording is below.

Reviewed wording

Air at ANY step means STOP the pump, clamp the arterial line and de-air

First-pass proposal

Suspected arterial air embolism is a perfusion emergency requiring the team’s specific emergency protocol. Response depends on air location, amount and circulation state; do not treat normal reservoir gas or every venous-line bubble as the same arterial-embolism event. This schematic is not an emergency algorithm.

Independent review wording

Arterial-line air / massive air embolism: stop pump, clamp, de-air.

Review scope

Video decoded at 2-second intervals; contact sheet and each distinct sampled teaching panel read against recovered source. No full continuous video/audio review; transient overlays or unsampled material may remain.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: All ten component descriptions, gas/sweep/ultrafiltration physiology, circuit arrows and location-specific perfusion-emergency protocol.

Still unreviewed

  • All10component bullets, membrane gas/sweep physiology, ultrafiltration and diagram tubing/flow arrows.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — Safety devices and suction/protamine precaution

Original safety text and current recommendation passages support listed devices and stopping cardiotomy suction when protamine starts.

correction-needed — Air atANYstep meansSTOPpump,clamp arterialline

Current primary guideline explicitly makes air-embolism treatment dependent on situation/amount; a universal ANYstep rule lacks location/context.

unresolved — All ten component descriptions, gas/sweep physiology, ultrafiltration and circuit arrows

Temperature subset is resolved separately against the exact recorded 2015 primary guideline; complete circuit-system and emergency-protocol review remains open.

qualified — Original 2015 temperature limits and measurement sites

Full primary recommendations and Table 4 read: outlet <37°C; cooling/rewarming gradient ≤10°C; for arterial outlet ≥30°C, gradient ≤4°C and rate ≤0.5°C/min are reasonable. Card values agree in scope but its above-30 wording/omitted rate are abbreviated.

Qualifications on the reviewed points

  • Schematic is not a perfusion crisis protocol. Reservoir gas, venous-line air and arterial embolism are different situations; use trained team and local emergency checklist.
  • Temperature limits refer to oxygenator arterial outlet and venous inflow, not heater-water versus patient-core difference. Original 2015 guidance uses arterial outlet ≥30°C for the ≤4°C/≤0.5°C/min rewarming recommendations.

References recorded with the episode

Recorded with the episode

2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery

Alexander Wahba, Gudrun Kunst, Filip De Somer

2020

DOI 10.1093/ejcts/ezz267

Open source at pmc.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Dedicated safety equipment includes level/bubble detectors, arterial-line filter, pressure transducer, one-way vent valve and backup systems.
  • Primary sections describe CPB component technologies and safety limitations.
Limits and what this source leaves unreviewed
  • Recorded original title/authorship. Full open text retrieved, but all diagram arrows, component bullets and temperature recommendation tables have not been signed off. Title year 2019 differs from journal volume year 2020.

Recorded with the episode

STS/SCA/AmSECT Clinical Practice Guidelines for Cardiopulmonary Bypass—Temperature Management During Cardiopulmonary Bypass

Engelman R, Baker RA, Likosky DS, Grigore A, Dickinson TA, Shore-Lesserson L, Hammon JW

2015

DOI 10.1016/j.athoracsur.2015.03.126

Open source at sts.org

Link check recorded

Recorded as supporting
  • Arterial oxygenator outlet temperature <37°C; arterial-outlet minus venous-inflow temperature gradient ≤10°C during cooling and rewarming.
  • At arterial outlet temperature ≥30°C, gradient ≤4°C and rewarming rate ≤0.5°C/min are reasonable (IIa B).
  • At arterial outlet temperature <30°C, maximum gradient 10°C is reasonable (IIa C).
  • Arterial outlet temperature can underestimate cerebral perfusate temperature during warming; no single optimal temperature for bypass separation is recommended.
Limits and what this source leaves unreviewed
  • Exact original is explicitly named in recovered infographic footer. Measurement sites and the ≥30°C condition matter.
  • The compact card omits the rewarming-rate recommendation and says above 30°C; qualify the boundary rather than treating the schematic as the complete guideline.
  • This source does not validate every circuit component, flow arrow or air-emergency action.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

2024 EACTS/EACTAIC/EBCP Guidelines on cardiopulmonary bypass in adult cardiac surgery

EACTS/EACTAIC/EBCP Task Force

2025

DOI 10.1093/ejcts/ezae354

Open source at iperfusion.org

Link check recorded

Recorded as supporting
  • Maximum arterial outlet temperature 37°C; cardiotomy suction should stop when protamine starts.
  • Air-embolism treatment depends on the situation and amount of air entering the vasculature; crisis checklists/team preparedness matter.
Limits and what this source leaves unreviewed
  • Current supporting update, not the original recorded2019 source. Full primary publisher PDF read through public perfusion-society mirror. Does not certify every temperature-gradient, gas-flow or circuit-layout statement.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Recorded visual footer: Sources: Wahba A et al. 2019 EACTS/EACTA/EBCP guidelines on CPB in adults, EJCTS 2020;57:210–51; temperature limits: Engelman R et al. STS/SCA/AmSECT guideline, Ann Thorac Surg 2015;100:748–57. Schematic, not to scale. Attribution only; not complete claim verification.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Every part of the bypass circuit on one page 👇 venous cannula to reservoir, pump, oxygenator, arterial filter and back to the aorta, plus vent, suckers, cardioplegia, gas blender and heater–cooler, with the one exam point that matters for each.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #CardiopulmonaryBypass #CPB #Perfusion #CardiacSurgery #Oxygenator #DMCardiacAnaesthesia #Anaesthesiology #ExamPrep #MedEd #FOAMed #Viva

Sequence 28 in this tracked set.

Postiz publish time (3 November 2026, 11:11 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Cardiac Action Potential: Every Phase (infographic)

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Cardiac Action Potential: Every Phase (infographic): claim-level review remains incomplete; see qualifications, source limitations and unresolved claims.

Review scope

Video decoded at 2-second intervals; contact sheet and each distinct sampled teaching panel read against recovered source. No full continuous video/audio review; transient overlays or unsampled material may remain.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Every action-potential ion/phase/drug/refractory/ECG mapping and nodal-versus-ventricular exceptions against exact originals.

Still unreviewed

  • Exact textbook pages and phase-by-phase schematic/voltage/refractory endpoint review.
  • Every ECG mapping, tissue-specific Brugada/hyperkalaemia statement and beta-blocker/nodal-drug nuance.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — Phases, principal currents, classI/III/IV and ivabradine mechanism

Full original Figure1 and drug sections support broad mechanisms. Drug actions are multichannel/context-dependent, not one-to-one clinical prescriptions.

unresolved — All typical voltages, fixedARPto−50mV, Brugada notch, hyperkalaemia and ECG phase mapping

Recorded Guyton14ed chapters9–10 not obtained at exact pages. Original review does not alone certify each diagram coordinate or categorical link.

Qualifications on the reviewed points

  • Illustrative single-cell traces are not a surface ECG or universal voltages/times. Refractoriness depends on channel recovery, tissue and conditions, not one universal voltage cutoff.

References recorded with the episode

Recorded with the episode

Modernized Classification of Cardiac Antiarrhythmic Drugs

Ming Lei, Lin Wu, David A. Terrar, Christopher L.-H. Huang

2018

DOI 10.1161/CIRCULATIONAHA.118.035455

Open source at ora.ox.ac.uk

Link check recorded

Recorded as supporting
  • Figure1 describes phases0–4 and inward Na/Ca and outward K currents; IK1 contributes to late repolarization and stable diastolic resting potential.
  • Na-channel block reduces phase0 slope; HCN/If inhibition by ivabradine reduces sinus-node phase4 depolarization rate.
  • L-type calcium current contributes to plateau/excitation-contraction coupling; classIII K-current blockers and classIV calcium handling are described.
Limits and what this source leaves unreviewed
  • Exact original citation recorded in visual footer; full University of Oxford author-deposited paper retrieved. Supporting passages do not validate every schematic voltage, ECG mapping, Brugada statement or absolute-refractory endpoint. Guyton/Hall14th chapters9–10 are recorded but exact textbook pages not obtained.

Supporting literature checked separately

None recorded in this review.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Recorded visual footer: Sources: Guyton & Hall Textbook of Medical Physiology, 14th ed., ch. 9–10; Lei M et al. Modernized classification of cardiac antiarrhythmic drugs, Circulation 2018;138:1879–96. Attribution only; not complete claim verification.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

One waveform, every phase 👇 the ventricular action potential next to the SA node: what happens in phases 0–4, the ion current behind each one, where Class I–IV antiarrhythmics and ivabradine act, the refractory periods and how it all maps onto the ECG.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #ActionPotential #CardiacPhysiology #Antiarrhythmics #ECG #Electrophysiology #DMCardiacAnaesthesia #Anaesthesiology #Cardiology #ExamPrep #MedEd #FOAMed #Viva

Sequence 29 in this tracked set.

Postiz publish time (3 November 2026, 08:14 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Reversing Anticoagulants Before Urgent Surgery

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Reversing Anticoagulants Before Urgent Surgery. Safety/accuracy corrections are required; see the correction and qualifications.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Confirmed error

The independent review confirmed an error against the checked source.

Reviewed wording

Apixaban/rivaroxaban: andexanet alfa, or 4-factor PCC ~50 IU/kg.

First-pass proposal

In cardiac surgery needing heparinised CPB, avoid preoperative andexanet because of heparin resistance/circuit thrombosis risk. Use specialist, drug- and urgency-specific reversal guidance. FDA also reports end of US Andexxa manufacture/sales after 22 December 2025; availability elsewhere differs.

Independent review wording

For cardiac surgery: prefer 4F-PCC (~50 U/kg); avoid andexanet before CPB (heparin resistance); Andexxa withdrawn from US market Dec 2025.

Rejected proposal

This proposal was rejected. It is not a confirmed error.

Reviewed wording

UFH: protamine 1 mg per 100 units.

First-pass proposal

Estimate protamine from heparin remaining in circulation, elapsed time and coagulation testing, not blindly from all prior heparin; administer slowly under specialist monitoring.

Independent review wording

Optional: reduce dose with time since heparin; give slowly, ≤50 mg per dose.

Review scope

Original caption plus three decoded rendered frames and exact recorded body where recoverable. No full-frame-sequence/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Native upload identity verified: no

Remaining priority: Original FFP/vitamin-K ranges/time course, product-specific off-label PCC, renal/dialysis details and local reversal/CPB policy.

Still unreviewed

  • Original sources for FFP 15–20 mL/kg, vitamin K 5–10 mg and 6–12 h effect.
  • Exact off-label PCC regimen for anti-Xa DOAC urgent surgery, renal/dialysis details and local 2026 policy.

Checks recorded in this pass

These checks do not clear the post.

  • Six distinct reversal-source checks; critical CPB-specific hazard identified.
  • No direct validation of every table dose or every clinical scenario.

Qualifications on the reviewed points

  • Do not use andexanet as an interchangeable pre-CPB reversal choice; it may prevent effective heparinisation.
  • Dabigatran idarucizumab dose is 5 g, not 5 mg.
  • PCC is dosed in product-specific units; balance thrombotic risk and residual drug activity.
  • Protamine depends on recent heparin exposure and monitoring; rapid administration can be dangerous.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

2024 EACTS Guidelines on perioperative medication in adult cardiac surgery

EACTS guideline task force

2024

DOI 10.1093/ejcts/ezae355

Open source at academic.oup.com

Link check recorded

Recorded as supporting
  • Idarucizumab 5 g IV reverses dabigatran for emergency procedures.
  • Andexanet should be avoided before heparinised CPB because of heparin resistance risk.
Limits and what this source leaves unreviewed
  • Supporting guideline checked now; no exact original reversal source recorded.
  • Current jurisdictional availability/safety must also be checked.

Supporting literature checked separately. Not the episode’s recorded source.

Update on the Safety of Andexxa — FDA Safety Communication, December 18, 2025

US Food and Drug Administration

2025

DOI not recorded

Open source at fda.gov

Link check recorded

Recorded as supporting
  • FDA considers serious risks to outweigh benefits; company confirmed end of US sales and manufacture for US market after 22 December 2025.
Limits and what this source leaves unreviewed
  • US-specific; do not generalise market withdrawal to every country.
  • This safety update was not an original source of the reel.

Supporting literature checked separately. Not the episode’s recorded source.

KCENTRA prescribing information

CSL Behring

Year not recorded

DOI not recorded

Open source at dailymed.nlm.nih.gov

Link check recorded

Recorded as supporting
  • VKA urgent reversal: INR 2–<4:25 IU/kg; INR 4–6:35 IU/kg; INR >6:50 IU/kg, with maxima 2500/3500/5000 IU; administer vitamin K concurrently.
Limits and what this source leaves unreviewed
  • Product-specific Factor IX unit dosing, weight capped at 100 kg; not a general endorsement of PCC for all anticoagulants.
  • Vitamin K dose is not specified by this label.

Supporting literature checked separately. Not the episode’s recorded source.

PRAXBIND prescribing information

Boehringer Ingelheim

Year not recorded

DOI not recorded

Open source at dailymed.nlm.nih.gov

Link check recorded

Recorded as supporting
  • 5 g IV idarucizumab, supplied as two 2.5 g/50 mL vials; dabigatran-specific.
Limits and what this source leaves unreviewed
  • Clinical need and residual anticoagulant effect must be assessed.

Supporting literature checked separately. Not the episode’s recorded source.

Protamine sulfate injection prescribing information

DailyMed US prescribing information

Year not recorded

DOI not recorded

Open source at dailymed.nlm.nih.gov

Link check recorded

Recorded as supporting
  • 1 mg neutralises at least 100 USP heparin units; requirement decreases as heparin clears; give slowly and use coagulation monitoring.
Limits and what this source leaves unreviewed
  • Not a fixed dose for the entire historical heparin exposure; large CPB doses require specialist protocol.

Supporting literature checked separately. Not the episode’s recorded source.

LOVENOX prescribing information — Overdosage

Sanofi

Year not recorded

DOI not recorded

Open source at dailymed.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Protamine incompletely reverses enoxaparin anti-Xa activity (maximum ~60%); dose depends on elapsed time.
Limits and what this source leaves unreviewed
  • Enoxaparin-specific figure; not a universal percentage for every LMWH.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Reversing Anticoagulants Before Urgent Surgery

Reversal before urgent surgery: warfarin needs 4-factor PCC (25-50 IU/kg by INR) plus IV vitamin K 5-10 mg, dabigatran is reversed by idarucizumab 5 g, factor Xa inhibitors by andexanet or about 50 IU/kg PCC, heparin by protamine 1 mg per 100 units, and LMWH only partly by protamine. PCC acts in minutes, vitamin K over 6-12 hours.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #Anticoagulation #Haematology #PatientBloodManagement #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 30 in this tracked set.

Postiz publish time (3 November 2026, 00:44 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

NYHA Class vs ACC/AHA Heart Failure Stage

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

NYHA Class vs ACC/AHA Heart Failure Stage: claim-level review remains incomplete; see qualifications, source limitations and unresolved claims.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Missing qualifier

The point needs a qualifier. The independent wording is below.

Reviewed wording

Stage B: structural heart disease but no symptoms

First-pass proposal

Stage B (pre-HF): no current or prior HF symptoms/signs, but structural disease OR evidence of increased filling pressures OR qualifying persistent cardiac biomarker elevation in an at-risk patient after excluding competing causes. Use the full 2022 definition, not structural disease alone.

Independent review wording

Stage B also includes raised filling pressures or biomarkers without symptoms (2022).

Review scope

Video decoded at 2-second intervals; contact sheet and each distinct sampled teaching panel read against recovered source. No full continuous video/audio review; transient overlays or unsampled material may remain.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Every NYHA class and stage A/C/D definition, current/prior symptoms and stage transitions against full original material.

Still unreviewed

  • ExactNYHAprimarydefinitions/recordedoriginalstillunresolved;StageB/Cprimary2022scopeimprovedinbatch08.
  • Continuousvideo/audioandnativeversionremainunverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

correction-needed — StageB described onlyasstructuraldiseasewithout symptoms

Current issuing-society source includes raised filling pressures and qualifying biomarker elevation, even without overt structural disease.

qualified — StagesC/D and symptom versus stage distinction

Source supports currentORpast symptoms forC and advanced symptoms despitecareforD.

unresolved — Exact NYHAI–IV wording; stagesonlyforward

All rendered panels read; full primary NYHA table and stage-progression/HF-improvedEF text not retrieved.

Qualifications on the reviewed points

  • Symptoms, EF and structure can improve; prior symptomatic HF remains clinically relevant. Do not equate remembered stage with biological impossibility of recovery.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

ACC, AHA, HFSA Issue Heart Failure Guideline: new stages and recommendations

American College of Cardiology, American Heart Association, Heart Failure Society of America

2022

DOI not recorded

Open source at acc.org

Link check recorded

Recorded as supporting
  • StageB pre-HF includes structural disease OR raised filling pressures OR risk factors with persistently elevated troponin/natriuretic peptides without competing explanation.
  • StageC includes current or past symptoms; stageD advanced symptoms despite guideline-directed care.
Limits and what this source leaves unreviewed
  • Official issuing-society explanation, supporting only; not a recorded original source or a full guideline-table audit. Full NYHA definitions and progression wording remain unresolved.

Supporting literature checked separately. Not the episode’s recorded source.

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure — official slide set

Paul A. Heidenreich, Biykem Bozkurt, David Aguilar

2022

DOI 10.1161/CIR.0000000000001063

Open source at professional.heart.org

Link check recorded

Recorded as supporting
  • Table4: HFrEF≤40%; HFimpEF previous≤40% and follow-up>40%; HFmrEF41–49% and HFpEF≥50% require evidence of spontaneous/provokable increased filling pressures. EF categorises established HF, not HF diagnosis by EF alone.
  • Table3: StageB includes structural disease OR increased filling pressures OR qualifying biomarker elevation in at-risk patients; patients with resolved StageC symptoms remain StageC.
  • HFimpEF: continue HFrEF GDMT. HFrEF four medication classes; HFmrEF/HFpEF SGLT2i recommendations also exist.
Limits and what this source leaves unreviewed
  • Newlycheckedprimaryguideline,notrecordedoriginalforindex30. OfficialStageA–D/remissiontextread;completeNYHAdefinitiontablenotfullyretrieved.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

NYHA Class vs ACC/AHA Heart Failure Stage

Two heart failure scales: NYHA I-IV grades current symptoms (I none, II slight limitation, III marked limitation, IV symptoms at rest). ACC/AHA stages A-D describe disease progression, from at-risk (A) and structural disease without symptoms (B) to symptomatic (C) and advanced HF (D). NYHA class can improve with treatment, but stages only move forward.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #HeartFailure #NYHA #Cardiology #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 31 in this tracked set.

Postiz publish time (2 November 2026, 21:57 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Humour: Muscle relaxants ranked by how long they stay at the party

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Humour: Muscle relaxants ranked by how long they stay at the party: claim-level review remains incomplete; see qualifications, source limitations and unresolved claims.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Confirmed error

The independent review confirmed an error against the checked source.

Reviewed wording

Shortest → longest: durations to ~25% twitch recovery (or succinylcholine recovery window)

First-pass proposal

Illustrative label-based windows at specified doses and anaesthetics, not a universal or head-to-head ranking. Atracurium 0.4–0.5 mg/kg: 20–35 min clinical block, but 35–45 min to 25% control recovery. Rocuronium 0.6 mg/kg: median 31 min (range 15–85) to 25% T1 under opioid/N2O/O2. Keep endpoints explicit; do not infer extubation readiness from these times.

Independent review wording

Ranking depends on endpoint: at 25% recovery atracurium (~35–45 min) exceeds rocuronium (~31 min median).

Review scope

All six locally recovered candidate carousel panels read at full size; only cover identity is matched, not independently confirmed full native upload.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Full actual uploaded carousel identity, exact label versions/Canadian monograph, comparative metabolism and current neuromuscular monitoring/reversal.

Still unreviewed

  • Confirm all6candidate carousel panels actually uploaded, not just exact-matched localcover.
  • Resolve exact recorded USlabel versions, Canadian monograph and comparative metabolic/histamine claims; current neuromuscular-monitoring/reversal guidance.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — Five individual duration examples and specified doses

Actual regulatory texts support core values, but atracurium20–35 is not25%T1 recovery (35–45); pancuroniumED95≈22 is measured from maximum effect, not injection.

correction-needed — Universal shortest-to-longest ranking using25%recovery

Ranking mixes endpoints and non-equivalent doses/anaesthetics with wide overlapping ranges. Representative values are not a head-to-head or reliable individual ranking.

unresolved — Cis less histamine/laudanosine; Canadianpanc60–90; sugammadex/current reversal statements

Historical label comparisons not sufficient for every comparative statement; named Canadian monograph and current reversal authority not obtained.

Qualifications on the reviewed points

  • Recovery of25%T1 is not adequate recovery for extubation; elapsed time is not a substitute for appropriate quantitative neuromuscular assessment.
  • Drug dose, anaesthetic, temperature, organ function and patient variability confound duration comparison. This is not an administration/reversal protocol.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

ANECTINE prescribing information

US prescribing information / regulatory label

Year not recorded

DOI not recorded

Open source at dailymed.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Single adult IV administration: onset about1min, maximal block about2min, recovery4–6min; phaseII/repeated administration or reduced plasma cholinesterase may prolong.
Limits and what this source leaves unreviewed
  • Source footer names brands/US labels without exact product/version; this newly retrieved label is supporting, not proven original. Historical FDA labels are explicitly not necessarily current. Does not validate a cross-drug ranking, every comparative histamine/laudanosine assertion or current reversal recommendation.

Supporting literature checked separately. Not the episode’s recorded source.

Atracurium besylate prescribing information

US prescribing information / regulatory label

Year not recorded

DOI not recorded

Open source at dailymed.nlm.nih.gov

Link check recorded

Recorded as supporting
  • 0.4–0.5mg/kg balanced anaesthesia: clinical block20–35min; recovery to25% control35–45min and95%60–70min; isoflurane/enflurane prolong approximately35%.
  • Ester hydrolysis and Hofmann elimination; laudanosine described.
Limits and what this source leaves unreviewed
  • Source footer names brands/US labels without exact product/version; this newly retrieved label is supporting, not proven original. Historical FDA labels are explicitly not necessarily current. Does not validate a cross-drug ranking, every comparative histamine/laudanosine assertion or current reversal recommendation.

Supporting literature checked separately. Not the episode’s recorded source.

Rocuronium bromide prescribing information

US prescribing information / regulatory label

Year not recorded

DOI not recorded

Open source at dailymed.nlm.nih.gov

Link check recorded

Recorded as supporting
  • 0.6mg/kg under opioid/N2O/O2: median clinical relaxation31min, range15–85; clinical duration endpoint return to25% T1.
Limits and what this source leaves unreviewed
  • Source footer names brands/US labels without exact product/version; this newly retrieved label is supporting, not proven original. Historical FDA labels are explicitly not necessarily current. Does not validate a cross-drug ranking, every comparative histamine/laudanosine assertion or current reversal recommendation.

Supporting literature checked separately. Not the episode’s recorded source.

NIMBEX FDA label (historical 2010)

US prescribing information / regulatory label

2010

DOI not recorded

Open source at accessdata.fda.gov

Link check recorded

Recorded as supporting
  • Table1 adult0.15mg/kg opioid/N2O/O2:25% recovery55min(44–74); propofol section also55(44–74).
  • Dose doubling lengthens clinically effective block approximately25min; Hofmann elimination described.
Limits and what this source leaves unreviewed
  • Source footer names brands/US labels without exact product/version; this newly retrieved label is supporting, not proven original. Historical FDA labels are explicitly not necessarily current. Does not validate a cross-drug ranking, every comparative histamine/laudanosine assertion or current reversal recommendation.

Supporting literature checked separately. Not the episode’s recorded source.

PAVULON FDA label (historical 2010)

US prescribing information / regulatory label

2010

DOI not recorded

Open source at accessdata.fda.gov

Link check recorded

Recorded as supporting
  • 0.1mg/kg balanced anaesthesia: injection-to25% recovery about100min.
  • ED95 about0.05mg/kg balanced; maximum-effect-to25% recovery about22min. Repeated doses prolong block; heart rate may rise.
Limits and what this source leaves unreviewed
  • Source footer names brands/US labels without exact product/version; this newly retrieved label is supporting, not proven original. Historical FDA labels are explicitly not necessarily current. Does not validate a cross-drug ranking, every comparative histamine/laudanosine assertion or current reversal recommendation.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Muscle relaxants ranked by how long they stay at the party 🍸🚪

Swipe the guest list — five NMBAs, ranked by clinical duration from FDA labels. The joke never bends the science.

1. Succinylcholine → ~4–6 min (single IV dose recovery window)

2. Atracurium 0.4–0.5 mg/kg → 20–35 min clinical block

3. Rocuronium 0.6 mg/kg → median ~31 min (range 15–85)

4. Cisatracurium 0.15 mg/kg → ~55 min to 25% recovery

5. Pancuronium 0.1 mg/kg → ~100 min to 25% recovery

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #NeuromuscularBlockade #NMBA #Rocuronium #Succinylcholine #Atracurium #Cisatracurium #Pancuronium #Anaesthesiology #DMCardiacAnaesthesia #CriticalCare #MedEd #FOAMed #ExamPrep

Sequence 32 in this tracked set.

Postiz publish time (2 November 2026, 19:18 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Shock Types: Haemodynamic Profiles

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Shock Types: Haemodynamic Profiles: claim-level review remains incomplete; see qualifications, source limitations and unresolved claims.

Review scope

Video decoded at 2-second intervals; contact sheet and each distinct sampled teaching panel read against recovered source. No full continuous video/audio review; transient overlays or unsampled material may remain.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Every shock-profile direction and mixed-shock exception, source provenance and whether numbers are examples rather than diagnostic rules.

Still unreviewed

  • Exact tamponade haemodynamic criteria and all rendered filling-pressure rows/units with measurement conditions.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — Typical shock profiles and SvO2

Primary review supports typical directions and expressly notes mixed aetiologies/concurrent septic cardiac dysfunction may reverse simplified patterns.

unresolved — TamponadeCVP≈PAdiast≈PCWP; all filling-pressure/SVR directions

Full script and both panels compared, but exact pericardial authority and exceptions (lowpressure/loculated/PPV/pre-existingPH) not obtained.

Qualifications on the reviewed points

  • Profiles are teaching patterns, not diagnostic rules or automatic fluid/vasopressor choices. Shock mechanisms may coexist.
  • High SvO2 does not assure adequate tissue oxygenation; low SvO2 may reflect low delivery or increased consumption. ScvO2 is not interchangeable.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Cardiopulmonary Monitoring of Shock

James Simmons, Corey E. Ventetuolo

2017

DOI 10.1097/MCC.0000000000000407

Open source at pmc.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Hypovolaemic/cardiogenic/obstructive shock generally low CO; distributive shock often high CO/low SVR. Mixed causes may coexist.
  • SvO2 often rises in distributive shock but concurrent cardiac dysfunction can lower it; ScvO2 and SvO2 are not necessarily equivalent.
Limits and what this source leaves unreviewed
  • Retrospective supporting review, not original provenance. Does not establish every rendered numerical normal range or tamponade pressure-equalisation exception.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Shock Types: Haemodynamic Profiles

Shock haemodynamics in one table: hypovolaemic (low CO, high SVR, low filling pressures), cardiogenic (low CO, high SVR, high PCWP), distributive (normal or high CO, low SVR) and obstructive (low CO, high CVP). Tamponade equalises the diastolic pressures. SvO2 is low in low-output states and normal or high in distributive shock.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #Shock #Haemodynamics #CriticalCare #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 33 in this tracked set.

Postiz publish time (2 November 2026, 17:03 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

PA Catheter Normal Values

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

PA Catheter Normal Values: claim-level review remains incomplete; see qualifications, source limitations and unresolved claims.

Review scope

Video decoded at 2-second intervals; contact sheet and each distinct sampled teaching panel read against recovered source. No full continuous video/audio review; transient overlays or unsampled material may remain.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: All PA-catheter normal-value conditions, wedge technique/safety, PVR/SVR indexing and population-specific reference ranges.

Still unreviewed

  • Recover exact original adult normal-range source and model-specific IFU; check all values/population/measurement sites.
  • Full balloon inflation/deflation/withdrawal algorithm and overwedging/rupture prevention, end-expiratory/West-zone/mitral/PEEP caveats.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — PAC capabilities, mixedvenous sampling and deflateafterwedge

Manufacturer guide describes capabilities and balloon-deflation step.

qualified — NormalRA2–6,RV15–30/2–8,PA15–30/8–15,PCWP6–12,CI2.5–4,SvO265–75

Retrieved manufacturer source uses different legitimate example ranges, including RAP0–8 and SvO260–80; do not silently certify exact narrow bands or call variation erroneous.

unresolved — SvO2<60 interpretation and full wedge safety/measurement algorithm

All numerical bands and exact population/measurement convention not mapped to original; model-specific IFU and all wedging/withdrawal hazards remain unreviewed.

Qualifications on the reviewed points

  • Educational ranges are not universal normality, treatment thresholds or direct blood-volume measurements.
  • Do not withdraw a catheter with its balloon inflated; follow the specific catheter IFU/local trained procedure. Wedge pressure is not automatically LVEDP or preload responsiveness.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Edwards Lifesciences: hemodynamic monitoring clinical reference guide

Edwards Lifesciences

Year not recorded

DOI not recorded

Open source at edwardsprodjp.blob.core.windows.net

Link check recorded

Recorded as supporting
  • PAC measures right-heart and occlusion pressures, samples mixed venous blood, and measures thermodilution output.
  • Once wedge position identified, deflate balloon; interpret wedge/preload relationships with compliance and clinical context.
  • Normal-range examples vary: this guide uses adult RAP0–8, PA15–30/6–12, wedge4–12 mmHg; SvO2 60–80%.
Limits and what this source leaves unreviewed
  • Supporting manufacturer educational document, not exact recorded original or catheter-model-specific IFU. Its ranges differ from the rendered narrow teaching ranges: this is not proof of error. A 65–75% range elsewhere in this guide concerns jugular oximetry and is NOT evidence for mixed-venous range.

Supporting literature checked separately. Not the episode’s recorded source.

Cardiopulmonary Monitoring of Shock

James Simmons, Corey E. Ventetuolo

2017

DOI 10.1097/MCC.0000000000000407

Open source at pmc.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Hypovolaemic/cardiogenic/obstructive shock generally low CO; distributive shock often high CO/low SVR. Mixed causes may coexist.
  • SvO2 often rises in distributive shock but concurrent cardiac dysfunction can lower it; ScvO2 and SvO2 are not necessarily equivalent.
Limits and what this source leaves unreviewed
  • Retrospective supporting review, not original provenance. Does not establish every rendered numerical normal range or tamponade pressure-equalisation exception.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

PA Catheter Normal Values

Normal PA catheter values: RA 2-6 mmHg, RV 15-30/2-8, PA 15-30/8-15, PCWP 6-12 mmHg, cardiac index 2.5-4.0 L/min/m² and SvO2 65-75%. The step from RV to PA is a rise in diastolic pressure with similar systolic pressure. Wedge only briefly and always deflate before withdrawing.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #PACatheter #Monitoring #Haemodynamics #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 34 in this tracked set.

Postiz publish time (2 November 2026, 13:54 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

RV Systolic Function on Echo: Every Method (infographic)

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

RV Systolic Function on Echo: Every Method (infographic): exact rendered2015table values compared with original guideline; full media and final clinical sign-off remain incomplete.

Review scope

Nine decodedsamples at2-secondintervals andfull-size staticpanel compared with complete source specification; no continuousvideo/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Every RV measurement method, thresholds/units/load dependence, dP/dt/Tei details and contemporary RV guidance.

Still unreviewed

  • Full continuous video/audio and native-upload version remain unreviewed.
  • Exact every schematic leader/anatomical-placement validation is not a substitute for real acquisition training. Entire2025guideline/corrigenda not audited.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — All rendered2015RVnumeric means/SDs/cutoffs and basal/mid dimensions

Each table cell compared against original Tables8/10; values and original strict inequalities match.

qualified — TAPSE/S′site/angle/translation, FACdefinition/trabeculae, RIMPformula/highRAP,3DEFload/window/rhythm

Primary technique sections support; writeFAC%=100×fraction and RIMPdimensionless; annularindices do not measure allRVcomponents.

qualified — PostoperativeTAPSE/S′versusglobalfunction

Original recommends3DEF particularly aftersurgery absentmarkedseptalshift; current2025supportsFACwhenannularindicesunreliable,notautomaticnormality.

qualified — RVdP/dt1→2m/s,12mmHg/time,<400

Exact originalpage700 supports likelyabnormal; timeinseconds (or12000/timeinms),limitednormativedata,severeTR/load limits; currentretains.

qualified — 2015RIMP versuscurrent2025

2015PW>0.43/TDI>0.54 are accuratelyhistorical;2025normalPW<0.40/TDI<0.55. Keepversion/boundaryexplicit.

Qualifications on the reviewed points

  • Do not use any one RVindex alone; clinical context, imagingquality, loading, severeTR and postoperative mechanics matter.
  • RVstrain here is three-segment freewall magnitude,not six-segment globalstrain; vendor/software matters.2015states no definitive universalstrainreference.
  • Current2025RIMPnormalPW<0.40/TDI<0.55 differs from accuratelyrecorded2015values. RIMP is dimensionless,notmilliseconds.
  • RVdP/dt is an adjunct,notroutine;12/time(s)=12000/time(ms). FAC%=100×(EDA−ESA)/EDA.

References recorded with the episode

Recorded with the episode

Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from ASE and EACVI

Roberto M. Lang, Luigi P. Badano, Victor Mor-Avi

2015

DOI 10.1016/j.echo.2014.10.003

Open source at asecho.org

Link check recorded

Recorded as supporting
  • Table8 basal25–41/mid19–35mm; Table10 TAPSE24±3.5mm/<17; pulsedS′14.1±2.3cm/s/<9.5; FAC49±7%/<35; RV freewall strain magnitude29±4.5%/<20;3DEF58±6.5%/<45.
  • Table10 RIMP PW0.26±0.085/>0.43 andTDI0.38±0.08/>0.54.
  • RIMP=(IVCT+IVRT)/ET and highRAP can falselylower it. Include trabeculae inRVcavity forFAC; FAC%=100×(EDA−ESA)/EDA.
  • Post-cardiac-surgery TAPSE/S′ generally reduced and not representative of overallRVperformance;3DEF considered, with load/quality/rhythm/septal-motion limits.
Limits and what this source leaves unreviewed
  • Exact recorded original. Relevant Tables2,4,6,8,9,10, LV mass/geometry, LA volume and RV function sections read. Adult normal cohorts/reference methods; not a universal treatment threshold or all populations.

Recorded with the episode

Guidelines for the Echocardiographic Assessment of the Right Heart in Adults

Lawrence G. Rudski, Wyman W. Lai, Jonathan Afilalo

2010

DOI 10.1016/j.echo.2010.05.010

Open source at asecho.org

Link check recorded

Recorded as supporting
  • Page700: TRvelocity1→2m/s corresponds to12mmHg; divide by time inSECONDS. RVdP/dt<approximately400mmHg/s likelyabnormal.
  • Not recommended routinely because normal data limited; load-dependent and inaccurate with severeTR.
Limits and what this source leaves unreviewed
  • Exact original recorded for dP/dt only. Official archive explicitly marks2010documentSUPERSEDED. Do not use its older TAPSE/S′/dimension thresholds as current.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Guidelines for the Echocardiographic Assessment of the Right Heart in Adults and Special Considerations in Pulmonary Hypertension

Monica Mukherjee, Lawrence G. Rudski

2025

DOI 10.1016/j.echo.2025.01.006

Open source at asecho.org

Link check recorded

Recorded as supporting
  • Current normal TAPSE>1.70cm, S′>9.5cm/s, FAC>35%,3DRVEF>45%; use multiparametric/contextual assessment, including postoperative limitations.
  • Current normal RVMPI<0.40 byPW and<0.55 byTDI, distinct from2015table; MPI isDIMENSIONLESS.
  • Current dP/dt12mmHg divided bytime1→2m/s; <400abnormal but notroutinebecause normative data limited; severeTR/load affect accuracy.
Limits and what this source leaves unreviewed
  • Supporting current comparison, not original attribution. Exact boundary comparators differ from2015. Source prose contains an erroneous ms unit forMPI despite defining dimensionless; do not propagate it. Not a complete2025right-heart algorithm.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Recorded visual footer: Sources: Lang RM et al. ASE/EACVI chamber quantification, JASE 2015;28:1-39 (Tables 8 & 10); RV dP/dt: Rudski LG et al. JASE 2010;23:685-713. Attribution only; not complete claim verification.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

TAPSE is only one way to judge the RV 👇 every echo method for RV systolic function on one page: where each is measured, the ASE/EACVI 2015 normal values and cut-offs, and why TAPSE and S′ mislead after cardiac surgery.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #RVFunction #TAPSE #Echocardiography #TEE #RightHeart #PerioperativeEcho #DMCardiacAnaesthesia #Anaesthesiology #CardiacSurgery #ExamPrep #MedEd #FOAMed

Sequence 35 in this tracked set.

Postiz publish time (2 November 2026, 10:42 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

LV Normals: Men vs Women (infographic)

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

LV Normals: Men vs Women (infographic): exact rendered2015table values compared with original guideline; full media and final clinical sign-off remain incomplete.

Review scope

Nine decodedsamples at2-secondintervals andfull-size staticpanel compared with complete source specification; no continuousvideo/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Every LV table value and indexing/sex convention, measurement technique and whether clinical thresholds differ from reference limits.

Still unreviewed

  • Full continuous video/audio and native-upload version remain unreviewed.
  • Formal diagram-placement assessment and possible guidelinecorrigenda/newer normativecohorts not exhaustively reviewed.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — Allmale/femaleLVdimension,volume,EF,wall,mass,RWT andLAVIcells

Allrenderednumericcells/units compared with fullprimary Tables2/6 andLAvolumesection; matches.

supported — All EFseveritycells

Primary Table4 male/female ranges match bothrenderedrows;these are consensuspartitionvalues,notindividualriskproof.

supported — RWTformulaandthreegeometryclasses

Primary LVmasssectionformulaand>0.42/≤0.42categories match;sameunitsforwall/diameterrequired.

qualified — SchematicPLAXmeasurement/enddiastole andwomen~10%smaller

Primary supports measurementplane/timing. Diagram explicitlyschematic anddrawing-scale noteis not a universalbiological10%difference.

Qualifications on the reviewed points

  • Adult2015noncontrast2Dreferencevalues,notinterchangeablewith3D,CMR orcontrast measurements;methodandbody-size/population context essential.
  • LVmasslinear-method and2Darea-basedmethod have different reference limits. Use thespecifiedmethod andsameunits inRWT.
  • EFseveritypartitions are consensus descriptors,notautomaticinterventionthresholds;ethnicity,body size,loading andimagequality influenceinterpretation.
  • Women drawn~10%smaller is anillustration,notanindividualnormalityrule.

References recorded with the episode

Recorded with the episode

Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from ASE and EACVI

Roberto M. Lang, Luigi P. Badano, Victor Mor-Avi

2015

DOI 10.1016/j.echo.2014.10.003

Open source at asecho.org

Link check recorded

Recorded as supporting
  • Table2 male/female LVIDd42.0–58.4/37.8–52.2mm,LVIDs25.0–39.8/21.6–34.8mm; biplaneEDV62–150/46–106mL,indexed34–74/29–61mL/m²;ESV21–61/14–42mL,indexed11–31/8–24mL/m²;EF52–72/54–74%.
  • Table6 linear-method LVmass88–224/67–162g,index49–115/43–95g/m²; septal/posterior wall0.6–1.0/0.6–0.9cm;RWT0.24–0.42/0.22–0.42.
  • Table4 EF severity male mild41–51/female41–53,moderate30–40,severe<30%; LAvolume upper2Dlimit34mL/m²bothsexes.
  • RWT=2×posteriorwall/LVIDd at enddiastole; normalmass+RWT>0.42 concentricremodelling,increasedmass+>0.42concentricLVH,increasedmass+≤0.42eccentricLVH.
  • Linear measurements perpendicular toLVlongaxis at/immediatelybelowMVleaflettips,enddiastole;2D-guided preferred;2D biplanemodifiedSimpson volume method.
Limits and what this source leaves unreviewed
  • Exact recorded original. Relevant Tables2,4,6,8,9,10, LV mass/geometry, LA volume and RV function sections read. Adult normal cohorts/reference methods; not a universal treatment threshold or all populations.

Supporting literature checked separately

None recorded in this review.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Recorded visual footer: Source: Lang RM et al. ASE/EACVI chamber quantification, JASE 2015;28:1-39 (Tables 2 & 6, Suppl. Table 3; LA volume section). Diagrams schematic, women drawn ~10% smaller. Attribution only; not complete claim verification.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Same echo, different normal 👇 LV diameters, wall thickness, volumes, mass and EF for men and women side by side, straight from the ASE/EACVI 2015 chamber quantification guideline, with the LVEF severity bands and LVH geometry rules underneath.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #Echocardiography #TEE #LVFunction #EjectionFraction #LVH #PerioperativeEcho #DMCardiacAnaesthesia #Anaesthesiology #Cardiology #ExamPrep #MedEd #FOAMed

Sequence 36 in this tracked set.

Postiz publish time (2 November 2026, 07:36 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Aortic Regurgitation 5/5: Intra-op TEE and Bypass Pearls

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Aortic Regurgitation 5/5: Intra-op TEE and Bypass Pearls: primary-source and rendered-panel audit staged; not a fully verified clinical reference.

Review scope

All2-second contact-sheet samples examined; each distinct main teaching panel read at full size (AR3:four panels; other AR posts:three). No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: All AR TEE/operative coronary/afterload/LV-distension claims and actual final-version qualifiers.

Still unreviewed

  • Exact original citations for every non-cardioplegia claim, repair measurements, LV recovery and support decisions.
  • All distinct main teaching panels read from2-second decoded samples; transient unsampled overlays, entire continuous video/audio and native-upload identity unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — Cardioplegia leak with significant AR; direct ostial/retrograde options

Primary supports alternative/combined delivery in aortic insufficiency. Retrograde alone may incompletely protect RV; not interchangeable in all cases.

unresolved — Fibrillation before clamp: LV distension, vent and clamp promptly; TEE before cannulation

Exact protocol sequence, circumstances and all safety exceptions not resolved from recorded original. Do not promote panel to stand-alone CPB instructions.

unresolved — Repair effective height≥9mm/coaptation≥4mm; >mild residual AR; ostial flow/new RWMA; heart block/pacing

Exact primary sources, valve/anatomy/repair population, measurement definitions and decision algorithms not recovered.

unresolved — Large LV/low preop EF may need inotrope; later LV/EF improvement

Plausibility is not verification: exact original cohort/guideline and predictors not recovered.

Qualifications on the reviewed points

  • Retrograde cardioplegia alone may inadequately protect the RV; individual protection strategy is a surgical/perfusion-team decision.
  • Effective height and coaptation length are different measurements; 9/4mm are not signed off as universal repair-success criteria.
  • Venting/clamping, residual-regurgitation revision, pacing and vasoactive choices require case-specific assessment; this table is not a complete operating protocol.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

2024 EACTS/EACTAIC/EBCP Guidelines on cardiopulmonary bypass in adult cardiac surgery

Alexander Wahba, Gudrun Kunst, Filip De Somer

2025

DOI 10.1093/ejcts/ezae354

Open source at iperfusion.org

Link check recorded

Recorded as supporting
  • In aortic valvular insufficiency combined antegrade plus retrograde cardioplegia can ensure distribution; antegrade delivery may be directly into coronary ostia.
  • Retrograde cardioplegia can incompletely perfuse RV microvasculature; route selection is not a simple interchangeable either/or.
Limits and what this source leaves unreviewed
  • New supporting source, not recorded original. Relevant myocardial-protection section pp26–27 read; does not establish every proposed vent/clamp action, anaesthetic target or repair metric.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Series-wide recorded header: ESC/EACTS2021, ACC/AHA2020, ASE/EACVI. Exact ASE edition/claim mapping not recorded. AR3 final spec_v2/V9 body explicitly identifies2021/2020 recommendation tables; old spec_series AR3 is superseded locally.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Aortic Regurgitation 5/5: Intra-op TEE and Bypass Pearls

AR part 5, the last AR part: intra-op pearls. With significant AR, antegrade root cardioplegia runs into the LV, so give it directly into the ostia or retrograde via the coronary sinus. A fibrillating heart on bypass distends quickly, so vent the LV and cross-clamp promptly. After repair, check residual AR, effective height (≥9 mm) and coaptation length (≥4 mm), coronary flow and conduction.

Save this for your exam 📌

Next: Mitral Stenosis series, Part 1/5. Starts this Wednesday.

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #AorticRegurgitation #TEE #Cardioplegia #CardiopulmonaryBypass #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 37 in this tracked set.

Postiz publish time (2 November 2026, 00:43 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Aortic Regurgitation 4/5: Anaesthetic Goals and Haemodynamics

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Aortic Regurgitation 4/5: Anaesthetic Goals and Haemodynamics: primary-source and rendered-panel audit staged; not a fully verified clinical reference.

Review scope

All2-second contact-sheet samples examined; each distinct main teaching panel read at full size (AR3:four panels; other AR posts:three). No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: All AR anaesthetic rate/preload/afterload/drug/neuraxial targets, acute-versus-chronic disease and operative exceptions.

Still unreviewed

  • Exact authoritative perioperative/acute-AR source, IABP IFU, all haemodynamic targets and volume/afterload/heart-rate exceptions.
  • All distinct main teaching panels read from2-second decoded samples; transient unsampled overlays, entire continuous video/audio and native-upload identity unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

unresolved — HR80–100, keep preload full, lower SVR, maintain contractility/sinus rhythm

Exact recorded source and evidence for numeric HR range/universal underfilling→higher regurgitant fraction not recovered. Do not endorse fixed targets or blanket fluid loading.

unresolved — Low DBP/bradycardia coronary perfusion; IABP contraindicated moderate–severe AR

No exact primary device IFU/recorded source checked in this batch; physiology alone is not full contraindication validation.

qualified — Before induction: VC>0.6cm/PHT<200ms/descending-aortic reversal

Grading signs supported, but integrate findings; PHT is load/compliance-dependent and reversal has mimics. Not all required or sufficient individually.

qualified — Root cardioplegia, direct ostial/retrograde and LV venting

Protection route supported with RV-perfusion caveat; exact vent/clamp timing not audited.

unresolved — Acute AR: vasodilator±inotrope bridge, urgent surgery

Exact complete acute-severe-AR pathway, perfusion-pressure limits and exceptions not source-completely checked.

Qualifications on the reviewed points

  • No universal instruction to keep full: assess congestion and perfusion; fixed HR80–100 and lower-SVR targets remain unresolved rather than verified.
  • Confirm severity with integrated imaging and haemodynamics, not mandatory satisfaction of three isolated cutoffs.
  • No drug doses or stand-alone induction/rescue algorithm have been validated. This partial entry must not be used as one.
  • Retrograde-only cardioplegia may inadequately protect RV.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the ASE Developed in Collaboration with the SCMR

William A. Zoghbi, David Adams, Robert O. Bonow

2017

DOI 10.1016/j.echo.2017.01.007

Open source at asecho.org

Link check recorded

Recorded as supporting
  • VC>0.6cm/PHT<200ms and prominent holodiastolic reversal are integrated grading findings, with compliance/loading and reversal-mimic limitations.
Limits and what this source leaves unreviewed
  • New supporting source, not proven exact original from the generic ASE/EACVI series attribution. AR section Tables9/11 and relevant Doppler caveats read. Not a perioperative drug/repair-threshold guideline.

Supporting literature checked separately. Not the episode’s recorded source.

2024 EACTS/EACTAIC/EBCP Guidelines on cardiopulmonary bypass in adult cardiac surgery

Alexander Wahba, Gudrun Kunst, Filip De Somer

2025

DOI 10.1093/ejcts/ezae354

Open source at iperfusion.org

Link check recorded

Recorded as supporting
  • In aortic valvular insufficiency combined antegrade plus retrograde cardioplegia can ensure distribution; antegrade delivery may be directly into coronary ostia.
  • Retrograde cardioplegia can incompletely perfuse RV microvasculature; route selection is not a simple interchangeable either/or.
Limits and what this source leaves unreviewed
  • New supporting source, not recorded original. Relevant myocardial-protection section pp26–27 read; does not establish every proposed vent/clamp action, anaesthetic target or repair metric.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Series-wide recorded header: ESC/EACTS2021, ACC/AHA2020, ASE/EACVI. Exact ASE edition/claim mapping not recorded. AR3 final spec_v2/V9 body explicitly identifies2021/2020 recommendation tables; old spec_series AR3 is superseded locally.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Aortic Regurgitation 4/5: Anaesthetic Goals and Haemodynamics

AR part 4: go beyond "fast, full, forward". Low aortic diastolic pressure is the coronary-perfusion trap — the same diastole that fills the LV backwards under-perfuses the myocardium. Keep HR 80-100, preload full, SVR low, contractility up. Bradycardia lengthens regurgitant time and worsens coronary driving pressure. IABP is contraindicated in moderate–severe AR. Confirm vena contracta over 0.6 cm, PHT under 200 ms and holodiastolic reversal before induce, and plan ostial or retrograde cardioplegia plus an LV vent because root cardioplegia fails and a fibrillating LV distends fast.

Save this for your exam 📌

Next, Part 5/5: Intra-op TEE and Bypass Pearls (coming up in the next post).

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #AorticRegurgitation #Haemodynamics #AnaestheticGoals #IABP #Cardioplegia #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 38 in this tracked set.

Postiz publish time (1 November 2026, 22:11 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Aortic Regurgitation 3/5: Intervention Criteria (ESC 2021 + ACC/AHA 2020)

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Aortic Regurgitation 3/5: Intervention Criteria (ESC 2021 + ACC/AHA 2020): primary-source and rendered-panel audit staged; not a fully verified clinical reference.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Missing qualifier

The point needs a qualifier. The independent wording is below.

Reviewed wording

ACC/AHA2020 IIb row/caption: progressive LVEF fall to55–60% on≥3 studies, or LVEDD>65mm

First-pass proposal

ACC/AHA 2020 IIb B-NR: in asymptomatic chronic severe AR with LVEF >55% and low surgical risk, AVR may be considered for a progressive fall in LVEF to 55–60% on at least three serial studies OR a progressive increase in LV dilation into the severe range (LVEDD >65 mm).

Independent review wording

Minor wording; cite ACC/AHA 2020 IIb criteria exactly.

Rejected proposal

This proposal was rejected. It is not a confirmed error.

Reviewed wording

ESC2021 table: Valve surgery primary: replace root or tubular ascending aorta if≥45mm

First-pass proposal

For patients having primary aortic-valve surgery, concomitant aortic replacement at 45 mm is a should-be-considered recommendation with body-size, aetiology and anatomical context, not automatic replacement.

Independent review wording

No change.

Review scope

All2-second contact-sheet samples examined; each distinct main teaching panel read at full size (AR3:four panels; other AR posts:three). No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: All remaining serial-LV/aortic/root/genetic-context footnotes and current-guideline comparison; preserve actual V9 IIb C, not superseded script.

Still unreviewed

  • Complete2024aortic-disease pathway, all associated footnotes/corrigenda, native-upload version and continuous media.
  • All distinct main teaching panels read from2-second decoded samples; transient unsampled overlays, entire continuous video/audio and native-upload identity unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — All five rendered ESC2021 severe-AR rows/class/LOE

Actual V9 table matches primary: IB/IB/IIbC/IC/IIbC. Older script with IIa is NOT the rendered post.

qualified — All four rendered ESC2021 aortic/root rows/class/LOE

2021 primary matches class/LOE and diameters; final45mm row must retain should-be-considered and individual age/body-size/aetiology context, not compulsory replacement.

supported — ACC2020 three classI plus two IIa rows and TAVI classIII harm

Official primary slide set rows match rendered conditions/class/LOE. TAVI harm is for isolated severe AR in surgical candidates, not all inoperable patients.

correction-needed — ACC2020 IIb row: isolated LVEDD>65mm alternative

Rendered panel/caption omit progressive increase in LV dilation. Primary requires progressive severe LV dilation to LVEDD>65mm, not a single isolated diameter.

qualified — Current2025 comparison versus explicitly historical tables

Current low-risk criteria >22mm/m² or >45mL/m² or EF≤55 now IIbB; repair IIaB; selected inoperable TAVI IIbB. Do not erase guideline version.

Qualifications on the reviewed points

  • Classes and LOE apply only to full populations/selection criteria; historical2020/2021 tables are not a complete current2026 decision algorithm.
  • Aortic surgery is individualised by genotype, family history, growth, size/indexing, surgical risk and specialist assessment; not every45/50/55mm threshold is a mandatory operation.
  • ACC IIb early surgery concerns asymptomatic chronic severe AR, normal LVEF>55%, low surgical risk and serial progression.
  • Keep ESC2021 low-risk LVESDi>20mm/m² or LVEF≤55% as IIbC: the ACTUAL V9 render is already correct. Do not report the stale older-script IIa as a published error.

References recorded with the episode

Recorded with the episode

2021 ESC/EACTS Guidelines for the management of valvular heart disease

Alec Vahanian, Friedhelm Beyersdorf

2021

DOI 10.1093/eurheartj/ehab395

Open source at eurointervention.pcronline.com

Link check recorded

Recorded as supporting
  • All five severe-AR2021 recommendation rows and all four aortic/root2021 rows checked against primary pp13–14; classes/LOE match actual V9 render.
Limits and what this source leaves unreviewed
  • Historical2021 recommendation, not automatically current2026 guidance. Explicit original for AR3; series-wide attribution elsewhere does not establish claim-by-claim provenance.

Recorded with the episode

2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease — official slide set

Catherine M. Otto, Rick A. Nishimura

2020

DOI 10.1016/j.jacc.2020.11.018

Open source at professional.heart.org

Link check recorded

Recorded as supporting
  • All seven rendered AR recommendation rows/classes/LOE compared with official source: six supported; IIb row needs explicit progressive LV dilation.
Limits and what this source leaves unreviewed
  • Exact recorded guideline; official issuing-society recommendation slide rows read. This is not exhaustive full-guideline, literature or corrigenda review. Local binary request403, WebFetch full readable source succeeded.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

2025 ESC/EACTS Guidelines for the management of valvular heart disease

ESC/EACTS Task Force

2025

DOI 10.1093/eurheartj/ehaf194

Open source at doi.org

Link check recorded

Recorded as supporting
  • RecommendationTable3: low-risk asymptomatic severe AR with LVESDi>22 mm/m², LVESVi>45 mL/m² or LVEF≤55%: IIbB; main LVESD>50mm/index>25mm/m² or LVEF≤50%: IB.
  • Selected durable AV repair at experienced centres now IIaB; TAVI for symptomatic severe AR ineligible for surgery by Heart Team and anatomically suitable: IIbB.
  • Concomitant root/ascending-aorta replacement ≥45mm with indicated AV surgery and low predicted surgical risk: IIaC; individual age/BSA/aetiology/anatomy matter.
Limits and what this source leaves unreviewed
  • Supporting current comparison only, not original. Aortic-disease criteria now also refer to2024aortic guideline; that complete separate pathway not audited.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Series-wide recorded header: ESC/EACTS2021, ACC/AHA2020, ASE/EACVI. Exact ASE edition/claim mapping not recorded. AR3 final spec_v2/V9 body explicitly identifies2021/2020 recommendation tables; old spec_series AR3 is superseded locally.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Aortic Regurgitation 3/5: Intervention Criteria (ESC 2021 + ACC/AHA 2020)

AR part 3: indications for surgery with class and level of evidence. ESC/EACTS 2021: symptomatic severe AR (I B); asymptomatic with LVESD >50 mm, >25 mm/m² or LVEF ≤50% (I B); LVESD >20 mm/m² or LVEF ≤55% at low risk may be considered (IIb C); severe AR at other cardiac surgery (I C). Aorta: Marfan root ≥50 mm (I C), ≥55 mm in all patients (IIa C), valve-sparing root replacement in young patients (I B). ACC/AHA 2020: symptomatic severe AR (I B-NR), asymptomatic LVEF ≤55% (I B-NR), other cardiac surgery (I C-EO); LVESD >50 mm or >25 mm/m² (IIa B-NR); progressive LVEF fall or LVEDD >65 mm (IIb B-NR); TAVI should not be performed in isolated AR in surgical candidates (III: Harm).

Save this for your exam 📌

Next, Part 4/5: Anaesthetic Goals and Haemodynamics (coming up in the next post).

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #AorticRegurgitation #ESCGuidelines #CardiacSurgery #ValvularHeartDisease #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 39 in this tracked set.

Postiz publish time (1 November 2026, 19:06 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Aortic Regurgitation 2/5: Grading Severity on Echo

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Aortic Regurgitation 2/5: Grading Severity on Echo: primary-source and rendered-panel audit staged; not a fully verified clinical reference.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Confirmed error

The independent review confirmed an error against the checked source.

Reviewed wording

PHT also shortens with a high LVEDP (acute AR, vasodilators)

First-pass proposal

Proposed reference-page wording: PHT shortens with higher LV diastolic pressure and can also shorten during vasodilator therapy because aortic diastolic pressure falls independently of AR severity. Do not imply vasodilators cause high LVEDP.

Independent review wording

Vasodilators shorten PHT through lower aortic pressure; list separately from raised LVEDP.

Missing qualifier

The point needs a qualifier. The independent wording is below.

Reviewed wording

so it overcalls severity

First-pass proposal

Replace so it overcalls severity with PHT can mislead when interpreted in isolation; acute AR may be genuinely severe. Integrate morphology, quantitative and flow findings.

Independent review wording

Minor.

Confirmed error

The independent review confirmed an error against the checked source.

Reviewed wording

Jet width/LVOT (%) cutoffs without central-jet qualifier

First-pass proposal

Explicitly label jet-width/LVOT ratio cutoffs as CENTRAL jets; they are not valid for eccentric or multiple jets.

Independent review wording

Add 'central jets only'.

Review scope

All2-second contact-sheet samples examined; each distinct main teaching panel read at full size (AR3:four panels; other AR posts:three). No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Every AR quantitative cutoff/measurement caveat, eccentric/multiple jets and pressure-half-time context in the actual rendered final version.

Still unreviewed

  • Original exact ASE document/year was not individually recorded;2017 is new verified support, not proven original.
  • Entire acute-vs-chronic/discordance algorithm and continuous video/audio remain unreviewed.
  • All distinct main teaching panels read from2-second decoded samples; transient unsampled overlays, entire continuous video/audio and native-upload identity unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — All15 mild/moderate/severe cells: VC, jet/LVOT, RVol, RF, EROA

ASE2017 Table11 matches all15 cells and units; collapsed moderate subdivisions valid. Jet-width/LVOT ratio applies to CENTRAL jets, not eccentric/multiple jets.

qualified — PHT>500/<200ms and loading/compliance

Primary pp339–340 supports suggestions, not independent diagnosis; compensated severe chronic AR can have moderate PHT, mild AR with severe diastolic dysfunction can have short PHT.

correction-needed — Vasodilators in parenthesis as cause of high LVEDP; so PHT overcalls severity

Primary specifically explains vasodilators lower aortic DBP independent of AR; high LV diastolic pressure is another cause. Acute AR can be genuinely severe, so shortened PHT is not automatically overcalling.

qualified — Holodiastolic descending-aortic reversal with EDV>20cm/s supports severe AR

Exact ESC2021 Table5 supports >20cm/s. ASE notes reversal mimics and acute-AR/bradycardia equilibration can remove holodiastolic pattern.

qualified — Normal LV argues against severe chronic AR; integrate findings

ASE says usually dilated, exception acute AR; exclude other dilation causes and integrate all findings. Normal size alone cannot exclude severe disease.

Qualifications on the reviewed points

  • Jet-width/LVOT bands are for central jets only; use integrated assessment and reconcile discordant measures.
  • PHT depends on LV/aortic compliance and pressures; neither PHT nor flow reversal is a stand-alone severity diagnosis.
  • Chronic/acute distinction matters: normal LV size is not a general exclusion of severe AR.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the ASE Developed in Collaboration with the SCMR

William A. Zoghbi, David Adams, Robert O. Bonow

2017

DOI 10.1016/j.echo.2017.01.007

Open source at asecho.org

Link check recorded

Recorded as supporting
  • Table11 all15 rendered numerical cells/units match chronic-AR severity bands; jet/LVOT ratio for central jets only.
  • PHT>500ms suggests mild/<200 suggests severe; affected by LV compliance/diastolic pressure and vasodilator-lowered aortic DBP independently of AR.
  • Chronic severe AR usually dilates LV; acute severe AR may not; integrate multiple parameters.
  • Descending-aortic reversal has mimics; acute severe AR/bradycardia can lack holodiastolic pattern.
Limits and what this source leaves unreviewed
  • New supporting source, not proven exact original from the generic ASE/EACVI series attribution. AR section Tables9/11 and relevant Doppler caveats read. Not a perioperative drug/repair-threshold guideline.

Supporting literature checked separately. Not the episode’s recorded source.

2021 ESC/EACTS Guidelines for the management of valvular heart disease

Alec Vahanian, Friedhelm Beyersdorf

2021

DOI 10.1093/eurheartj/ehab395

Open source at eurointervention.pcronline.com

Link check recorded

Recorded as supporting
  • Table5 severe-AR descending-aortic holodiastolic reversal EDV>20cm/s; VC>6mm; PHT<200ms; EROA≥30mm²; RVol≥60mL/beat.
Limits and what this source leaves unreviewed
  • Historical2021 recommendation, not automatically current2026 guidance. Explicit original for AR3; series-wide attribution elsewhere does not establish claim-by-claim provenance.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Series-wide recorded header: ESC/EACTS2021, ACC/AHA2020, ASE/EACVI. Exact ASE edition/claim mapping not recorded. AR3 final spec_v2/V9 body explicitly identifies2021/2020 recommendation tables; old spec_series AR3 is superseded locally.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Aortic Regurgitation 2/5: Grading Severity on Echo

AR part 2: grading on echo. Severe AR means a vena contracta >0.6 cm, jet width ≥65% of the LVOT, regurgitant volume ≥60 ml, regurgitant fraction ≥50% and EROA ≥0.30 cm². A pressure half-time under 200 ms and holodiastolic flow reversal in the descending aorta (end-diastolic velocity >20 cm/s) support severe AR, but a high LVEDP also shortens the PHT. Always integrate several parameters.

Save this for your exam 📌

Next, Part 3/5: Intervention Criteria (ESC 2021 + ACC/AHA 2020) (coming up in the next post).

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #AorticRegurgitation #Echocardiography #TEE #ValvularHeartDisease #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 40 in this tracked set.

Postiz publish time (1 November 2026, 15:58 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Aortic Regurgitation 1/5: Aetiology and Pathophysiology

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Aortic Regurgitation 1/5: Aetiology and Pathophysiology: primary-source and rendered-panel audit staged; not a fully verified clinical reference.

Review scope

All2-second contact-sheet samples examined; each distinct main teaching panel read at full size (AR3:four panels; other AR posts:three). No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Every AR cause/physiology statement, historical outcome claims and acute-versus-chronic exceptions against original authorities.

Still unreviewed

  • Exact original clinical-examination/haemodynamic source and all pressure/pulse/coronary claims.
  • All distinct main teaching panels read from2-second decoded samples; transient unsampled overlays, entire continuous video/audio and native-upload identity unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — Listed leaflet and root causes

ASE2017 Table9 lists bicuspid, calcification, IE, rheumatic, annuloaortic ectasia/connective-tissue disease, hypertension/aortitis/dissection/trauma.

qualified — Acute AR normal LV/high LVEDP; chronic progressive LV volume/size adaptation

Primary supports acute severe AR non-dilated LV with rapidly raised LV diastolic pressure, versus progressive chronic volume overload. Acute-on-chronic AR can have an already dilated LV.

unresolved — Pulse-pressure pattern, silent years, combined pressure/volume overload, large SV

Exact original source and every circumstance/exception for these physiology statements not recovered. Table portrays typical severe patterns, not all AR.

unresolved — Collapsing pulse, early diastolic left-sternal murmur, Austin Flint; low DBP/angina without CAD

Exact clinical-examination/physiology primary source not checked; signs are not diagnostic proof and coexisting CAD not excluded.

Qualifications on the reviewed points

  • Acute AR can occur on pre-existing chronic disease with a dilated LV; normal size/high LVEDP/shock are typical acute-severe patterns, not mandatory findings in every case.
  • Aetiologies and bedside signs are not exhaustive or individually diagnostic. Angina must not be used to exclude obstructive CAD.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the ASE Developed in Collaboration with the SCMR

William A. Zoghbi, David Adams, Robert O. Bonow

2017

DOI 10.1016/j.echo.2017.01.007

Open source at asecho.org

Link check recorded

Recorded as supporting
  • Table9 confirms all listed leaflet/root aetiologies.
  • Acute severe AR may have non-dilated LV with rapidly raised diastolic pressure; chronic AR causes progressive volume-overload dilation/remodelling.
Limits and what this source leaves unreviewed
  • New supporting source, not proven exact original from the generic ASE/EACVI series attribution. AR section Tables9/11 and relevant Doppler caveats read. Not a perioperative drug/repair-threshold guideline.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Series-wide recorded header: ESC/EACTS2021, ACC/AHA2020, ASE/EACVI. Exact ASE edition/claim mapping not recorded. AR3 final spec_v2/V9 body explicitly identifies2021/2020 recommendation tables; old spec_series AR3 is superseded locally.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Aortic Regurgitation 1/5: Aetiology and Pathophysiology

New valve series: Aortic Regurgitation, part 1. AR comes from the leaflets (bicuspid, rheumatic, endocarditis) or from the root (annuloaortic ectasia, Marfan, dissection, aortitis). Acute AR dumps volume into a normal-sized LV, so LVEDP soars and the patient presents in pulmonary oedema or shock. Chronic AR is a volume plus pressure load that builds a large, compliant LV with a wide pulse pressure, often silent for years. Low diastolic pressure also reduces coronary perfusion.

Save this for your exam 📌

Next, Part 2/5: Grading AR Severity on Echo (coming up in the next post).

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #AorticRegurgitation #ValvularHeartDisease #Cardiology #Echocardiography #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 41 in this tracked set.

Postiz publish time (1 November 2026, 14:17 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Coronary Anatomy: Dominance and Territories

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Coronary Anatomy: Dominance and Territories: rendered-panel and scoped source audit staged; unresolved claims not endorsed.

Review scope

Every2-second contact-sheet sample examined and all distinct main teaching panels read full size; infographic source image/spec also read where recovered. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Dominance/territory variants, nodal supply, percentage denominators and operative-coronary implications against exact sources.

Still unreviewed

  • Exact recorded originals absent; clinical frequency/mechanism of inferiorMI bradycardia/AVblock and anatomical variants remain unresolved.
  • Full continuous video/audio, possible transient unsampled overlays and actual native-upload identity remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — Dominance definition and70/10/20% approximate proportions

Full surgical-anatomy review supports conventional definition and ranges containing these estimates. Cohort/definition variation means not a universal70/10/20 split.

qualified — LAD/LCx/RCA territories and SA/AV node estimates

Review supports typical territories and SA60–70%/AV~90%; dominance, branches and coronary variants change territories.

qualified — Posteromedial papillary singlePDA supply/more vulnerable

Review supports usual PDA versus dual anterolateral supply and greater vulnerability; not a universal anatomic invariant or rule that allinferiorMI rupture.

unresolved — InferiorMI often bradycardia/heartblock specifically due AV-nodal ischaemia

Anatomical supply alone does not validate incidence or exclude vagal/other mechanisms; exact primary clinical source not read.

Qualifications on the reviewed points

  • Use typical not exclusive territories; review angiographic anatomy/dominance in an individual.
  • Rounded prevalence estimates and nodal percentages vary with cohorts and definitions.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Comprehensive Review of Coronary Artery Anatomy Relevant to Cardiac Surgery

Emeka B. Kesieme, Benjamin Omoregbee, Dumbor L. Ngaage, Mark H. D. Danton

2025

DOI 10.2174/011573403X321942241023112517

Open source at pmc.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Dominance definition and typical ranges right70–80%,left5–10%,codominant10–20%; not fixed universal percentages.
  • RCA SA-node origin60–70%, AV-node origin about90% with left-dominant LCx alternative; LAD anterior septal2/3/anterolateral/apex and LCx lateral territories.
  • PDA-dependent posteromedial papillary supply versus dual LAD/LCx anterolateral supply underlies greater vulnerability.
Limits and what this source leaves unreviewed
  • New authoritative surgical-anatomy REVIEW, not original recorded source or independent audit of every underlying anatomical cohort.2024online/2025issue. Territorial patterns and numerical estimates vary.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Coronary Anatomy: Dominance and Territories

Coronary dominance is defined by which artery gives the posterior descending artery: right dominant in about 70%, left dominant in about 10% and co-dominant in about 20%. The LAD supplies the anterior wall, anterior two-thirds of the septum and apex; the circumflex the lateral wall; the RCA the RV, inferior wall, SA node (about 60%) and AV node (80-90%). The posteromedial papillary muscle has a single blood supply, so it ruptures more often.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #CoronaryAnatomy #Anatomy #CoronaryArteryDisease #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 42 in this tracked set.

Postiz publish time (1 November 2026, 08:48 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

LAST After Chest Wall Blocks

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

LAST recognition and rescue. Some doses agree with RCUK 2025, but original provenance, full algorithm and maximum local-anaesthetic doses remain unresolved.

Review scope

Original caption plus three decoded rendered frames and exact recorded body where recoverable. No full-frame-sequence/audio review.

Reclassified correction-needed to partial after finding current RCUK support; original source/version still unresolved.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Native upload identity verified: no

Remaining priority: Exact original LAST protocol/version, local-anaesthetic dose ceilings and all patient/site/block-specific risk claims; no ASRA-only mismatch inference.

Still unreviewed

  • Exact original guideline/version behind one-minute bolus instruction.
  • Bupivacaine/lidocaine maximum-dose ceilings and patient/site-specific reductions.
  • All early-symptom and block-specific risk claims.

Checks recorded in this pass

These checks do not clear the post.

  • Infusion-rate conversion explicitly calculated.
  • Version-specific bolus duration and rescue omissions identified.
  • Follow-up comparison shows the ≤1 µg/kg adrenaline and 15 mL/kg/hour lipid are consistent with current RCUK 2025; prior ASRA-only mismatch flag was not a proven dose error.

Qualifications on the reviewed points

  • 0.25 mL/kg/min ×60 =15 mL/kg/hour; the reel infusion conversion is correct.
  • Use 20% lipid emulsion; propofol is not a lipid-rescue substitute.
  • Maximum local-anaesthetic dose depends on drug, site, vascularity and patient; a numerical ceiling does not prevent intravascular-injection LAST.
  • Audit refinement: ASRA 2020 and RCUK 2025 use different presentation/dose schemes. A difference from ASRA alone is not proof that the reel dose is wrong. RCUK 2025 explicitly gives 15 mL/kg/hour lipid and adrenaline ≤1 µg/kg.
  • The reel omits escalation by doubling the lipid infusion in persistent instability; follow a complete named local/current LAST checklist.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Local Anesthetic Systemic Toxicity Checklist, 2020 v1.1

American Society of Regional Anesthesia and Pain Medicine

2020

DOI not recorded

Open source at asra.com

Link check recorded

Recorded as supporting
  • 20% lipid for <70 kg: ~1.5 mL/kg over 2–3 min, then ~0.25 mL/kg/min; >70 kg: ~100 mL over 2–3 min, ~250 mL over 15–20 min.
  • If unstable repeat bolus and double infusion; maximum lipid dose 12 mL/kg; continue >15 min after haemodynamic stability.
  • Prefer benzodiazepine for seizure; smaller epinephrine starting dose <1 µg/kg; avoid vasopressin, beta-blockers, calcium-channel blockers and additional local anaesthetic.
Limits and what this source leaves unreviewed
  • Supporting checklist checked now; inspected reel did not record an exact source/version.
  • Checklist does not validate the reel maximum local-anaesthetic dose figures or every early-symptom claim.

Supporting literature checked separately. Not the episode’s recorded source.

Special circumstances Guidelines 2025 — Local anaesthetic systemic toxicity

Resuscitation Council UK

2025

DOI not recorded

Open source at resus.org.uk

Link check time not recorded

Recorded as supporting
  • Initial lipid bolus 1.5 mL/kg of 20% emulsion; infusion 15 mL/kg/hour, repeat boluses up to twice, increase infusion to 30 mL/kg/hour if needed, max 12 mL/kg.
  • Adrenaline ≤1 µg/kg rather than 1 mg bolus; benzodiazepines for seizures.
Limits and what this source leaves unreviewed
  • Reel source/version remains unidentified. This source does not establish its one-minute bolus duration or local-anaesthetic maximum-dose figures.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

LAST After Chest Wall Blocks

Chest wall blocks for sternotomy (parasternal, ESP) often use large bilateral volumes, so calculate local anaesthetic doses first: bupivacaine about 2 mg/kg, lidocaine 3 mg/kg plain or 7 mg/kg with adrenaline. If toxicity develops, stop injecting, control the airway and seizures, and give 20% lipid 1.5 ml/kg over a minute then 15 ml/kg/h (max 12 ml/kg). Use small adrenaline doses and consider bypass or ECMO.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #RegionalAnaesthesia #LAST #LipidEmulsion #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 43 in this tracked set.

Postiz publish time (1 November 2026, 00:59 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Oxyhaemoglobin Dissociation Curve Shifts

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Oxyhaemoglobin Dissociation Curve Shifts: rendered-panel and scoped source audit staged; unresolved claims not endorsed.

Review scope

Every2-second contact-sheet sample examined and all distinct main teaching panels read full size; infographic source image/spec also read where recovered. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Every dissociation-curve shift/affinity claim, fetal-Hb/CO/temperature/pH exceptions, source identity and clinical extrapolation.

Still unreviewed

  • Exact original citation absent; HbF/metHb/storage-specific sources and complete CPBtemperature/acidbase context remain unresolved.
  • Full continuous video/audio, possible transient unsampled overlays and actual native-upload identity remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — All eight paired CO2/pH/temperature/2,3-DPG shift cells

Full physiology review explicitly supports right-shift factors and converse affinity shifts.

qualified — NormalP50≈3.5kPa/26.6mmHg; higherP50 means loweraffinity

Review supports approximately26mmHg adultP50 and definition at50%saturation. Unit arithmetic:3.5kPa≈26.3mmHg,26.6mmHg≈3.55kPa; approximate normal values, not exact equality.

qualified — CO left shift

Source confirms CO also removes oxygen-carrying sites, not merely a benign affinity shift; normalPaO2/ordinarySpO2 can mislead.

unresolved — FetalHb,metHb,storage2,3DPG and hypothermicCPB specifics

Exact source for each remaining added claim not recovered. Do not infer full dyshemoglobin or CPB management from basic shift table.

Qualifications on the reviewed points

  • P50 depends on specified pH/temperature/CO2/Hb type; approximate adultreference, not a treatment threshold.
  • CO/metHb imply impaired oxygen carriage, not only an ordinary curve shift; standard PaO2/pulseox do not establish adequate delivery.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Relating oxygen partial pressure, saturation and content: the haemoglobin–oxygen dissociation curve

Julie-Ann Collins, Aram Rudenski, John Gibson, Luke Howard, Ronan O’Driscoll

2015

DOI 10.1183/20734735.001415

Open source at pmc.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Higher CO2/acidity/temperature and2,3-DPG shift right; converses left; increased affinity is lowerP50 and normal adultP50 approximately26mmHg.
  • CO both occupies Hb binding sites and left-shifts remaining oxygen-binding; normal PaO2/ordinary pulse oximetry can be misleading.
  • Oxygen delivery is arterial content×cardiac output; normal oxygen carrying capacity about20mL/dL and resting mixed venous saturation about75%.
Limits and what this source leaves unreviewed
  • New authoritative physiology REVIEW, not recorded original. This source does not resolve every HbF/metHb/storage/CPB-specific claim or exact26.6mmHg convention.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Oxyhaemoglobin Dissociation Curve Shifts

The oxyhaemoglobin curve shifts right (higher P50, more O2 released to tissues) with acidosis, hypercapnia, fever and raised 2,3-DPG, and left (O2 held more tightly) with alkalosis, hypocapnia, hypothermia, low 2,3-DPG in stored blood, fetal Hb, CO and methaemoglobin. Normal P50 is about 3.5 kPa (26.6 mmHg). Hypothermic bypass and stored blood both shift it left.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #Physiology #OxygenDelivery #Haemoglobin #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 44 in this tracked set.

Postiz publish time (31 October 2026, 21:13 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Wiggers Diagram: Key Cardiac Cycle Events

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Wiggers Diagram: Key Cardiac Cycle Events: rendered-panel and scoped source audit staged; unresolved claims not endorsed.

Review scope

Every2-second contact-sheet sample examined and all distinct main teaching panels read full size; infographic source image/spec also read where recovered. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: All Wiggers event timing/valve/pressure/sound labels and cycle/rhythm/loading assumptions against original pages.

Still unreviewed

  • Exact original absent; full CVP and S3 physiology/clinical-exception source still required.
  • Full continuous video/audio, possible transient unsampled overlays and actual native-upload identity remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — Ordered normal valve/ventricular events, dicrotic notch, S1/S2

Full official publisher cardiac-cycle chapter read; normal phase sequence and valve-sound associations match.

qualified — Isovolumetric all-four-valves statement

Supported as simplified normal textbook cycle; do not assert perfectly simultaneous biventricular timing or intact isovolumetric phases in regurgitation.

qualified — S4 atrial kick against stiffventricle

Textbook supports stiff/hypertrophic ventricle; not a universal diagnostic proof of failure.

unresolved — CVPa/c/v timing; S3 rapidfilling mechanism

Exact full authoritative CVP/S3 section not retrieved. NCBIchapter access returned challenge, not readable source; title/search snippet is not validation.

Qualifications on the reviewed points

  • Normal simplified cycle assumes competent valves; severe regurgitation changes isovolumetric behaviour.
  • S3/S4 are not independently diagnostic; age/context and auscultatory correlation matter.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Anatomy and Physiology2e —19.3 Cardiac Cycle

OpenStax

2022

DOI not recorded

Open source at openstax.org

Link check recorded

Recorded as supporting
  • Normal cardiac-cycle ordering: AV closure→isovolumetric contraction→semilunar opening/ejection→semilunar closure→isovolumetric relaxation→AV opening/filling.
  • S1 AV closure, S2 semilunar closure; S4 atrial contraction against stiff/hypertrophic ventricle.
  • Normal idealised isovolumetric phases have inlet/outlet valves closed.
Limits and what this source leaves unreviewed
  • New authoritative publisher TEXTBOOK, not original. Not used as definitive evidence for S3 mechanism or CVP waveform; actual biventricular closure timing/valvular disease exceptions not fully audited.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Wiggers Diagram: Key Cardiac Cycle Events

The cardiac cycle in order: mitral closure, isovolumetric contraction, aortic opening and ejection, then aortic closure (the dicrotic notch and S2), isovolumetric relaxation, mitral opening and filling. On the CVP trace, 'a' follows the P wave, 'c' is tricuspid bulging and 'v' is venous filling. S3 is rapid filling and S4 is the atrial kick into a stiff ventricle.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #CardiacCycle #Physiology #WiggersDiagram #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 45 in this tracked set.

Postiz publish time (31 October 2026, 17:18 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Stopping DOACs Before Cardiac Surgery

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Stopping DOACs Before Cardiac Surgery. Selected claim-source mappings checked; remaining claims and full media review are unresolved.

Review scope

Original caption plus three decoded rendered frames and exact recorded body where recoverable. No full-frame-sequence/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Native upload identity verified: no

Remaining priority: Every DOAC hold row and renal equation, accumulation/interactions, high-thrombotic-risk exceptions and local cardiac/neuraxial policy.

Still unreviewed

  • Exact original source and renal-function equation for every table row.
  • Extra interruption for accumulation/drug interactions and exceptions to no-bridging statement.
  • Reconciliation with differing 2024 perioperative medication text and later guidance.

Checks recorded in this pass

These checks do not clear the post.

  • Selected 48/72/96-hour dabigatran schedule matches indexed 2024 cardiac PBM guidance; not a complete perioperative-plan sign-off.

Qualifications on the reviewed points

  • Specify drug, renal-function measure, bleeding risk and local guideline/version; hold-times are not universal.
  • Routine bridging is generally unnecessary; specialist exceptions/high-thrombotic-risk scenarios require individual consideration.
  • Dabigatran renal clearance is particularly important; the table does not cover severe impairment or neuraxial requirements.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

2024 EACTS/EACTAIC Guidelines on patient blood management in adult cardiac surgery in collaboration with EBCP

EACTS/EACTAIC/EBCP task force

2024

DOI not recorded

Open source at pmc.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Generally stop DOACs at least 48 h with normal renal function; dabigatran 72 h for renal function 50–80 and an additional 24 h for 30–50 in this document.
Limits and what this source leaves unreviewed
  • Supporting guideline checked now; no exact original source/version recorded.
  • Document uses renal-function terminology that must not be silently interchanged with the reel Cockcroft–Gault CrCl.
  • Other perioperative documents differ in interruption details; patient-specific accumulation and urgent surgery need separate protocols.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Stopping DOACs Before Cardiac Surgery

For high-bleeding-risk surgery like cardiac surgery, stop apixaban, rivaroxaban or edoxaban at least 48 hours before (CrCl ≥30). Dabigatran is renally cleared, so stop it 48 hours before with CrCl ≥80, 72 hours with CrCl 50-79 and 96 hours with CrCl 30-49. DOACs do not need heparin bridging (EHRA/ESC timings).

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #Anticoagulation #DOAC #PreOp #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 46 in this tracked set.

Postiz publish time (31 October 2026, 13:49 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Oxygen content and delivery on one page

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Oxygen content and delivery on one page: rendered-panel and scoped source audit staged; unresolved claims not endorsed.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Confirmed error

The independent review confirmed an error against the checked source.

Reviewed wording

On bypass: keep DO2i≥280mL/min/m² (EACTS/EACTA/EBCP2019 CPB guideline,ClassIIa,LevelB)

First-pass proposal

The 2019 guideline IIa B recommendation adjusts pump flow to arterial oxygen content to maintain a minimum DO2 under moderate hypothermia; it does not state 280 in that recommendation. The 2024 guideline (published 2025), Table 41, explicitly recommends minimum indexed DO2 280 mL/min/m² to reduce AKI stage 1 (I A). The current source is supporting, not the recorded original.

Independent review wording

Cite 2024 EACTS/EACTAIC/EBCP CPB guideline (I A) for DO2i ≥280.

Rejected proposal

This proposal was rejected. It is not a confirmed error.

Reviewed wording

×10 converts dL→L

First-pass proposal

Multiply flow in L/min by 10 dL/L so its volume unit matches oxygen content in mL/dL; the factor 10 in the equation is correct.

Independent review wording

No change.

Rejected proposal

This proposal was rejected. It is not a confirmed error.

Reviewed wording

Raise flow before you transfuse; Or transfuse to Hb9 worked-example row

First-pass proposal

Assess correctable causes and safe circuit-flow limits before selecting flow or transfusion treatment. Do not automatically transfuse solely to reach Hb 9 g/dL or a single DO2i target.

Independent review wording

No change.

Review scope

Every2-second contact-sheet sample examined and all distinct main teaching panels read full size; infographic source image/spec also read where recovered. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: All original Ranucci paper outcomes/threshold populations, oxygen-content assumptions and full safe flow/transfusion decision context.

Still unreviewed

  • Every remaining normal VO2/O2ER/SvO2 threshold and all clinical intervention decisions require exact source/exception review.
  • Ranucci2005 full paper unavailable; abstract scope explicit.
  • Full continuous video/audio, possible transient unsampled overlays and actual native-upload identity remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — CaO2/DO2/DO2i dimensional factors and kPa conversion

Arithmetic/dimensional check: Hb g/dL,SaO2fraction,PaO2mmHg;0.003×7.5006=0.0225 for kPa; DO2=CaO2×flowL/min×10dL/L. Retrieved original equation notation inconsistent; do not copy literal units.

qualified — All four worked examples and Hb/PaO2 effects

Independent arithmetic:20.0×5×10≈1000; Hb8/PaO2200 yields11.32×2.4×10≈271.7 and×2.6≈294.3; Hb9 gives12.66×2.4×10≈303.8. Posted271 uses rounded intermediate11.3. Hb15/higherPaO2 illustrations not automatic treatment advice.

correction-needed — Specific≥280/ClassIIaB attributed to2019guideline

Full actual2019 recommendation is qualitative minimumDO2 under MODERATEHYPOTHERMIA,IIaB; no280 in that row.2024guideline published2025 Table41 explicitly minimum280 to reduce AKIstage1,IA.

qualified — 262–272 nadirDO2 associated with renal injury

Exact recorded original2005abstract1048coronary cases critical272; exact2011fullpaper359adultCPB cases threshold262. Observational associations and cohort/temperature limits, not a universal causal cliff.

correction-needed — ×10 converts dL→L wording

Equation factor10 is correct but label reverses direction:10dL/L converts flow L/min to dL/min to cancel content mL/dL.

unresolved — VO2≈250/O2ER≈25%,normalDO2i500–600,SvO2<65–70% watch,raiseflow beforetransfusion

Exact every numerical reference/clinical trigger not recovered. Currentguideline says no validated universal metabolic adequacy threshold in citedrow; transfusion-toHb9 example is not an indication.

Qualifications on the reviewed points

  • CPB renal-protection targets have temperature/population/measurement context; do not apply to circulatory arrest or use one target as a complete perfusion algorithm.
  • Worked transfusion example is arithmetic only, not instruction to transfuse Hb8→9. Consider individual bleeding, oxygenbalance and circuit/flow constraints.
  • Oxygen saturation must be a fraction in this equation; Hb g/dL,PaO2mmHg or explicitly converted kPa; avoid factor100/unit errors.

References recorded with the episode

Recorded with the episode

2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery

Alexander Wahba, Milan Milojevic, Christa Boer

2019

DOI 10.1093/ejcts/ezz267

Open source at arcothova.com

Link check recorded

Recorded as supporting
  • Pump-flow recommendation IIaB: adjust flow to arterial oxygen content to maintain a minimal DO2 threshold UNDER MODERATE HYPOTHERMIA. The actual recommendation does NOT specify280.
  • Assess adequacy with SvO2,O2ER,NIRS,VCO2/lactate; determine baseline flow from BSA/planned temperature.
Limits and what this source leaves unreviewed
  • Exact recorded original.2019guideline published in2020journal. Do not attach specific≥280 to this recommendation as if quoted; numeric current recommendation is in2024update.

Recorded with the episode

Oxygen delivery during cardiopulmonary bypass and acute renal failure after coronary operations

Marco Ranucci, Federica Romitti, Giuseppe Isgrò, Mauro Cotza, Simonetta Brozzi, Alessandra Boncilli, Antonio Ditta

2005

DOI 10.1016/j.athoracsur.2005.05.069

Open source at pubmed.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Original ABSTRACT:1048 consecutive coronary-operation patients; lowest DO2 critical value272mL/min/m² predicted postoperative acute renal failure/creatinine rise.
Limits and what this source leaves unreviewed
  • Exact recorded original; PubMed primary abstract actually read, not full paper. Observational association, not proof of a universal causal threshold or transfusion trigger.

Recorded with the episode

O2 delivery and CO2 production during cardiopulmonary bypass as determinants of acute kidney injury: time for a goal-directed perfusion management?

Filip de Somer, John W. Mulholland, Megan R. Bryan, Tommaso Aloisio, Guido J. Van Nooten, Marco Ranucci

2011

DOI 10.1186/cc10349

Open source at link.springer.com

Link check recorded

Recorded as supporting
  • 359adults in two centres, retrospective analysis of prospectively collected data; nadirDO2<262mL/min/m² independently associated with AKI; AKIstage2OR3.1.
  • Indexed DO2=10×indexed pump flow(L/min/m²)×arterial oxygen content(mL/dL); normal awakeDO2 approximately500mL/min/m².
  • Moderate hypothermia27–36°C; dialysis/transplant excluded; observational study explicitly cannot establish causation, no<27°C population.
Limits and what this source leaves unreviewed
  • Exact recorded original full publisher article read. Retrieved equation text contains inconsistent Hb/saturation notation: do not copy literal mg/dL or percent without conversion; standard equation uses Hb g/dL and saturation fraction.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

2024 EACTS/EACTAIC/EBCP Guidelines on cardiopulmonary bypass in adult cardiac surgery

Alexander Wahba, Gudrun Kunst, Filip De Somer

2025

DOI 10.1093/ejcts/ezae354

Open source at iperfusion.org

Link check recorded

Recorded as supporting
  • Table41 recommends minimum indexedDO2 of280mL/min/m² to reduce AKIstage1: ClassI,LevelA.
  • Oxygenation/metabolic measures used to assess pump flow; no validated universal SvO2/O2ER/NIRS/VCO2/lactate adequacy threshold in that row.
Limits and what this source leaves unreviewed
  • Supporting current update, NOT recorded original. Does not establish automatic transfusion to Hb9 or a universal perfusion protocol.

Supporting literature checked separately. Not the episode’s recorded source.

Relating oxygen partial pressure, saturation and content: the haemoglobin–oxygen dissociation curve

Julie-Ann Collins, Aram Rudenski, John Gibson, Luke Howard, Ronan O’Driscoll

2015

DOI 10.1183/20734735.001415

Open source at pmc.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Higher CO2/acidity/temperature and2,3-DPG shift right; converses left; increased affinity is lowerP50 and normal adultP50 approximately26mmHg.
  • CO both occupies Hb binding sites and left-shifts remaining oxygen-binding; normal PaO2/ordinary pulse oximetry can be misleading.
  • Oxygen delivery is arterial content×cardiac output; normal oxygen carrying capacity about20mL/dL and resting mixed venous saturation about75%.
Limits and what this source leaves unreviewed
  • New authoritative physiology REVIEW, not recorded original. This source does not resolve every HbF/metHb/storage/CPB-specific claim or exact26.6mmHg convention.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Recorded exact visual footer:2019EACTS/EACTA/EBCP CPB guideline;Ranucci2005;deSomer2011. Identity is not endorsement of every quoted claim.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Oxygen content and delivery on one page 👇 the CaO₂ and DO₂ equations, why Hb matters more than PaO₂, worked examples, and the DO₂i ≥280 mL/min/m² target on bypass from the 2019 EACTS/EACTA/EBCP guideline.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily high-yield cardiac anaesthesia.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #OxygenDelivery #CPB #Perfusion #GoalDirectedPerfusion #AKI #Physiology #CardiacSurgery #Anaesthesiology #DMCardiacAnaesthesia #CriticalCare #MedEd #FOAMed

Sequence 47 in this tracked set.

Postiz publish time (31 October 2026, 10:23 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

9 arterial line waveforms to read at a glance

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

9 arterial line waveforms to read at a glance: rendered-panel and scoped source audit staged; unresolved claims not endorsed.

Review scope

Every2-second contact-sheet sample examined and all distinct main teaching panels read full size; infographic source image/spec also read where recovered. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: All nine arterial-waveform identifications, measurement-artifact mimics, quantitative cutoffs and escalation claims.

Still unreviewed

  • Original textbook editions/pages and Michard2000primary content not retrieved.
  • All9waveform geometry/clinical-specificity, paradoxus threshold, postCPBgradient and device-timing verification remain open.
  • Full continuous video/audio, possible transient unsampled overlays and actual native-upload identity remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — Over/underdamping pressure directions,causes and levelling

Full technicalreview supports displayed SBP/DBP patterns, air/clot/kink and hydrostatic offset≈7.5mmHg/10cm;7.4 is conventional approximation. MAP not protected against zero/level/occlusion/system errors.

unresolved — Fastflush1–2optimal/>3under/nooscillationover

Qualitative heuristic not exact validated cutoff from retrieved source; quantitative assessment requires natural frequency plus amplitude ratio and correct system.

qualified — PPV>13% suggests fluidresponsiveness in listedconditions

Original Michard paper identity resolved but primary content unavailable; supporting fullreview shows9–13%greyzone and more validity limits than listed. Response is not need forfluid.

unresolved — All9 schematic shapes, disease associations, paradoxus>10mmHg and IABPtiming

Complete textbook edition/pages, device IFU and waveform-by-waveform primary comparisons not recovered; no diagnostic or pump-setting endorsement.

unresolved — Distal amplification/radial under-read afterCPB

Exact primary periCPBcohort and situations not checked in this batch.

Qualifications on the reviewed points

  • PPV requires controlled breaths/no spontaneous effort, valid rhythm, appropriate tidal volume/compliance and other conditions; open chest/highabdominalpressure/highRR may invalidate.13% is not universal and fluid responsiveness is not a fluid prescription.
  • Damping artefacts must be resolved; do not assume MAP always accurate. Zero/level errors affect all pressure readings.
  • Waveforms are illustrative, not scaled diagnostic tests; IABP timing must use actual trace/device-trained assessment.

References recorded with the episode

Recorded with the episode

Relation between Respiratory Changes in Arterial Pulse Pressure and Fluid Responsiveness in Septic Patients with Acute Circulatory Failure

F. Michard, S. Boussat, D. Chemla

2000

DOI 10.1164/ajrccm.162.1.9903035

Open source at doi.org

Link check recorded

Recorded as supporting

No supported claim was recorded for this source.

Limits and what this source leaves unreviewed
  • Exact recorded original citation resolved by title/DOI. Primary full paper/abstract not successfully retrieved in this batch;13% cohort result not counted as verified from search synthesis. Miller/Kaplan editions/pages likewise unspecified.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

How to measure blood pressure using an arterial catheter: a systematic5-step approach

Bernd Saugel, Karim Kouz, Agnes S. Meidert

2020

DOI 10.1186/s13054-020-02859-w

Open source at pmc.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Underdamping causes systolic overshoot/lowDBP/ringing; overdamping lowSBP/highDBP/slurred upstroke/absent notch; air/clot/kink are overdamping causes.
  • Level vessel of interest, conventionally fourthICS midaxillary right-atrium/aortic-root level, zero to atmosphere;10cm causes about7.5mmHg hydrostatic offset.
  • Quantitative fast-flush assessment uses natural frequency and successive amplitude ratio; whole measurement-system configuration matters.
Limits and what this source leaves unreviewed
  • New technical-method REVIEW, not original textbook attribution. Published corrigendum read: Figure4 first-amplitude A1 arrow was too short; do not validate shape quantitatively by counting oscillations alone. Not a source for all9 disease patterns/IABP/PPV thresholds.

Supporting literature checked separately. Not the episode’s recorded source.

Prediction of fluid responsiveness: an update

Xavier Monnet, Paul E. Marik, Jean-Louis Teboul

2016

DOI 10.1186/s13613-016-0216-7

Open source at pmc.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting
  • PPV has context-dependent threshold and9–13% grey zone; unreliable with spontaneous breathing, arrhythmia, lowVt/compliance, open chest, high abdominal pressure/very highRR.
  • Fluid responsiveness is not equivalent to a clinical need for fluid; fluid overload can harm.
Limits and what this source leaves unreviewed
  • New supporting REVIEW, not original Michard2000paper. Right-heart-failure false positives discussed with explicitly limited evidence; all Vt/body-weight conventions not independently audited.

Recorded source note

Stored with the release. This note is not itself a checked reference.

  • Recorded exact visual footer:Miller’s Anesthesia arterial monitoring;Kaplan’s Cardiac Anesthesia, editions/pages unspecified;Michard etal.AJRCCM2000;162:134 (PPV13%).

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

9 arterial line waveforms to read at a glance 👇 normal, over- and underdamped, AS, AR, HOCM spike and dome, pulsus alternans and paradoxus, IABP timing, plus the fast-flush test, PPV and transducer levelling.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily high-yield cardiac anaesthesia.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #ArterialLine #Haemodynamics #Monitoring #IABP #AorticStenosis #HOCM #CardiacSurgery #Anaesthesiology #DMCardiacAnaesthesia #CriticalCare #MedEd #FOAMed

Sequence 48 in this tracked set.

Postiz publish time (31 October 2026, 07:16 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Aortic Dissection: Stanford vs DeBakey

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Aortic Dissection: Stanford vs DeBakey: rendered-panel and scoped source audit staged; unresolved claims not endorsed.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Missing qualifier

The point needs a qualifier. The independent wording is below.

Reviewed wording

StanfordB: descending only (distal to left subclavian)

First-pass proposal

Stanford B in ACC/AHA 2022 means no ascending-aorta involvement; arch involvement can occur when the ascending aorta is spared. Acknowledge the European non-A-non-B category.

Independent review wording

Stanford B: ascending aorta not involved.

Missing qualifier

The point needs a qualifier. The independent wording is below.

Reviewed wording

DeBakeyI whole aorta in caption; III descending only

First-pass proposal

Define DeBakey I by an ascending tear extending to the arch and typically the descending aorta; III by a descending tear, with IIIa confined to the thoracic aorta and IIIb extending below the diaphragm. Do not equate I with mandatory whole-aorta involvement.

Independent review wording

Minor.

Guideline version difference

The cited edition and a later or other edition differ.

Reviewed wording

heart rate<60bpm, then systolicBP100–120mmHg; give beta blocker BEFORE vasodilator without exceptions

First-pass proposal

Name the guideline and use perfusion-safe targets. ACC/AHA 2022: HR 60–80 bpm and SBP <120 mmHg, or the lowest pressure maintaining end-organ perfusion. Use an IV beta blocker unless contraindicated; add a vasodilator if needed after appropriate rate control. Preserve acute AR, heart-block and bradycardia exceptions.

Independent review wording

Name the guideline (ESC 2024); beta-blocker first unless contraindicated.

Review scope

Every2-second contact-sheet sample examined and all distinct main teaching panels read full size; infographic source image/spec also read where recovered. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Every dissection subtype/diagnostic/management exception, acute AR/perfusion/heart-block context and local emergency pathway.

Still unreviewed

  • Exact recorded original absent; comparison with current2024ESC fullguideline and entire emergency imaging/operative algorithm remains incomplete.
  • Full continuous video/audio, possible transient unsampled overlays and actual native-upload identity remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

correction-needed — StanfordA versus B definitions

A correct; B descending-only excludes arch-involving but ascending-sparing dissections that2022primary explicitly includes. Some European schemes label these non-A-non-B: name classification scheme.

qualified — DeBakeyI/II/III extent

II matches; I ascending origin→arch and usually descending, not obligatorily WHOLEaorta; III defined by descending origin,IIIb can extend below diaphragm. Caption too compressed.

qualified — TypeA emergency surgery; B medical/TEVAR ifcomplicated

Initial uncomplicatedB medical and complication intervention supported; selected high-risk uncomplicated cases may also have endovascular management, anatomy matters.

correction-needed — Universal HR<60,SBP100–120 and beta blocker first

Must retain adequate end-organ perfusion and beta-blocker contraindications.2022ACC/AHA explicitly HR60–80,SBP<120orlowestperfusion-safe; acuteAR/heartblock/bradycardia caution. Otherguidelines may use different HR targets, so do not declare all<60 targets intrinsically wrong.

Qualifications on the reviewed points

  • Do not reduce BP below organ-perfusion needs or use unconditional beta blockade in acuteAR, heartblock or bradycardia.
  • Arch-only/non-A-non-B nomenclature differs across schemes; use explicit definition and full imaging extent.
  • This abbreviated table is not a complete acute-aortic-syndrome algorithm; analgesia, invasive monitoring, urgent specialist assessment and complications matter.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease

Eric M. Isselbacher, Ourania Preventza, James Hamilton Black III

2022

DOI 10.1016/j.jacc.2022.08.004

Open source at pmc.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting
  • §2.4.1.2: StanfordA any ascending involvement; B no ascending involvement, including arch-only. DeBakeyI originates ascending and reaches arch, typically descending; III originates descending, IIIb extends below diaphragm.
  • §7.3.1 targetHR60–80bpm; SBP<120mmHg OR lowest maintaining end-organ perfusion. IVbeta blocker unless contraindicated, vasodilator after rate control ifBPuncontrolled; analgesia and monitored setting.
  • §7.3.1 caution beta blocker in acuteAR, heartblock, bradycardia; alternative non-DHP CCB for intolerance/contraindication as appropriate.
  • §7.4.2: uncomplicated acuteB initial medical; rupture/complications intervention, endovascular where anatomy appropriate; selected high-risk uncomplicated cases may also undergo endovascular management.
Limits and what this source leaves unreviewed
  • New supporting2022primary guideline, not recorded original. Does not establish that all other societies use identical HR targets; newer ESC/aortic and complete imaging/operative pathways not audited.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Aortic Dissection: Stanford vs DeBakey

Stanford type A dissections involve the ascending aorta and need emergency surgery; type B are confined to the descending aorta and are treated medically or with TEVAR if complicated. DeBakey I involves the whole aorta, II the ascending only and III the descending only. Start anti-impulse therapy: heart rate under 60, then systolic BP 100-120 mmHg, with the β-blocker before any vasodilator.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #AorticDissection #AorticSurgery #Cardiology #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 49 in this tracked set.

Postiz publish time (31 October 2026, 00:01 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Modified Duke Criteria for Endocarditis

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Modified Duke Criteria for Endocarditis. Safety/accuracy corrections are required; see the correction and qualifications.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Confirmed error

The independent review confirmed an error against the checked source.

Reviewed wording

Fever ≥38 °C.

First-pass proposal

The 2023 Duke-ISCVID minor fever criterion is documented temperature >38.0°C, not ≥38.0°C. Label this threshold by the specific diagnostic system.

Independent review wording

Fever >38.0 °C.

Guideline version difference

The cited edition and a later or other edition differ.

Reviewed wording

Modified Duke Criteria (no historical edition/context).

First-pass proposal

Present as a historical abbreviated criteria aid, not a complete current diagnostic algorithm; the 2023 Duke-ISCVID update adds important microbiological, imaging and surgical criteria.

Independent review wording

Name Modified Duke (Li 2000); note 2023 Duke-ISCVID update.

Review scope

Original caption plus three decoded rendered frames and exact recorded body where recoverable. No full-frame-sequence/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Native upload identity verified: no

Remaining priority: Exact historical Modified Duke original and all microbiology/imaging/prosthetic/clinical/pathological pathways; current criteria are separate.

Still unreviewed

  • Exact recorded original Modified Duke source (not inferred from title).
  • All historical major/minor definitions, culture timing, imaging terms, prosthetic-valve criteria and clinical/pathological diagnosis pathways.

Checks recorded in this pass

These checks do not clear the post.

  • Updated fever comparator checked; exact old table source remains unresolved.

Qualifications on the reviewed points

  • Label the depicted system as historical Modified Duke, with edition/date; distinguish 2023 Duke-ISCVID and ESC systems.
  • A typical organism in two cultures is an abbreviated description; organism eligibility, blood-culture requirements and exceptions matter.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis: Updating the Modified Duke Criteria

Fowler VG Jr et al.

2023

DOI 10.1093/cid/ciad271

Open source at academic.oup.com

Link check recorded

Recorded as supporting
  • 2023 update expands microbiologic, imaging and surgical criteria; documented fever minor criterion is >38.0°C.
Limits and what this source leaves unreviewed
  • Supporting update, not established original source.
  • Historical Modified Duke score combinations alone do not convey the updated criteria or replace clinical judgement.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Modified Duke Criteria for Endocarditis

Modified Duke criteria: the major criteria are positive blood cultures with typical organisms and imaging evidence (vegetation, abscess, new prosthetic dehiscence or new regurgitation). Minor criteria are predisposition, fever ≥38 °C, vascular and immunological phenomena and non-major microbiology. Definite IE = 2 major, 1 major + 3 minor, or 5 minor; possible IE = 1 major + 1 minor or 3 minor.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #Endocarditis #DukeCriteria #Cardiology #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 50 in this tracked set.

Postiz publish time (30 October 2026, 20:07 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Type 5 MI After CABG: Fourth Universal Definition

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Type 5 MI After CABG: Fourth Universal Definition. Safety/accuracy corrections are required; see the correction and qualifications.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Missing qualifier

The point needs a qualifier. The independent wording is below.

Reviewed wording

Type 5 MI: >10× URL plus one feature, from normal baseline.

First-pass proposal

That is the normal-baseline pathway, not the whole definition. For elevated stable/falling baseline, require >20% increase with final cTn >10×URL. New pathological Q waves with elevated/rising cTn may qualify even below 10×URL. Imaging evidence must be consistent with ischaemia.

Independent review wording

Add 'within 48 h of CABG' and the specific supporting features.

Rejected proposal

This proposal was rejected. It is not a confirmed error.

Reviewed wording

Troponin rise alone ... is not an MI.

First-pass proposal

Troponin rise alone does not establish MI; assess baseline, dynamics and corroborating ischaemic evidence rather than categorically excluding MI.

Independent review wording

No change.

Review scope

Original caption plus three decoded rendered frames and exact recorded body where recoverable. No full-frame-sequence/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Native upload identity verified: no

Remaining priority: Complete type 4a definition and exceptions plus current postoperative-ischaemia comparison; type 5 alone is not a lab cutoff.

Still unreviewed

  • Full type 4a definition/exception check and all current postoperative-ischaemia guideline comparisons.

Checks recorded in this pass

These checks do not clear the post.

  • Normal-baseline threshold, elevated-baseline pathway and Q-wave exception checked.

Qualifications on the reviewed points

  • Troponin elevation alone indicates injury, not automatically MI; do not use the shorthand as a complete diagnostic rule.
  • Type 4a threshold applies with its own accompanying evidence and baseline/within-48-hour conditions, not an isolated >5× laboratory value.

References recorded with the episode

Recorded with the episode

Fourth Universal Definition of Myocardial Infarction (2018)

Thygesen K et al.

2018

DOI 10.1161/CIR.0000000000000617

Open source at ahajournals.org

Link check recorded

Recorded as supporting
  • CABG type 5 MI ≤48 h with normal baseline: cTn >10×99th-percentile URL plus specified Q-wave, angiographic or ischaemic imaging evidence.
  • Elevated stable/falling baseline requires >20% rise, with final value still >10×URL.
  • New pathological Q waves with elevated/rising cTn can meet type 5 even when cTn <10×URL.
Limits and what this source leaves unreviewed
  • Exact definition named in title/caption, hence original provenance.
  • The sampled reel omits the elevated-baseline and Q-wave exception pathways; imaging evidence must have an ischaemic pattern.

Supporting literature checked separately

None recorded in this review.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Type 5 MI After CABG: Fourth Universal Definition

The Fourth Universal Definition of MI defines type 5 (CABG-related) MI as troponin >10 times the 99th percentile upper reference limit within 48 hours from a normal baseline, plus new pathological Q waves, angiographic graft or native vessel occlusion, or imaging evidence of new loss of viable myocardium. A troponin rise alone is expected after surgery. PCI-related type 4a uses >5 times.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #MyocardialInfarction #CABG #Troponin #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 51 in this tracked set.

Postiz publish time (30 October 2026, 16:42 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Heart Failure by Ejection Fraction

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Heart Failure by Ejection Fraction: scoped rendered-panel and claim review; qualifications and unresolved groups remain. Not approved for publication.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Rejected proposal

This proposal was rejected. It is not a confirmed error.

Reviewed wording

HFmrEF (mildly reduced) | 41–49%

First-pass proposal

After establishing clinical HF, specify the definition used. ACC/AHA 2022 HFmrEF requires LVEF 41–49% plus evidence of spontaneous or provokable increased LV filling pressures; HFpEF with LVEF ≥50% also requires such evidence. Avoid a hybrid ESC/ACC diagnostic table.

Independent review wording

No change.

Evidence already listed on this post

  • 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure — official slide set

Review scope

Every2-second decoded sample contact sheet examined; all distinct recovered main teaching panels also read at full image resolution and compared with recovered exact scripts/specs where available. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Full ESC 2021/2023 update comparison and exact perioperative fluid/rate original; avoid hybrid EF-only HF diagnosis.

Still unreviewed

  • FullESC2021/2023 focused-update comparison and exact perioperative fluid/rate-management original.
  • Continuous video/audio, transient between-sample overlays and identity with the native Instagram upload remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

correction-needed — LVEFcategories and HFdiagnosis

Numeric categories match2022Table4, but post leaves filling-pressure evidence out of HFmrEF and offers a broad structural/diastolic ORNP shorthand for HFpEF. HF is a clinical syndrome; isolated EF is insufficient.

supported — HFimpEF

Previous≤40now>40 matches. ContinueHFrEFtherapy; improvement is not cure.

qualified — Prognostic drugs mainlyHFrEF

Four-class evidence is strongestHFrEF, not absent above40;2022SGLT2i recommendations exist inHFmrEF/HFpEF, with laterESCupdates needing comparison.

unresolved — Stiff/preload-dependent HFpEF; avoidtachy/fluid

Broad perioperative shorthand not a fluid protocol; HFpEFheterogeneous. Exact perioperative source and congestion/hypovolaemia exceptions not recovered.

Qualifications on the reviewed points

  • Require symptoms/signs and objective HF evidence; structural abnormality alone is not universal HFpEFdiagnosis.
  • HFimpEFshould retainGDMT; avoidunqualified preload loading and do not imply SGLT2i benefit limited toHFrEF.

References recorded with the episode

Recorded with the episode

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure — official slide set

Paul A. Heidenreich, Biykem Bozkurt, David Aguilar

2022

DOI 10.1161/CIR.0000000000001063

Open source at professional.heart.org

Link check recorded

Recorded as supporting
  • Table4: HFrEF≤40%; HFimpEF previous≤40% and follow-up>40%; HFmrEF41–49% and HFpEF≥50% require evidence of spontaneous/provokable increased filling pressures. EF categorises established HF, not HF diagnosis by EF alone.
  • Table3: StageB includes structural disease OR increased filling pressures OR qualifying biomarker elevation in at-risk patients; patients with resolved StageC symptoms remain StageC.
  • HFimpEF: continue HFrEF GDMT. HFrEF four medication classes; HFmrEF/HFpEF SGLT2i recommendations also exist.
Limits and what this source leaves unreviewed
  • Caption explicitly names ACC/AHA2022 for index51, but not index30. No proof of specific PDF used. ESC2021 definition wording differs; avoid hybrid attribution. 2023 ESC focused HF update not fully compared.

Supporting literature checked separately

None recorded in this review.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Heart Failure by Ejection Fraction

Heart failure by ejection fraction (ESC 2021 / ACC/AHA 2022): HFrEF ≤40%, HFmrEF 41-49%, HFpEF ≥50% with evidence of structural or diastolic disease or raised natriuretic peptides, and HFimpEF for an EF that has improved from ≤40% to >40%. HFpEF hearts are stiff and preload-dependent, so avoid tachycardia and fluid overload.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #HeartFailure #ESCGuidelines #Cardiology #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 52 in this tracked set.

Postiz publish time (30 October 2026, 14:02 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Which ECG leads should be on your screen?

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Which ECG leads should be on your screen?: scoped rendered-panel and claim review; qualifications and unresolved groups remain. Not approved for publication.

Review scope

Every2-second decoded sample contact sheet examined; all distinct recovered main teaching panels also read at full image resolution and compared with recovered exact scripts/specs where available. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: London 1988 full original numeric tables, technical lead/filter/ST criteria and population-specific diagnostic performance.

Still unreviewed

  • Londonfullpaper; exactAHA/ACCmonitoring-standard edition; all electrode/colour/filter/STcriteria technical checks.
  • Continuous video/audio, transient between-sample overlays and identity with the native Instagram upload remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

unresolved — Londonlead sensitivities33/75/80/96%

Exact original study resolved; do not universalise population-specific STmonitoring detection percentages. Direct primary paper not read successfully.

qualified — PostoperativeV3/V4 preference

Matches recorded2002study abstract with vascular cohort, monitored period and originalSTdefinition; not universal everypostopsetting.

unresolved — 5lead positions/AHAversusIECcolours, CM5leadI mapping

Actual full diagram/spec read; electrode conventions, modified-lead polarity and geometric placements not independently checked against exact technical standard.

unresolved — ST1mm60–80ms and0.05vs0.5Hz filter

Need exact monitor-standard settings, diagnosticSTdefinition/population and baseline/artefact exceptions; neither study alone establishes all cardsettings.

Qualifications on the reviewed points

  • These percentages are detection within selected studies, not sensitivity for all infarction or all cardiac-surgery patients.
  • A modifiedCM5lead is not a trueprecordialV5. Diagnostic filter/device instructions and standard12lead assessment matter.

References recorded with the episode

Recorded with the episode

Intraoperative myocardial ischemia: localization by continuous12-lead electrocardiography

Martin J. London

1988

DOI 10.1097/00000542-198808000-00013

Open source at pubmed.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting

No supported claim was recorded for this source.

Limits and what this source leaves unreviewed
  • Recorded exact1988paper identity resolved. PubMed access returned challenge/rate-limit; publisher full text unavailable. Indexed percentages not counted as freshly full-primary validated. Full author list not recovered.

Recorded with the episode

Perioperative myocardial ischemia and infarction: identification by continuous12-lead electrocardiogram with online ST-segment monitoring

Giora Landesberg, Morris Mosseri, Yehuda Wolf, Yellena Vesselov, Charles Weissman

2002

DOI 10.1097/00000542-200202000-00007

Open source at cris.tau.ac.il

Link check recorded

Recorded as supporting
  • 185vascular-surgery patients monitored intraoperatively and48–72hpostoperatively; V3identified86.8%ischemia,V478.9%,V565.8%; V4most sensitive single lead to infarction83.3%; two precordial leads approached>95%sensitivity.
Limits and what this source leaves unreviewed
  • Recorded original identity verified; primary article abstract actually read on author-institution repository, not full paper. Cohort/ischemia definition-specific; not universal cardiac-surgery performance.

Supporting literature checked separately

None recorded in this review.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Which ECG leads should be on your screen? 👇 5-electrode placement, why II + V5 is the standard, the London 1988 sensitivities, CM5 when you only have 3 electrodes, ST criteria, filter mode and post-op V3/V4.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily high-yield cardiac anaesthesia.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #ECG #Ischaemia #Monitoring #V5 #CardiacSurgery #Anaesthesiology #DMCardiacAnaesthesia #PerioperativeMedicine #Cardiology #CriticalCare #MedEd #FOAMed

Sequence 53 in this tracked set.

Postiz publish time (30 October 2026, 11:06 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

A1 to P3 on one page

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

A1 to P3 on one page: scoped rendered-panel and claim review; qualifications and unresolved groups remain. Not approved for publication.

Review scope

Every2-second decoded sample contact sheet examined; all distinct recovered main teaching panels also read at full image resolution and compared with recovered exact scripts/specs where available. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Operative LCx/CS/His risk, papillary blood supply, P2 frequency and exact views; reconcile internal Hahn prose/figure discrepancy without false error claim.

Still unreviewed

  • Exactoperative-neighbour injury source, P2frequency cohort and papillaryblood-supply variations; fullCarpentier1983 andIIIa/IIIbdiseaseexamples.
  • Continuous video/audio, transient between-sample overlays and identity with the native Instagram upload remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — Surgeonsegmentmap, annularfractions, TEEplanes

Hahn2013supportsP1lateral/P3medial,Ao12o’clock,1/3vs2/3circumference and standardplanes. Multiple probe views needed; lateralLAAorientation diagram schematic.

qualified — Anterior2/3area

2013Figure7states2/3surfacearea, but same original adjacent prose says roughlyequalleafletareas. Flag source inconsistency rather than arbitrarily declare published fractionfalse.

qualified — CarpentierI/II/IIIa/IIIb table

Mechanism groups supported in2017source. Exact1983fulltext and eachdiseaseexample/systolic-versus-diastolic III subcategory not fully traced.

unresolved — LCx/CS/AVnode-His neighbours; P2commonest; PMpapillary singlebloodsupply

All rendered labels read but precise surgical-neighbour anatomy, frequency and vascular variation not fully matched to authoritative exact sources. Single supply is a usualpattern, not an invariant.

Qualifications on the reviewed points

  • Segment labels depend on explicit surgeon/LAorientation and imagingplane; diagramnotproceduralnavigation.
  • Do not imply everyposteromedialpapillarymuscle has identical single-artery supply; anatomyvaries.

References recorded with the episode

Recorded with the episode

Guidelines for Performing a Comprehensive Transesophageal Echocardiographic Examination: Recommendations from ASE and SCA

Rebecca T. Hahn, Theodore Abraham, Mark S. Adams

2013

DOI 10.1016/j.echo.2013.07.009

Open source at asecho.org

Link check recorded

Recorded as supporting
  • Mitral anatomy pp942–943 and Figure7: P1 lateral/P3 medial, aortic valve12o’clock, anterior1/3 annular circumference, posterior2/3; Figure7 says anterior2/3 surface area, whereas adjacent prose says roughly equal leaflet areas. This internal inconsistency is retained, not silently settled.
  • Standard MEcommissural P3–A2–P1 and MELAX P2–A2 sections; scallops vary with probe plane and multiple views are needed.
  • AV/LVOT pp945–946: MEAVSAX for cusp/orifice morphology, MELAX for LVOT size; deepTG/TGLAX align CW Doppler; TEE may underestimate transaortic velocities.
  • AV anatomy and MEAVSAX cusp identification: NCC adjacent IAS, RCC anterior. RootLAX120–140°; angles approximate.
Limits and what this source leaves unreviewed
  • Full original2013PDF retrieved/read in scoped sections. Not complete surgical-neighbour injury, papillary blood-supply, TAVI complication or treatment authority.

Recorded with the episode

Cardiac valve surgery—the French correction

Alain Carpentier

1983

DOI 10.1016/S0022-5223(19)39144-5

Open source at jtcvs.org

Link check recorded

Recorded as supporting

No supported claim was recorded for this source.

Limits and what this source leaves unreviewed
  • Exact recorded citation resolved to1983;86:323–337. Full original blocked; not used to certify every modernIIIa/IIIb table detail.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the ASE Developed in Collaboration with the SCMR

William A. Zoghbi, David Adams, Robert O. Bonow

2017

DOI 10.1016/j.echo.2017.01.007

Open source at asecho.org

Link check recorded

Recorded as supporting
  • MRmechanism section/Figure10: typeI normal motion with annular dilation/perforation; IIexcess motion/prolapse/flail; IIIrestriction in ventricular remodelling/rheumatic/postinflammatory disease.
Limits and what this source leaves unreviewed
  • New supporting source, not proven exact original from the generic ASE/EACVI series attribution. AR section Tables9/11 and relevant Doppler caveats read. Not a perioperative drug/repair-threshold guideline.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

A1 to P3 on one page 👇 the Carpentier map in the surgeon's view, what sits next to each segment (LCx, coronary sinus, AV node), the functional classes I, II, IIIa and IIIb, and which TEE views show which scallops.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily high-yield cardiac anaesthesia.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #MitralValve #MitralRegurgitation #Carpentier #TEE #Echocardiography #MitralRepair #CardiacSurgery #Anaesthesiology #DMCardiacAnaesthesia #CardiacAnatomy #MedEd #FOAMed

Sequence 54 in this tracked set.

Postiz publish time (30 October 2026, 08:19 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Magnesium in Cardiac Surgery

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Magnesium in Cardiac Surgery: scoped rendered-panel and claim review; qualifications and unresolved groups remain. Not approved for publication.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Confirmed error

The independent review confirmed an error against the checked source.

Reviewed wording

Torsades de pointes: 2 g IV over 1–2 min, even if Mg is normal

First-pass proposal

Distinguish pulse, stability and protocol. RCUK 2025 peri-arrest tachyarrhythmia guidance gives 8 mmol magnesium IV over 10 min for QT-prolongation polymorphic VT (approximately 2 g magnesium sulfate heptahydrate). Pulseless VT requires immediate appropriate CPR/defibrillation and the applicable resuscitation protocol. Do not apply a 1–2 min infusion to every torsades patient.

Independent review wording

Torsades with a pulse: magnesium 2 g (8 mmol) IV over 10 min (RCUK ALS 2025). In pulseless torsades a rapid bolus is used. The 1-2 min rate is not universal.

Evidence already listed on this post

  • Adult tachyarrhythmia algorithm2025

Review scope

Every2-second decoded sample contact sheet examined; all distinct recovered main teaching panels also read at full image resolution and compared with recovered exact scripts/specs where available. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Exact POAF-prevention trial/regimen and population, toxicity/Ca-rescue protocol, renal context and complete torsades/arrest algorithm.

Still unreviewed

  • PrimaryMglabel/SmPC; exactPOAFRCT/regimen; toxicitythreshold andcalciumrescuealgorithm.
  • Continuous video/audio, transient between-sample overlays and identity with the native Instagram upload remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

correction-needed — Torsades2gIVover1–2min irrespectivepulse/stability

UnqualifiedrapidIVinstruction unsafe to generalise:2025RCUKperfusing/periarrestalgorithm8mmolover10min. Pulselessarrest needs immediateappropriateCPR/defibrillation, not delayforinfusion.

unresolved — Single2g preventsPOAFandventriculararrhythmias

ExactoriginalRCT/regimen absent; prophylaxis effects varybyregimen/levels and cannot be certified as routine single-dose benefit.2024EACTS full prophylaxis passage not directly retrieved inthisbatch.

unresolved — PostCPBmagnesiumfall/causes

Need measuredlevel, supplementation/cardioplegiacomposition and timing; cardioplegia isnotuniformlymagnesium-depleting.

unresolved — Vasodilation/Caantagonism/NMBApotentiation; toxicity4–5mmol/L andIVcalcium

Plausiblepharmacology but noexactproductlabel/monitoringalgorithm recovered. Levels mustnotreplaceclinical assessment; renalfunction,infusionrate andcalciumproduct/dose remainunreviewed.

Qualifications on the reviewed points

  • Specify magnesiumSULFATEformulation/units, pulse,haemodynamicstatus, renalfunction andlocalmonitoredprotocol.
  • Do notdelayCPR/defibrillationorantidotalmanagement; avoid treatingthepost ascompletearrhythmia/toxicityprotocol.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Adult tachyarrhythmia algorithm2025

Resuscitation Council UK

2025

DOI not recorded

Open source at resus.org.uk

Link check recorded

Recorded as supporting
  • Peri-arrest polymorphicVTwith prolongedQT: magnesium8mmolIVover10minutes; considerpacing/isoprenaline and avoidamiodarone. Algorithmseparateslife-threateningfeatures.
Limits and what this source leaves unreviewed
  • Current supporting source, not recorded original. This is a perfusing/peri-arrest algorithm, not the pulselessarrest algorithm.8mmolMg≈2gmagnesiumsulfateheptahydrate, not2gelementalmagnesium.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Magnesium in Cardiac Surgery

Magnesium falls after bypass from haemodilution, diuresis and cardioplegia. Magnesium sulphate 2 g IV reduces post-op AF and ventricular arrhythmias, and 2 g over 1-2 minutes is first-line for torsades even when the level is normal. It potentiates neuromuscular block, and toxicity (reflex loss around 4-5 mmol/L, then respiratory depression and heart block) is treated with IV calcium.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #Magnesium #Arrhythmia #Electrolytes #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 55 in this tracked set.

Postiz publish time (30 October 2026, 00:53 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Adenosine: Doses and Cautions

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Adenosine: Doses and Cautions. Safety/accuracy corrections are required; see the correction and qualifications.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Confirmed error

The independent review confirmed an error against the checked source.

Reviewed wording

Avoid ... heart transplant (denervated heart: use ~1/3 dose).

First-pass proposal

Heart transplantation is not an unqualified absolute prohibition. Increased sensitivity requires a specialist, monitored, reduced-dose protocol. The reel simultaneously says avoid and give one-third; remove that ambiguity and cite the actual protocol.

Independent review wording

Heart transplant: use reduced dose (~1/3) with caution, or avoid — choose one consistent statement.

Review scope

Original caption plus three decoded rendered frames and exact recorded body where recoverable. No full-frame-sequence/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Native upload identity verified: no

Remaining priority: Exact central-line/transplant reduced-dose protocol and full rhythm-algorithm exclusions; pre-excited AF contraindication is now primary-source resolved.

Still unreviewed

  • Exact original source/protocol for central-line 3 mg and transplant one-third dose.
  • Complete current ALS rhythm algorithm, pediatric/structural-heart contexts and non-AF irregular/wide-complex exclusions; no whole-algorithm sign-off.

Checks recorded in this pass

These checks do not clear the post.

  • Peripheral 6/12/12 mg schedule and interaction directions checked against official label.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — Pre-excited AF exclusion

Actual 2023 AF guideline §10.6 Class III Harm explicitly includes adenosine among contraindicated AV-nodal blockers in pre-excited AF. Unstable pre-excited AF requires electrical cardioversion.

Qualifications on the reviewed points

  • Use rhythm- and patient-appropriate monitored resuscitation guidance; haemodynamic instability may require cardioversion rather than adenosine.
  • Pre-excited AF is distinct from a regular AV-node-dependent re-entrant tachycardia in someone with WPW.
  • Transplant patients are more sensitive; any use requires specialist caution/reduced-dose protocol, not an unqualified contraindication nor a universal one-third rule.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Adenosine injection US prescribing information

DailyMed US prescribing information

Year not recorded

DOI not recorded

Open source at dailymed.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Adult peripheral IV PSVT: 6 mg over 1–2 seconds then 12 mg after 1–2 min if needed, with one further 12 mg dose permitted.
  • Use proximal injection and rapid flush; methylxanthines antagonise and dipyridamole potentiates.
  • Avoid in bronchospasm/asthma; adenosine does not convert atrial flutter/AF to sinus rhythm.
Limits and what this source leaves unreviewed
  • Supporting label only; no original source recorded.
  • Central venous dosing has not been systematically studied in the label; it cannot validate the specific central-line 3 mg rule.

Supporting literature checked separately. Not the episode’s recorded source.

Prospective Study of Adenosine on Atrioventricular Nodal Conduction in Pediatric and Young Adult Patients After Heart Transplantation

Flyer JN et al.

2017

DOI 10.1161/CIRCULATIONAHA.117.028087

Open source at ahajournals.org

Link check recorded

Recorded as supporting
  • Study evaluated carefully titrated reduced-dose adenosine in monitored paediatric/young-adult transplant recipients.
Limits and what this source leaves unreviewed
  • Supporting study contradicts an unqualified absolute avoidance claim, but is not a universal adult-dose guideline.
  • Do not extrapolate its dosing protocol to all transplant recipients.

Supporting literature checked separately. Not the episode’s recorded source.

2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation

José A. Joglar, Mina K. Chung

2024

DOI 10.1016/j.jacc.2023.08.017

Open source at pmc.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting
  • 2023 AF guideline §10.6, Class III Harm: AV-nodal-blocking drugs including adenosine are contraindicated in pre-excited AF because of VF/hemodynamic deterioration risk.
  • Pre-excited AF with hemodynamic instability requires electrical cardioversion; this is not a blanket prohibition on adenosine for every regular AV-node-dependent tachycardia in a patient with WPW.
Limits and what this source leaves unreviewed
  • Supporting source selected now; not proof of the historical original source.
  • Does not establish central-line 3 mg or a universal transplant one-third dose.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Adenosine: Doses and Cautions

Adenosine terminates AV-node-dependent SVT: 6 mg rapid IV push with a flush, then 12 mg, then 12 mg again (start at 3 mg via a central line). Its half-life is under 10 seconds. Avoid it in asthma and pre-excited AF, and cut the dose to about a third after heart transplant. Dipyridamole potentiates it; theophylline and caffeine blunt it.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #Adenosine #SVT #Pharmacology #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 56 in this tracked set.

Postiz publish time (29 October 2026, 21:46 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Amiodarone in Cardiac Surgery

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Amiodarone in Cardiac Surgery. Selected claim-source mappings checked; remaining claims and full media review are unresolved.

Review scope

Original caption plus three decoded rendered frames and exact recorded body where recoverable. No full-frame-sequence/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Native upload identity verified: no

Remaining priority: Exact POAF 300/900 mg protocol/selection, solvent-causation evidence and complete current formulation/jurisdiction comparison.

Still unreviewed

  • Recover exact original postoperative-AF 300/900 mg protocol, patient selection and stability/rate-versus-rhythm decisions.
  • Exact evidence for attributing acute hemodynamic effects to solvent alone; full current formulation/jurisdiction comparison.

Checks recorded in this pass

These checks do not clear the post.

  • 300 mg then 150 mg adult shock-refractory VF/pVT dose checked against 2025 AHA algorithm.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — Class effects, adverse effects and digoxin/warfarin interaction

Exact named SmPC §§4.4–4.8/5.1 supports these scoped claims; monitoring and dose adaptation remain essential.

qualified — Formulation and infusion safety

This named product is glucose-5%-only, saline-incompatible, with ECG/BP monitoring and central venous administration recommended for repeated/continuous infusion. Do not generalise product instructions to every formulation.

unresolved — Postoperative AF 300 mg over 20–60 min then 900 mg/day; solvent attribution

Exact POAF protocol/original remains untraced. SmPC standard regimen differs in presentation; difference alone is not proof of error. Excipient listing is not proof of sole causation of hypotension/bradycardia.

Qualifications on the reviewed points

  • Keep cardiac-arrest bolus dosing separate from perfusing AF infusion dosing; state adult/monitored context.
  • Postoperative AF management depends on stability, rate/rhythm strategy and contraindications.
  • Specific hameln concentrate SmPC: dilute only in glucose 5%, not saline; continuous ECG/BP monitoring; central venous catheter recommended for repeated/continuous infusion. Other formulations require their own instructions.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Amiodarone Hydrochloride 50 mg/mL Concentrate for Solution for Injection/Infusion: Summary of Product Characteristics

UK electronic Medicines Compendium

2022

DOI not recorded

Open source at medicines.org.uk

Link check recorded

Recorded as supporting
  • SmPC §5.1 describes class III potassium-current effects with sodium-channel, calcium-channel and noncompetitive adrenergic effects.
  • §§4.4–4.8 support hypotension/bradycardia, thyroid/lung/liver effects, corneal deposits, increased digoxin concentrations and warfarin interaction.
  • §4.2 supports 300 mg then 150 mg for defibrillation-resistant VF/pulseless VT, separate from perfusing-arrhythmia infusion.
  • This specific product uses glucose 5%, is incompatible with saline, recommends central venous administration for repeated/continuous infusion and continuous ECG/BP monitoring.
Limits and what this source leaves unreviewed
  • Supporting named product SmPC, not a recovered historical original. Text revised 22 July 2022, emc updated 20 January 2023; not asserted to be the latest jurisdiction-specific 2026 label.
  • Standard perfusing-arrhythmia dose is 5 mg/kg over 20 min–2 h, then response-adjusted infusion up to 1200 mg/24 h. It does not independently validate the exact 300 mg/900 mg postoperative-AF regimen for every patient.
  • Polysorbate 80 and benzyl alcohol are listed excipients, but this text alone does not prove all acute hypotension/bradycardia is caused solely by solvent.

Supporting literature checked separately. Not the episode’s recorded source.

Adult Cardiac Arrest Circular Algorithm, 2025

American Heart Association

2025

DOI not recorded

Open source at heart.org

Link check recorded

Recorded as supporting
  • Adult shock-refractory VF/pVT: amiodarone IV/IO first 300 mg, second 150 mg.
Limits and what this source leaves unreviewed
  • Supporting current ALS algorithm, not recorded original; shockable-arrest regimen is not the perfusing AF regimen.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Amiodarone in Cardiac Surgery

Amiodarone is a class III antiarrhythmic with class I, II and IV actions. For post-op AF give 300 mg IV over 20-60 minutes, then about 900 mg over 24 hours; in VF or pulseless VT arrest give 300 mg, then 150 mg. Watch for hypotension and bradycardia acutely, and for thyroid, lung and liver toxicity long-term. It raises digoxin and warfarin levels.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #Amiodarone #Arrhythmia #Pharmacology #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 57 in this tracked set.

Postiz publish time (29 October 2026, 17:24 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Vasoactive Drugs: Receptor Table

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Vasoactive Drugs: Receptor Table: scoped rendered-panel and claim review; qualifications and unresolved groups remain. Not approved for publication.

Review scope

Every2-second decoded sample contact sheet examined; all distinct recovered main teaching panels also read at full image resolution and compared with recovered exact scripts/specs where available. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Every receptor-selectivity/dose-response/HR/CO/SVR/PVR table entry and context against exact recorded original pharmacology.

Still unreviewed

  • Exactoriginalpharmacology/receptor-affinitysources, allrelativepotencies anddopamineranges.
  • Continuous video/audio, transient between-sample overlays and identity with the native Instagram upload remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

unresolved — Noradrenaline/adrenaline/dobutamine/phenylephrine relativepluspotencies

Recoveredall5rows andscript; relative+++ notationnotstandardised acrossreceptors/doses. Zerois notproofabsoluteabsence; noexactoriginalpotencydata recovered.

unresolved — VasopressinV1ratherthanadrenergic

Mechanisticallyreasonable butexactlabel/receptorsubtypesandclinicaldosecontext notmappedhere.

qualified — MilrinonePDE3, worksdespitebetablockade

Mechanismnotbetaagonism supported; no receptor meansnotadrenergicagonist, notabsenceofanybiologicaltarget. Labelmechanismdoesnotproveuniversalclinicalresponseunderbetablockade.

unresolved — Dopaminedose-dependentD1/β1/α1

Simplifiedoverlappingdose-response, notdiscretefixedswitches orrenal-protectionrecommendation. Exactlabel/clinicaldosegroup sourceopen.

Qualifications on the reviewed points

  • Qualitative receptor mnemonics are not dose/potencycomparisons or agentselectionalgorithms.
  • No renal-protection inference from low-doseD1 shorthand.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Milrinone lactate injection prescribing information

DailyMed / US prescribing information

Year not recorded

DOI not recorded

Open source at dailymed.nlm.nih.gov

Link check recorded

Recorded as supporting
  • MilrinonePDE3inhibition increasescAMP; positiveinotropy/vasodilation isnotbeta-adrenergicreceptoragonism.
Limits and what this source leaves unreviewed
  • Omitting loading is a clinical practice modification, not the label regimen; does not establish superiority for every RV-failure/PH/post-CPB case. Exact original product unidentified.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Vasoactive Drugs: Receptor Table

Vasoactive receptors at a glance: noradrenaline is mainly α1 with some β1, adrenaline hits α1, β1 and β2, dobutamine is mainly β1 with β2, phenylephrine is pure α1 and vasopressin works on V1 receptors. Milrinone bypasses receptors as a PDE3 inhibitor, so it still works with β-blockade. Dopamine changes receptor profile with dose.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #Vasopressors #Inotropes #Pharmacology #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 58 in this tracked set.

Postiz publish time (29 October 2026, 13:32 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Why inhaled NO drops PVR without dropping SVR

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Why inhaled NO drops PVR without dropping SVR: scoped rendered-panel and claim review; qualifications and unresolved groups remain. Not approved for publication.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Missing qualifier

The point needs a qualifier. The independent wording is below.

Reviewed wording

Taper to 1–5 ppm and ↑ FiO₂ before stopping → avoids rebound PH and ↓ PaO₂

First-pass proposal

Wean gradually under an appropriate protocol with oxygenation and haemodynamic monitoring; rebound may still occur. The read US label specifies several steps, pausing several hours at each step. Avoid abrupt discontinuation; immediately reinstate INOmax if rebound syndrome occurs. Identify an adult protocol separately.

Independent review wording

Taper gradually to reduce (not eliminate) rebound.

Evidence already listed on this post

  • INOmax(nitricoxide) USprescribinginformation — FDA2023copy

Review scope

Every2-second decoded sample contact sheet examined; all distinct recovered main teaching panels also read at full image resolution and compared with recovered exact scripts/specs where available. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Exact 2005 mechanism review and all molecular labels, adult off-label cardiac evidence, current local device/label and complete MetHb treatment exceptions.

Still unreviewed

  • Latestlocalproduct/deviceinstructions; exact2005reviewidentity/fulltext, allmolecularillustrationclaims andadultsurgeryevidence; completeMetHbtreatmentexceptions.
  • Continuous video/audio, transient between-sample overlays and identity with the native Instagram upload remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

unresolved — NOselectivepulmonaryvasodilation,sGC-cGMP/VQ/Hbscavenging

Mechanisticdiagramandfullspecread; exactGriffithsEvans2005paperfulltextnotretrieved, so allmolecularsteps/terminalbronchioleillustrationnotcertified.

qualified — 20ppmneonatalvs5–20adult

Neonatal20labelmatched. Adult5–20cardiacusesareofflabelunderUSPI; specificadulttrial/protocolnotfullychecked.

qualified — NO2andmetHbmonitoring

3ppmisanassessment/recalibrationthresholdinthereadUSlabel, notuniversal safetarget<2–3; measuremetHb4–8handperiodically,notonlyhigherdoses. Do notpresentmethylene blueasautomaticwithoutcontraindications.

correction-needed — Taper1–5andincreaseFiO2avoidsrebound; stoppingforMetHb

Gradualweaningreducesriskbutdoesnotguaranteeabsenceofrebound; unplannedabruptstoppingmayprecipitatehypoxemia/collapse. Detailedsteps/devicespecific.

qualified — R-to-Ldependentneonates/LVcaution/vasoreactivity

LabelcontraandLVriskmatch; vasoreactivitycutoffmatchesPH2022butCCBrespondertestinglimitedIPAH/HPAH/DPAH.

Qualifications on the reviewed points

  • Adultcardiacuseneedsnamedlocalofflabelprotocol; labeljurisdictionsvary.
  • Taperwithmonitoring; do notclaimtaperplusFiO2guaranteesnorebound. Methylene bluehasimportantcontraindications/interactionsnotcoveredhere.

References recorded with the episode

Recorded with the episode

INOmax(nitricoxide) USprescribinginformation — FDA2023copy

Mallinckrodt Pharmaceuticals

2023

DOI not recorded

Open source at accessdata.fda.gov

Link check recorded

Recorded as supporting
  • §1–2:20ppmfor>34weekneonatalhypoxicrespiratoryfailurewithPHandventilatorysupport; dose>20notrecommended.
  • §2.2 measuremetHb4–8hafterinitiationandperiodically; monitorPaO2/inspiredNO2; weaninseveralsteps,pausinghours,avoidabruptstop.
  • §4–5:neonatesdependentonR-to-Lshuntingcontraindicated; LVdysfunctionmaycausepulmonaryoedema; NO2reaches3ppmtriggerdelivery-systemassessment/recalibrationandappropriateNO/FiO2adjustment.
  • §5.1 reboundrequiresimmediatereinstatement; §5.2 persistentmetHbafterdoseadjustmentmayneedadditionaltreatment.
Limits and what this source leaves unreviewed
  • INOmaxUSPIexplicitlyrecorded,buteditionusedunknown;2023FDAlabelcopyread,notassertedlatest2026label. Adultsurgerydosing/useisnotthisUSapprovedindication; deliverydevice/localjurisdictioninstructionsmatter.

Recorded with the episode

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Marc Humbert, Gabor Kovacs, Marius M. Hoeper

2022

DOI 10.1093/eurheartj/ehac237

Open source at doi.org

Link check recorded

Recorded as supporting
  • Table5: PH mPAP>20mmHg; pre-capillary PAWP≤15,PVR>2WU; isolated post-capillary PAWP>15,PVR≤2; combined post-/pre-capillary PAWP>15,PVR>2, all with mPAP>20.
  • §5.1.12.2: acute positive response mPAP reduction≥10 to≤40mmHg with unchanged/increasedCO; CCB-responder testing only IPAH/HPAH/DPAH, with separate transplant/CHD purposes.
  • §3.1 upper normal PVR around2WU; §5.1.12.1 PVR=(mPAP−PAWP)/CO, directFick/thermodilution selection, indirectFick less reliable; shunts need special measurements.
Limits and what this source leaves unreviewed
  • Exact source explicitly named by PH/iNO posts. In other posts this is newly checked supporting evidence; no full PH diagnostic/therapeutic algorithm endorsement.

Supporting literature checked separately

None recorded in this review.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Why inhaled NO drops PVR without dropping SVR 👇 selective delivery to ventilated alveoli, the sGC–cGMP pathway, instant haemoglobin inactivation, dosing, NO₂ and metHb monitoring, weaning to avoid rebound, and when not to use it.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily high-yield cardiac anaesthesia.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #NitricOxide #iNO #PulmonaryHypertension #RVFailure #HeartTransplant #LVAD #CardiacSurgery #Anaesthesiology #DMCardiacAnaesthesia #CriticalCare #MedEd #FOAMed

Sequence 59 in this tracked set.

Postiz publish time (29 October 2026, 10:28 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Four CCS classes, exact wording — the pre-op and viva staple

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Four CCS classes, exact wording — the pre-op and viva staple: scoped rendered-panel and claim review; qualifications and unresolved groups remain. Not approved for publication.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Missing qualifier

The point needs a qualifier. The independent wording is below.

Reviewed wording

Class III–IV = recent limiting ischaemia → higher peri-op MI risk; optimise before elective surgery

First-pass proposal

CCS III–IV indicates marked activity limitation or angina with minimal activity/rest; it does not establish recency or acute coronary syndrome. Separately assess symptom onset, progression, rest pain and perioperative risk.

Independent review wording

Minor.

Evidence already listed on this post

  • CCN catheterisation referral data definitions: CCSclassification for stableCAD

Review scope

Every2-second decoded sample contact sheet examined; all distinct recovered main teaching panels also read at full image resolution and compared with recovered exact scripts/specs where available. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Original Campeau letter/full class wording and perioperative risk source; CCS severity does not establish recent ischaemia or ACS.

Still unreviewed

  • OriginalCampeauletter; exactEuroSCOREIIpaper/variableandcurrentACSassessmentguideline.
  • Continuous video/audio, transient between-sample overlays and identity with the native Instagram upload remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — CCSI–IVdefinitions

I/III/IVcorematchesreproduction;IIomits>2blocks/>1flightnormalconditions. Exactwordingclaimnottrueofabridgement.

correction-needed — III–IVmeansrecentlimitingischaemia

CCSdescribeseffortlimitation,notrecencyoracuteinstability. ClinicalformseparatesCCSstableCADfromACSclassification.

qualified — ClassIV/restangina treatunstableuntilprovenotherwise

New/rest/worseninganginaneedsurgentACSassessment,butCCSIValonecannotdiagnoseACS; stablechronicorvasospasticsyndromesexist. ExactcurrentACSsourceisstillrequired.

unresolved — EuroSCOREIIrestangina,90%LADcanstillclassI,NYHAdistinction

NeedexactEuroSCOREvariabledefinition/drugusecriterionandprimaryscorepaper; anatomicstenosisdoesnotdeterminefunctionalone,buttheexampleisnotclinicalvalidation.

Qualifications on the reviewed points

  • Functionalclassdoesnotestablishrecency,culpritanatomyorACSdiagnosis.
  • Current/rest/worseningchestpainrequiresurgentclinicalassessment; notashorthanddiagnosisfromCCSclass.

References recorded with the episode

Recorded with the episode

Grading of angina pectoris

Lucien Campeau

1976

DOI not recorded

Open source at pubmed.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting

No supported claim was recorded for this source.

Limits and what this source leaves unreviewed
  • RecordedoriginalCirculation54:522–523identityresolved; fullletternotobtained. Do notcallabridgedpostexactquotation.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

CCN catheterisation referral data definitions: CCSclassification for stableCAD

London Health Sciences Centre / Cardiac Care Network

Year not recorded

DOI not recorded

Open source at lhsc.on.ca

Link check recorded

Recorded as supporting
  • Table1reproducesfullCCSI–IV includingClassIIwalking>2blocks/>1flightnormalpace; symptomlimitationclassification separatefromACSrisktable.
Limits and what this source leaves unreviewed
  • Officialclinicalformreproduction,supportingonly; notoriginalCampeau1976letter. OtherolderACS/troponincontentinthisformnotendorsed.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Four CCS classes, exact wording — the pre-op and viva staple 👇 ordinary activity vs slight vs marked limitation vs rest angina, plus why Class III–IV changes your plan and the exam traps (symptom-based ≠ anatomy; don’t confuse with NYHA).

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily high-yield cardiac anaesthesia.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #CCSAngina #Angina #PreoperativeAssessment #EuroSCORE #CardiacSurgery #Anaesthesiology #DMCardiacAnaesthesia #Cardiology #ExamPrep #MedEd #FOAMed #Viva

Sequence 60 in this tracked set.

Postiz publish time (29 October 2026, 07:12 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Aortic Stenosis 5/5: Intra-op TEE and Post-bypass Pearls

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Aortic Stenosis 5/5: Intra-op TEE and Post-bypass Pearls: scoped rendered-panel and claim review; qualifications and unresolved groups remain. Not approved for publication.

Review scope

Every2-second decoded sample contact sheet examined; all distinct recovered main teaching panels also read at full image resolution and compared with recovered exact scripts/specs where available. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Original post-AVR LVOTO treatment algorithm, pacing/AF/prosthetic/TAVI differential and all hypotension-treatment exceptions.

Still unreviewed

  • OriginalperioperativeLVOTO/TAVIcomplicationandLVHfollowupsources; full2024ASEprostheticvalvealgorithm andallcardioplegiaqualifiers.
  • Continuous video/audio, transient between-sample overlays and identity with the native Instagram upload remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — TEEplanimetry/LVOT/deepTG

2013primarysupportssitesandDoppleralignment; calcificplanimetry/shadowinglimitedandTEEvelocitiesmayunderestimate,sointegratehemodynamics/multiplewindows.

qualified — ThickLVgenerouscardioplegia; postAVRcheckgradient/PVL/coronary/RWMA

Myocardialprotectionrequiresindividualiseddelivery/pressure/temperature/adequacy,notundefinedgenerousvolume. Fullpostprosthesischecklistrequires2024ASEprimaryguidelinebeyondsampleTEEviews.

unresolved — ConfirmedpostAVRdynamicLVOTO:volume,slowheart,stopinotropes,phenyl

PathophysiologicallycoherentifconfirmedLVOTO,butspecificprimaryperioperativealgorithmnotretrieved; dosenotappliestoallpostAVRhypotensionorventricularfailure.

qualified — Gradientsfallimmediately; LVHregressesmonths

Notguaranteednormalimmediategradients:flow,PPM,prosthesisobstruction,pressure-recoveryanddynamicLVOTOmatter. Exactlongitudinalremodellingpaperabsent.

unresolved — TAVIcoronaryobstruction/rupture/CHB/PVLclues

All4renderedrowsread; signsnotspecificorcomplete. Currentstructuralheartcomplication/urgentmanagementsourceandpericardialdiagnosticdifferentialopen.

Qualifications on the reviewed points

  • Do nottreatallhypotensionwiththeLVOTOrecipe; confirmmechanismandindividualisevolume/pressor/inotropy.
  • Aprostheticgradientmustbeinterpretedagainstflow,prosthesistype/size/baseline; noreassurancefromaroutineexpectationoffallinggradients.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Guidelines for Performing a Comprehensive Transesophageal Echocardiographic Examination: Recommendations from ASE and SCA

Rebecca T. Hahn, Theodore Abraham, Mark S. Adams

2013

DOI 10.1016/j.echo.2013.07.009

Open source at asecho.org

Link check recorded

Recorded as supporting
  • Mitral anatomy pp942–943 and Figure7: P1 lateral/P3 medial, aortic valve12o’clock, anterior1/3 annular circumference, posterior2/3; Figure7 says anterior2/3 surface area, whereas adjacent prose says roughly equal leaflet areas. This internal inconsistency is retained, not silently settled.
  • Standard MEcommissural P3–A2–P1 and MELAX P2–A2 sections; scallops vary with probe plane and multiple views are needed.
  • AV/LVOT pp945–946: MEAVSAX for cusp/orifice morphology, MELAX for LVOT size; deepTG/TGLAX align CW Doppler; TEE may underestimate transaortic velocities.
  • AV anatomy and MEAVSAX cusp identification: NCC adjacent IAS, RCC anterior. RootLAX120–140°; angles approximate.
Limits and what this source leaves unreviewed
  • Full original2013PDF retrieved/read in scoped sections. Not complete surgical-neighbour injury, papillary blood-supply, TAVI complication or treatment authority.

Supporting literature checked separately. Not the episode’s recorded source.

2024 EACTS/EACTAIC/EBCP Guidelines on cardiopulmonary bypass in adult cardiac surgery

Alexander Wahba, Gudrun Kunst, Filip De Somer

2025

DOI 10.1093/ejcts/ezae354

Open source at iperfusion.org

Link check recorded

Recorded as supporting
  • Myocardial protection section: severe aortic insufficiency complicates root cardioplegia; direct ostial and/or retrograde delivery may be needed; retrograde alone may inadequately protect RV and requires appropriate delivery/monitoring.
Limits and what this source leaves unreviewed
  • New supporting source, not recorded original. Relevant myocardial-protection section pp26–27 read; does not establish every proposed vent/clamp action, anaesthetic target or repair metric.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Aortic Stenosis 5/5: Intra-op TEE and Post-bypass Pearls

Part 5, the last AS part: intra-op TEE and post-bypass pearls. Planimetry is done in the ME AV short-axis view, the LVOT is measured in ME AV long-axis, and gradients come from deep transgastric views. The thick LV needs generous myocardial protection. After AVR, a hypertrophied septum can cause dynamic LVOT obstruction: give volume, slow the heart, stop inotropes and add phenylephrine. After TAVI, watch for coronary obstruction, annular rupture, heart block and paravalvular leak.

Save this for your exam 📌

Next: Aortic Regurgitation series, Part 1/5. Starts this Sunday.

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #AorticStenosis #TEE #TAVI #PostBypass #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 61 in this tracked set.

Postiz publish time (29 October 2026, 00:56 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Aortic Stenosis 4/5: Anaesthetic Goals and Haemodynamics

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Aortic Stenosis 4/5: Anaesthetic Goals and Haemodynamics: scoped rendered-panel and claim review; qualifications and unresolved groups remain. Not approved for publication.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Missing qualifier

The point needs a qualifier. The independent wording is below.

Reviewed wording

Cardiac arrest in severe AS: chest compressions are often ineffective, so prevention is everything

First-pass proposal

In cardiac arrest, start immediate high-quality CPR, call for help, defibrillate when indicated and treat reversible causes using the appropriate local ALS/cardiac-surgery protocol. Prevention is important but must not delay resuscitation.

Independent review wording

Cardiac arrest in severe AS: start standard CPR/ALS immediately without delay; compressions may be less effective, so prevention and early escalation (e.g. emergency valvuloplasty/ECMO where available) matter.

Evidence already listed on this post

  • Adult advanced life supportGuidelines2025

Missing qualifier

The point needs a qualifier. The independent wording is below.

Reviewed wording

Sinus; cardiovert new AF early

First-pass proposal

Preserve sinus rhythm when feasible. If AF causes haemodynamic instability, perform immediate electrical cardioversion. If stable, individualise rhythm/rate control and assess AF duration, thromboembolism risk and anticoagulation before elective cardioversion.

Independent review wording

Cardiovert promptly if haemodynamically unstable.

Evidence already listed on this post

  • 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation

Review scope

Every2-second decoded sample contact sheet examined; all distinct recovered main teaching panels also read at full image resolution and compared with recovered exact scripts/specs where available. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Exact severe-AS anaesthetic/neuraxial drug/rate/fluid advice and complete instability/AF strategy; no statement may discourage CPR.

Still unreviewed

  • PrimaryASanaesthetic/neuraxialsafetyandvasopressorprotocol; fullpatient-specificvolume/rate/contractilityexceptions.
  • Continuous video/audio, transient between-sample overlays and identity with the native Instagram upload remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

correction-needed — Chestcompressionsoftenineffective/preventioneverything

PreventionimportantbutarrestrequiresimmediatehighqualityCPR/appropriateearlydefibrillation; wordingcoulddiscouragelifesavingtreatmentanddoesnotstateactualALSpriority.

correction-needed — Sinus; cardiovertnewAFearly

ImmediatecardioversionforinstabilityattributabletoAF; stablepatientsrequireindividualisedrhythm/rateandthromboembolismassessment,notsimplyanynewAF.

unresolved — HR60–80/keepfull/SVRmaintainorraise/contractility; line/pads/inductionpressors

Recoveredexactgoalsandpanel; universalnumericrate/fullnessandpressorchoicewithoutseverity/ventricular/perfusioncontextnotindependentlysupportedbyexactoriginalanaesthesiasource.

unresolved — SlowlytitratedepiduralorCSEacceptablewithinvasivemonitoring

Monitoringalonecannotestablishsafety; selection,severity/symptoms,anticoagulation,techniqueandrescuecapabilitymatter. Noexactneuraxialprimarysource.

qualified — Tachycardiadiastolic/supplydemand

MechanisticLVcontextsupported,notafixedHRtargetoruniversaltreatmentprotocol.

Qualifications on the reviewed points

  • AnASdiagnosisdoesnotjustifywithholding/delayingCPRorindicateddefibrillation.
  • Neitheranarterialline nor aCSElabelaloneestablishesneuraxialsafety; needexpertselection/protocol.
  • Avoidbothhypovolaemiaandoverload; rate/SVRgoalsareindividualised,nonnumericguarantees.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Adult advanced life supportGuidelines2025

Resuscitation Council UK

2025

DOI not recorded

Open source at resus.org.uk

Link check recorded

Recorded as supporting
  • Highqualitychestcompressions,minimalinterruptionsandearlydefibrillationremainpriorities; severeASisnotanexceptionpermittingwithholdingCPR.
Limits and what this source leaves unreviewed
  • Supportingcurrentresuscitationsource,notanoriginalASpostcitation. Notacompletepostcardiotomy/arrestprotocol.

Supporting literature checked separately. Not the episode’s recorded source.

2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation

José A. Joglar, Mina K. Chung

2024

DOI 10.1016/j.jacc.2023.08.017

Open source at pmc.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting
  • HaemodynamicallyunstableAFattributabletoAF:immediateelectricalcardioversion. Electivecardioversionrequiresduration/thromboembolism/anticoagulationassessment.
Limits and what this source leaves unreviewed
  • Supporting source: not explicitly recorded. The 2023 guideline was published in 2024. Its HAS-BLED description uses age ≥65; recorded post uses >65, which requires version-specific reconciliation rather than an invented universal correction. ESC2024 full primary recommendations have not been checked here.

Supporting literature checked separately. Not the episode’s recorded source.

Regulation of Coronary Blood Flow

Adam G. Goodwill, Gregory M. Dick, Alexander M. Kiel, Johnathan D. Tune

2017

DOI 10.1002/cphy.c160016

Open source at pmc.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Mechanical determinants/extravascular compression: LV flow predominantly diastolic, subendocardial systolic flow minimal; normal RV has systolic and diastolic flow.
  • Diastolic arterial minus intraventricular pressure is a reasonable simplified estimate for innermost LV subendocardium, not an exact universal coronary gradient.
  • Metabolic control: resting LV oxygen extraction≈70–80%, greater demand met chiefly by flow. RV resting extraction≈45% with more extraction reserve.
Limits and what this source leaves unreviewed
  • New authoritative physiology review, NOT a recorded original or primary human trial. Specific experimental findings include animal studies. Do not universalise chamber-specific figures or equate a teaching CPP formula to complete autoregulation physiology.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Aortic Stenosis 4/5: Anaesthetic Goals and Haemodynamics

Part 4: anaesthetic goals in AS. Keep the heart rate low-normal and in sinus rhythm, keep it full, and keep the SVR up, because a stiff hypertrophied LV cannot raise output when pressure falls. Put in an arterial line before induction, have pads on, and treat hypotension at once with an alpha agonist. Tachycardia cuts diastolic coronary filling while raising demand. Avoid single-shot spinals, and remember that CPR rarely works in severe AS.

Save this for your exam 📌

Next, Part 5/5: Intra-op TEE and Post-bypass Pearls (coming up in the next post).

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #AorticStenosis #Haemodynamics #AnaestheticGoals #Vasopressors #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 62 in this tracked set.

Postiz publish time (28 October 2026, 22:23 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Aortic Stenosis 3/5: Intervention Criteria (ESC 2021 + ACC/AHA 2020)

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Aortic Stenosis 3/5: Intervention Criteria (ESC 2021 + ACC/AHA 2020): scoped rendered-panel and claim review; qualifications and unresolved groups remain. Not approved for publication.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Rejected proposal

This proposal was rejected. It is not a confirmed error.

Reviewed wording

Any age, high or prohibitive surgical risk: TAVI if predicted post-TAVI survival >12 months with acceptable QoL

First-pass proposal

ACC/AHA 2020: in symptomatic severe AS with high or prohibitive surgical risk, TAVI is recommended when predicted post-TAVI survival is >12 months with acceptable quality of life. Retain the symptom/severity qualifiers and appropriate anatomical/Heart Team assessment.

Independent review wording

No change.

Evidence already listed on this post

  • 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease — official slide set

Review scope

Every2-second decoded sample contact sheet examined; all distinct recovered main teaching panels also read at full image resolution and compared with recovered exact scripts/specs where available. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Every recommendation footnote, anatomy/suitability and BNP context plus explicit historical-versus-2025 criteria.

Still unreviewed

  • Allassociatedfootnotes/corrigendaandfullcurrentACC/ESCpathways; nativeversionandcontinuousmediaremainopen.
  • Continuous video/audio, transient between-sample overlays and identity with the native Instagram upload remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — ESC2021symptomatic/asymptomaticclassesandLOEs

All10rowsreadintheactual7-panelV9andprimarytable;retainBNPwithoutotherexplanation,diagnosticconfirmationandfootnotes. Actualpostisnotoldplanningfile.

qualified — ESC2021modeandotheroperations/valvotomy

All5modeand3ESCother-scenariorowsmatch; timeframehistorical. Risk/anatomy/HeartTeamandif-feasiblebridgecontextapply.

supported — ACC2020ClassIandIIa/IIbrows

All10rowsplusmoderateASotheroperationrowcheckedinofficialslides; differentESC/ACCexerciseSBPthresholdsarelegitimateguideline-specificdifferences.

correction-needed — ACC2020SAVR/TAVIlastriskrow

PostAnyagehigh/prohibitiveriskomitsSYMPTOMATICsevereASconditioninprimaryrecommendation.

qualified — Currentguidanceversushistoricaltables

2025recommendationsdiffer; historical2021≥75notarithmeticalerror. Publicreferencepagemustdate2021/2020tablesandseparatelyprovidereviewed2025changes.

Qualifications on the reviewed points

  • Historicalclasses/LOEsarenotacomplete2026interventionpathway. Donotmerge2020/2021/2025thresholds.
  • AllcandidatesrequireconfirmationofsevereAS,attributablesymptoms,lifeexpectancy,QoL,anatomyandHeartTeamdecision.

References recorded with the episode

Recorded with the episode

2021 ESC/EACTS Guidelines for the management of valvular heart disease

Alec Vahanian, Friedhelm Beyersdorf

2021

DOI 10.1093/eurheartj/ehab395

Open source at eurointervention.pcronline.com

Link check recorded

Recorded as supporting
  • §5.2recommendationtable:all5symptomaticASrows,5asymptomaticrows,5modeofinterventionrowsand3ESCother-scenariorowsmatchrecordedclass/LOEandthresholds,withretainedfootnotes. BNPmustbewithoutotherexplanation; TAVI/SAVRanatomicalsuitabilityandHeartTeamcontextapply.
Limits and what this source leaves unreviewed
  • Historical2021 recommendation, not automatically current2026 guidance. Explicit original for AR3; series-wide attribution elsewhere does not establish claim-by-claim provenance.

Recorded with the episode

2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease — official slide set

Catherine M. Otto, Rick A. Nishimura

2020

DOI 10.1016/j.jacc.2020.11.018

Open source at professional.heart.org

Link check recorded

Recorded as supporting
  • OfficialASslides:all5ClassIAVRrowsand5asymptomaticIIa/IIbrowsmatchthe2020source; moderateASothercardiacsurgeryIIbC-EO.
  • SAVRage<65orlife>20; symptomatic65–80sharedchoiceand>80/life<10TF-TAVI,withanatomicaleligibility. High/prohibitiveriskTAVIrecommendationappliestoSYMPTOMATICsevereASwithexpectedsurvival>12monthsandacceptableQoL.
Limits and what this source leaves unreviewed
  • Exact recorded guideline; official issuing-society recommendation slide rows read. This is not exhaustive full-guideline, literature or corrigenda review. Local binary request403, WebFetch full readable source succeeded.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

2025 ESC/EACTS Guidelines for the management of valvular heart disease

ESC/EACTS Task Force

2025

DOI 10.1093/eurheartj/ehaf194

Open source at doi.org

Link check recorded

Recorded as supporting
  • RecommendationTable4:currentTAVI≥70yearswithtricuspidASandsuitableanatomy(IA); SAVR<70iflowrisk(IB). Non-TFTAVIunsuitableforsurgery/TFaccessIIaB.
  • AsymptomaticseverehighgradientAS,LVEF≥50%,lowproceduralrisk:interventionshouldbeconsideredasanalternativetocloseactivesurveillance(IIaA),exerciseconfirmationiffeasible.
Limits and what this source leaves unreviewed
  • Supporting current comparison only, not original. Aortic-disease criteria now also refer to2024aortic guideline; that complete separate pathway not audited.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Aortic Stenosis 3/5: Intervention Criteria (ESC 2021 + ACC/AHA 2020)

Part 3 of the AS series: indications for intervention, with class of recommendation and level of evidence. ESC/EACTS 2021: symptomatic severe high-gradient AS (I B), low-flow low-gradient AS with reduced EF and flow reserve (I B), asymptomatic AS with LVEF <50% (I B) or symptoms on exercise testing (I C); LVEF <55% (IIa B), a sustained BP fall >20 mmHg on exercise (IIa C), and, with LVEF >55% and low risk, very severe AS (MG ≥60 mmHg or Vmax >5 m/s), rapid progression with severe calcification or BNP >3× normal (IIa B). SAVR for <75 y and low risk (STS/EuroSCORE II <4%) (I B); TAVI for ≥75 y or high risk >8% (I A). ACC/AHA 2020: AVR for D1 symptoms (I A), C2 LVEF <50%, other cardiac surgery, D2 and D3 (I B-NR); Vmax ≥5 m/s (IIa B-R), BNP >3×, velocity rise ≥0.3 m/s/yr or abnormal exercise test (IIa B-NR); SAVR <65 y, shared decision 65-80 y, TF-TAVI >80 y (all I A).

Save this for your exam 📌

Next, Part 4/5: Anaesthetic Goals and Haemodynamics (coming up in the next post).

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #AorticStenosis #TAVI #ESCGuidelines #ValvularHeartDisease #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 63 in this tracked set.

Postiz publish time (28 October 2026, 19:07 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Aortic Stenosis 2/5: Grading Severity on Echo

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Aortic Stenosis 2/5: Grading Severity on Echo: scoped rendered-panel and claim review; qualifications and unresolved groups remain. Not approved for publication.

Review scope

Every2-second decoded sample contact sheet examined; all distinct recovered main teaching panels also read at full image resolution and compared with recovered exact scripts/specs where available. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: All measurement/discordant-flow/DSE details and boundary conventions; CT calcium bands are probability categories, not binary diagnosis.

Still unreviewed

  • ExactrecordedoriginalASEeditionnotrecoverablefromgenericseriesattribution; updated2025integrateddiagnosticalgorithm/completefootnotesnotfullymapped.
  • Continuous video/audio, transient between-sample overlays and identity with the native Instagram upload remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — Continuityformula, squaredLVOT, CWalignment

Formulacorrect; primarysaysgreatestPOTENTIALsourceoferror,notthatoneparticular1mmerrorisempiricallycommonest. Alignment/multiplewindowsmatter.

qualified — Severity5-rowtable

2017Table3numericsmapped; sourceusesmoderate3.0–4.0and20–40whilepostrounded3.0–3.9/20–39. Donotimplydiscontinuitiesorglobalsingleparameterdiagnosis; AVA<1.0historicalechogradingdiffersstaging≤1.0.

qualified — Lowflowcategories/DSE/CT

Approachconsistentwithprimaryintegratedalgorithm,butnormalBPandmeasurementreviewneededbeforeparadoxicallowflowdiagnosis.

qualified — Reserve≥20andCT2000/1200

2017Table5supports≥CTvaluesasLIKELY,notbinaryproof. Sourceitselfusesboth>20and≥20SVreservephrasing; identifyprotocolratherthanmanufactureaboundaryerror.

Qualifications on the reviewed points

  • Useintegratedseverity,flow,BP,clinicalcontextandmultipleDopplerwindows; calcificationlimitsplanimetry.
  • CTcalciumburdenisprobabilisticandversion/populationdependent; cannotreplaceintegratedconfirmation.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Recommendations on the Echocardiographic Assessment of Aortic Valve Stenosis: A Focused Update from EACVI and ASE

Helmut Baumgartner, Judy Hung, Javier Bermejo

2017

DOI 10.1016/j.echo.2017.02.009

Open source at asecho.org

Link check recorded

Recorded as supporting
  • Table3: mildVmax2.6–2.9; AVA>1.5/1.0–1.5/<1.0; AVAi>0.85/0.60–0.85/<0.6; DVI>0.50/0.25–0.50/<0.25. Table moderateVmax3.0–4.0,MG20–40 overlaps severe≥4/≥40; integrate findings, not rounded labels alone.
  • Continuity equation and squaredLVOTdiameter major potential error; misaligned CW underestimates velocity/gradient; calcification limits planimetry.
  • Table5 CT severeAS likely men≥2000,women≥1200AU; verylikely≥3000/≥1600; unlikely<1600/<800. Probability/context, not universal binary test.
  • DSE sections: AVA≤1 with severe flow velocities/gradients and integrated flow response; document stage data. Source uses >20%SV reserve in several passages but ≥20% elsewhere, so do not invent one universal boundary.
Limits and what this source leaves unreviewed
  • New exact supporting guideline, not proven original from generic ASE attribution. Distinguish2017echograding from ACC2020stages and ESC2021/2025. Not every anaesthetic recommendation comes from this source.

Supporting literature checked separately. Not the episode’s recorded source.

Guidelines for Performing a Comprehensive Transesophageal Echocardiographic Examination: Recommendations from ASE and SCA

Rebecca T. Hahn, Theodore Abraham, Mark S. Adams

2013

DOI 10.1016/j.echo.2013.07.009

Open source at asecho.org

Link check recorded

Recorded as supporting
  • Mitral anatomy pp942–943 and Figure7: P1 lateral/P3 medial, aortic valve12o’clock, anterior1/3 annular circumference, posterior2/3; Figure7 says anterior2/3 surface area, whereas adjacent prose says roughly equal leaflet areas. This internal inconsistency is retained, not silently settled.
  • Standard MEcommissural P3–A2–P1 and MELAX P2–A2 sections; scallops vary with probe plane and multiple views are needed.
  • AV/LVOT pp945–946: MEAVSAX for cusp/orifice morphology, MELAX for LVOT size; deepTG/TGLAX align CW Doppler; TEE may underestimate transaortic velocities.
  • AV anatomy and MEAVSAX cusp identification: NCC adjacent IAS, RCC anterior. RootLAX120–140°; angles approximate.
Limits and what this source leaves unreviewed
  • Full original2013PDF retrieved/read in scoped sections. Not complete surgical-neighbour injury, papillary blood-supply, TAVI complication or treatment authority.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Aortic Stenosis 2/5: Grading Severity on Echo

Part 2 of the AS series: grading on echo. Severe AS is Vmax ≥4 m/s, mean gradient ≥40 mmHg, AVA <1.0 cm² (indexed <0.6 cm²/m²) and a velocity ratio <0.25. The continuity equation squares the LVOT diameter, so small measurement errors matter. When AVA and gradient disagree, check flow: classical low-flow (EF <50%) needs low-dose dobutamine echo, paradoxical low-flow (EF ≥50%, SVi ≤35 ml/m²) needs a CT calcium score (men ≥2000, women ≥1200 AU).

Save this for your exam 📌

Next, Part 3/5: Intervention Criteria (ESC 2021 + ACC/AHA 2020) (coming up in the next post).

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #AorticStenosis #Echocardiography #TEE #ValvularHeartDisease #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 64 in this tracked set.

Postiz publish time (28 October 2026, 16:04 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Aortic Stenosis 1/5: Aetiology and Pathophysiology

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Aortic Stenosis 1/5: Aetiology and Pathophysiology: scoped rendered-panel and claim review; qualifications and unresolved groups remain. Not approved for publication.

Review scope

Every2-second decoded sample contact sheet examined; all distinct recovered main teaching panels also read at full image resolution and compared with recovered exact scripts/specs where available. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Original historical symptom-survival and atrial-contribution estimates; no patient-specific survival prediction or universal 40% value.

Still unreviewed

  • Exactoriginalnatural-history,40%atrialfilling,physicalfindingsandHeydevWFsources; allnumericage/areaqualifiers.
  • Continuous video/audio, transient between-sample overlays and identity with the native Instagram upload remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — Aetiologyandageestimates

Calcific,bicuspid,rheumaticcausesconsistentwith2017aetiologysection; exact>65/10–20earlierisaliterature/individualrange,nothardrule.

unresolved — NormalAVA3–4,symptomsaround1; atrialkickupto40%

Exactnormalarea/40%cohortnotrecorded; EF/flow/severity/symptomrelationshipnotuniversal. DonotdiagnosesymptomsfromAVAalone.

qualified — PressureoverloadLVH/diastolicdysfunction; subendocardialischaemia

MechanismcoherentwithAS/physiologysources; CPPsimplificationnotuniversalexactgradientandlowdiastolicpressureisnotobligatoryinallAS.

unresolved — Untreatedangina5/syncope3/HF2yearssurvival

Historicalteachingestimates,notcontemporaryindividualprediction. Exactoriginalnatural-historycohortandapplicabilitynottraced; shouldnotberepublishedasunqualifiedprognosis.

unresolved — Pulse/A2/murmur/Heydesyndrome

Classicfindingsmayvarywithflow/mixedvalvedisease; sourcefordetailedphysicalfindingsandacquiredvWFpathophysiologynotfullyretrieved.

Qualifications on the reviewed points

  • Dateandcontextualisehistoricaluntreatedsurvivalfigures; notindividualprognosticcounselling.
  • Symptomstatusneedsexplicitassessment,notAVAcutoffalone; atrialcontributionvarieswithloading/rhythm.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Recommendations on the Echocardiographic Assessment of Aortic Valve Stenosis: A Focused Update from EACVI and ASE

Helmut Baumgartner, Judy Hung, Javier Bermejo

2017

DOI 10.1016/j.echo.2017.02.009

Open source at asecho.org

Link check recorded

Recorded as supporting
  • Table3: mildVmax2.6–2.9; AVA>1.5/1.0–1.5/<1.0; AVAi>0.85/0.60–0.85/<0.6; DVI>0.50/0.25–0.50/<0.25. Table moderateVmax3.0–4.0,MG20–40 overlaps severe≥4/≥40; integrate findings, not rounded labels alone.
  • Continuity equation and squaredLVOTdiameter major potential error; misaligned CW underestimates velocity/gradient; calcification limits planimetry.
  • Table5 CT severeAS likely men≥2000,women≥1200AU; verylikely≥3000/≥1600; unlikely<1600/<800. Probability/context, not universal binary test.
  • DSE sections: AVA≤1 with severe flow velocities/gradients and integrated flow response; document stage data. Source uses >20%SV reserve in several passages but ≥20% elsewhere, so do not invent one universal boundary.
Limits and what this source leaves unreviewed
  • New exact supporting guideline, not proven original from generic ASE attribution. Distinguish2017echograding from ACC2020stages and ESC2021/2025. Not every anaesthetic recommendation comes from this source.

Supporting literature checked separately. Not the episode’s recorded source.

Regulation of Coronary Blood Flow

Adam G. Goodwill, Gregory M. Dick, Alexander M. Kiel, Johnathan D. Tune

2017

DOI 10.1002/cphy.c160016

Open source at pmc.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Mechanical determinants/extravascular compression: LV flow predominantly diastolic, subendocardial systolic flow minimal; normal RV has systolic and diastolic flow.
  • Diastolic arterial minus intraventricular pressure is a reasonable simplified estimate for innermost LV subendocardium, not an exact universal coronary gradient.
  • Metabolic control: resting LV oxygen extraction≈70–80%, greater demand met chiefly by flow. RV resting extraction≈45% with more extraction reserve.
Limits and what this source leaves unreviewed
  • New authoritative physiology review, NOT a recorded original or primary human trial. Specific experimental findings include animal studies. Do not universalise chamber-specific figures or equate a teaching CPP formula to complete autoregulation physiology.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Aortic Stenosis 1/5: Aetiology and Pathophysiology

Valve series, part 1: why aortic stenosis behaves the way it does. Calcific degeneration, bicuspid valves (presenting 10-20 years earlier) and rheumatic disease are the big three. A normal AVA is 3-4 cm², and symptoms usually start below about 1 cm². Pressure overload drives concentric LVH and a stiff LV that depends on the atrial kick (up to 40% of filling). High LVEDP plus low diastolic pressure cuts coronary perfusion, so subendocardial ischaemia can occur even with normal coronaries. Untreated, survival after angina is about 5 years, after syncope 3 and after heart failure 2.

Save this for your exam 📌

Next, Part 2/5: Grading AS Severity on Echo (coming up in the next post).

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #AorticStenosis #ValvularHeartDisease #Echocardiography #Cardiology #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 65 in this tracked set.

Postiz publish time (28 October 2026, 12:48 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

SVR and PVR: Formulas and Normal Values

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

SVR and PVR: Formulas and Normal Values: scoped rendered-panel and claim review; qualifications and unresolved groups remain. Not approved for publication.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Confirmed error

The independent review confirmed an error against the checked source.

Reviewed wording

PVR = 80 × (mean PAP − PCWP) / CO; normal <250 dyn·s/cm⁵ (≈ <3 Wood units)

First-pass proposal

PVR = (mPAP − PAWP)/CO in Wood units; multiply by 80 for dyn·s·cm⁻⁵. Thus 250 dyn·s·cm⁻⁵ = 3.125 WU. Distinguish historical teaching ranges from the 2022 ESC/ERS upper normal around 2 WU and pre-capillary PH definition: mPAP >20 mmHg, PAWP ≤15 mmHg and PVR >2 WU. Do not use <3 WU to rule out disease.

Independent review wording

Normal PVR ≤2 WU (≈160 dyn·s·cm⁻⁵) (ESC/ERS 2022).

Evidence already listed on this post

  • 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Review scope

Every2-second decoded sample contact sheet examined; all distinct recovered main teaching panels also read at full image resolution and compared with recovered exact scripts/specs where available. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Exact original SVRI/TPG ranges and context, current normal PVR versus PH definitions and all indexing/units.

Still unreviewed

  • ExactrecordedoriginaladultSVR/SVRI/TPGrangesandallnormal-populationconditions.
  • Continuous video/audio, transient between-sample overlays and identity with the native Instagram upload remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — SVR/PVRformulas,80conversion,indexusingCI

CorrectwithpressuresmmHg,CO L/min,CI L/min/m²;1WU=80dyn·s·cm^-5.

correction-needed — NormalPVR<250≈<3WU

250/80=3.125WU(≈3isarounding,notexactequality); modernESC2022uppernormalaround2WU. Donotuseold<3boundarytoexcludepulmonaryvasculardisease.

unresolved — SVR800–1200 andSVRI1970–2390normals

Adultteachingrangesdependonsource/clinicalconditions. ExactnarrowSVRIoriginalabsent; cannotinferbyarbitraryBSAorlabeldifferentpublishedrangeserrors.

qualified — TPG=mPAP−PCWP;normal<12

Differencecorrect,notcurrentPHclassificationrule;TPGdependsflow/loadingandcannotreplacePVR/PAWP/mPAPintegratedclassification.

Qualifications on the reviewed points

  • Separatehistoricalnormalrangesfromcurrentdiagnosticdefinitions; normalrangeisnotatreatmentthreshold.
  • PAWPmeasurementquality,respiratoryconditions,cardiacoutputmethodandunitsmatter.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Marc Humbert, Gabor Kovacs, Marius M. Hoeper

2022

DOI 10.1093/eurheartj/ehac237

Open source at doi.org

Link check recorded

Recorded as supporting
  • Table5: PH mPAP>20mmHg; pre-capillary PAWP≤15,PVR>2WU; isolated post-capillary PAWP>15,PVR≤2; combined post-/pre-capillary PAWP>15,PVR>2, all with mPAP>20.
  • §5.1.12.2: acute positive response mPAP reduction≥10 to≤40mmHg with unchanged/increasedCO; CCB-responder testing only IPAH/HPAH/DPAH, with separate transplant/CHD purposes.
  • §3.1 upper normal PVR around2WU; §5.1.12.1 PVR=(mPAP−PAWP)/CO, directFick/thermodilution selection, indirectFick less reliable; shunts need special measurements.
Limits and what this source leaves unreviewed
  • Exact source explicitly named by PH/iNO posts. In other posts this is newly checked supporting evidence; no full PH diagnostic/therapeutic algorithm endorsement.

Supporting literature checked separately. Not the episode’s recorded source.

Edwards Lifesciences: hemodynamic monitoring clinical reference guide

Edwards Lifesciences

Year not recorded

DOI not recorded

Open source at edwardsprodjp.blob.core.windows.net

Link check recorded

Recorded as supporting
  • Adultresistanceformulasandunits:SVR=80(MAP−RAP)/CO; PVR=80(mPAP−PAWP)/CO; indexusingCI. Sourceadultnormalrangesvarybysection/population.
  • Ficksectionpp182–183:CO=VO2/(CaO2−CvO2),CI=CO/BSA; units/conversionmustmatch; assumednormalVO2mayproduceerrors.
Limits and what this source leaves unreviewed
  • Newmanufacturerauthoritativeeducationalmanual,notrecordedoriginaloramodel-specificIFU.2014edition; notcurrentPHnormaldefinitionauthority.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

SVR and PVR: Formulas and Normal Values

SVR = 80 × (MAP − CVP) / CO, normally 800-1200 dyn·s/cm⁵. PVR = 80 × (mean PAP − PCWP) / CO, normally under 250 dyn·s/cm⁵ (under about 3 Wood units). Multiply Wood units by 80 to convert. The transpulmonary gradient (mean PAP − PCWP) is normally under 12 mmHg.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #Haemodynamics #PulmonaryHypertension #Physiology #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 66 in this tracked set.

Postiz publish time (28 October 2026, 08:41 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Ventricular Interdependence

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Ventricular Interdependence: scoped rendered-panel and claim review; qualifications and unresolved groups remain. Not approved for publication.

Review scope

Every2-second decoded sample contact sheet examined; all distinct recovered main teaching panels also read at full image resolution and compared with recovered exact scripts/specs where available. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Original mechanics/septal timing and pericardial-disease sources; complete cause-specific RV/PE/tamponade/constriction algorithms.

Still unreviewed

  • Exactoriginalmechanics/echoseptal-timingandpericardialdiseaseguidelines; completeRVfailurepatient-specificalgorithm.
  • Continuous video/audio, transient between-sample overlays and identity with the native Instagram upload remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — Sharedseptum/pericardiumandRVdilationLVfilling

PH/RVassessmentprimaryphysiologyconsistentwithinterdependence; sourceforfullmechanicalrelationshipandallillustrateddiseaseexamplesstillopen.

qualified — D-shapedLV

SeptalflatteningnotuniquetoRVvolumeoverload: pressureversusvolumeloadandtimingmatter; identifyend-systolic/end-diastolicshapeandcombinedloading.

unresolved — PE/tamponade/constrictionexamples

Differentdisease-specificmechanisms/diagnosticcriteria; nofullexactpericardialguidelinecomparisonhere.

qualified — LowerPVR,avoidoverfilling,maintainsystemicpressure

BroadRVfailuresupportprinciples,notgenericmanagementofeverylistedcondition. PHprimarysupportsavoidingexcessfluid/hypotension;tamponaderequirescause-specificdrainageassessment,notthismnemonicalone.

qualified — Advanced PAH/right-HF fluid and systemic-pressure support

Exact 2022 ESC/ERS §6.3.7.1 passage read: most such patients need negative fluid balance; low CO may benefit from inotropes; maintaining mean systemic BP >60 mmHg is a key objective, sometimes requiring vasopressors. This is advanced PAH/right-HF context, not a generic PE/tamponade/constriction algorithm.

Qualifications on the reviewed points

  • SeptalshapealonecannotdiagnoseRVloadingcause; phasesandotherfindingsmustbeintegrated.
  • Do notapplyaPVR-lowering/pressorrecipeasthecompletemanagementoftamponadeorconstriction.

References recorded with the episode

Recorded with the episode

Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from ASE and EACVI

Roberto M. Lang, Luigi P. Badano, Victor Mor-Avi

2015

DOI 10.1016/j.echo.2014.10.003

Open source at asecho.org

Link check recorded

Recorded as supporting
  • Table14 all8 sex-specific root means/SDs match rendered millimetres after cm×10: annulus26±3/23±2; sinuses34±3/30±3; STJ29±3/26±3; proximalascending30±4/27±4.
  • §11–13: annulus mid-systolic inner-edge; other root dimensions end-diastolic leading-edge; use age/BSA nomograms, not population mean as individual cutoff.
Limits and what this source leaves unreviewed
  • Exact2015Table14 recorded in index71 footer and actually read. Does not validate all operative anatomy/TAVI risk statements.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Marc Humbert, Gabor Kovacs, Marius M. Hoeper

2022

DOI 10.1093/eurheartj/ehac237

Open source at doi.org

Link check recorded

Recorded as supporting
  • Table5: PH mPAP>20mmHg; pre-capillary PAWP≤15,PVR>2WU; isolated post-capillary PAWP>15,PVR≤2; combined post-/pre-capillary PAWP>15,PVR>2, all with mPAP>20.
  • §5.1.12.2: acute positive response mPAP reduction≥10 to≤40mmHg with unchanged/increasedCO; CCB-responder testing only IPAH/HPAH/DPAH, with separate transplant/CHD purposes.
  • §3.1 upper normal PVR around2WU; §5.1.12.1 PVR=(mPAP−PAWP)/CO, directFick/thermodilution selection, indirectFick less reliable; shunts need special measurements.
Limits and what this source leaves unreviewed
  • Exact source explicitly named by PH/iNO posts. In other posts this is newly checked supporting evidence; no full PH diagnostic/therapeutic algorithm endorsement.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Ventricular Interdependence

Ventricular interdependence: the two ventricles share the septum and the pericardium, so RV dilatation pushes the septum left, gives a D-shaped LV and reduces LV filling and output. It explains why acute RV failure, PE, tamponade and constriction cause low output. Avoid overfilling the RV, lower PVR and keep systemic pressure up to perfuse the RV.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #RVFailure #Physiology #Haemodynamics #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 67 in this tracked set.

Postiz publish time (28 October 2026, 00:32 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Fluid Responsiveness: PPV and SVV Cut-offs

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Fluid Responsiveness: PPV and SVV Cut-offs. Selected claim-source mappings checked; remaining claims and full media review are unresolved.

Review scope

Original caption plus three decoded rendered frames and exact recorded body where recoverable. No full-frame-sequence/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Full video reviewed: no
  • Native upload identity verified: no

Remaining priority: Original PPV/SVV cutoff/validity source, RV-failure limitations, PLR technique and low-tidal-volume challenge evidence.

Still unreviewed

  • Exact original source for PPV >13%, SVV >12% and the absolute validity-only/invalid wording.
  • Full cardiac/RV-failure contraindication/limitation and low-tidal-volume challenge approaches.

Checks recorded in this pass

These checks do not clear the post.

  • Grey-zone range and PLR CO threshold checked, with population/method limitations.

Qualifications on the reviewed points

  • Specify tidal volume in mL/kg predicted body weight, not an unspecified kg basis.
  • Fluid responsiveness does not establish benefit or safety of a fluid bolus; assess perfusion and congestion.
  • PPV/SVV cutoffs are context-specific and can mislead with RV dysfunction, rhythm/ventilation abnormalities or altered chest/abdominal conditions.
  • PLR needs real-time CO assessment and correct manoeuvre; measurement uncertainty matters near 10%.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Assessing the diagnostic accuracy of pulse pressure variations for the prediction of fluid responsiveness: a gray zone approach

Cannesson M et al.

2011

DOI 10.1097/ALN.0b013e318225b80a

Open source at doi.org

Link check recorded

Recorded as supporting
  • PPV 9–13% was an inconclusive grey zone in the studied perioperative cohort.
Limits and what this source leaves unreviewed
  • Supporting study; no exact original source recorded.
  • Not a universal binary threshold for all critically ill/cardiac surgery patients.

Supporting literature checked separately. Not the episode’s recorded source.

Prediction of fluid responsiveness: an update

Monnet X, Marik PE, Teboul JL

2016

DOI 10.1186/s13613-016-0216-7

Open source at link.springer.com

Link check recorded

Recorded as supporting
  • Passive-leg-raise CO increase around 10% predicts fluid responsiveness when measured with a sufficiently rapid/reliable CO method.
  • PPV/SVV require assessment of ventilatory/rhythm conditions; arterial pulse-pressure response is less reliable than measured CO for PLR.
Limits and what this source leaves unreviewed
  • Supporting review, not original provenance.
  • Does not make every PPV >13 or SVV >12 a mandate for fluid; fluid responsiveness is not fluid requirement.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Fluid Responsiveness: PPV and SVV Cut-offs

Dynamic indices beat CVP for predicting fluid response: PPV >13% or SVV >12% suggests the patient will respond, with a grey zone of 9-13%. They only work with controlled ventilation, tidal volumes ≥8 ml/kg, sinus rhythm and a closed chest, which rules them out once the sternum is open. Passive leg raising with a ≥10% rise in cardiac output is a useful alternative.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #FluidResponsiveness #Haemodynamics #Monitoring #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 68 in this tracked set.

Postiz publish time (27 October 2026, 21:52 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Myocardial O2 Supply vs Demand

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Myocardial O2 Supply vs Demand: scoped rendered-panel and claim review; qualifications and unresolved groups remain. Not approved for publication.

Review scope

Every2-second decoded sample contact sheet examined; all distinct recovered main teaching panels also read at full image resolution and compared with recovered exact scripts/specs where available. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: All demand/determinant/critical-stenosis assertions and exact original supply-demand diagram; distinguish LV from RV oxygen extraction.

Still unreviewed

  • Exactoriginalcitationnotrecorded; underlyinghumanexperimentalandpopulationcontextnotindependentlyauditedbeyondauthoritativereview.
  • Continuous video/audio, transient between-sample overlays and identity with the native Instagram upload remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — Supplyanddemandtable

Flow/perfusionpressure,oxygencontent,vasculartoneandmetabolicworkarecoupled; coronarydiameterisareductionofvascularresistancemechanisms,notindependentguaranteeofsupply.

qualified — Tachycardiaonsupplyanddemandsides

ShorterLVdiastolicperfusiontimeandgreaterworksupported; intactmetabolicvasodilationcanincreaseflow,soactualischaemiadependsonreserve/pressure/loading.

qualified — Myocardium70%extraction

SourceexplicitlyLV≈70–80%;RV≈45%andgreaterextractionreserve. ScopefiguretoLV/whole-heartteachingapproximation,noteverychamber.

Qualifications on the reviewed points

  • The70%statementprimarilydescribesrestingLV; notuniversalRVextraction.
  • Thisisaphysiologicframework,notanumerictransfusion/pressor/ratetreatmentprotocol.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Regulation of Coronary Blood Flow

Adam G. Goodwill, Gregory M. Dick, Alexander M. Kiel, Johnathan D. Tune

2017

DOI 10.1002/cphy.c160016

Open source at pmc.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Mechanical determinants/extravascular compression: LV flow predominantly diastolic, subendocardial systolic flow minimal; normal RV has systolic and diastolic flow.
  • Diastolic arterial minus intraventricular pressure is a reasonable simplified estimate for innermost LV subendocardium, not an exact universal coronary gradient.
  • Metabolic control: resting LV oxygen extraction≈70–80%, greater demand met chiefly by flow. RV resting extraction≈45% with more extraction reserve.
Limits and what this source leaves unreviewed
  • New authoritative physiology review, NOT a recorded original or primary human trial. Specific experimental findings include animal studies. Do not universalise chamber-specific figures or equate a teaching CPP formula to complete autoregulation physiology.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Myocardial O2 Supply vs Demand

Myocardial oxygen balance: supply depends on diastolic time, coronary perfusion pressure, arterial O2 content and coronary diameter; demand depends on heart rate, wall tension and contractility. Heart rate appears on both sides, which is why tachycardia is so harmful. The heart already extracts about 70% of delivered oxygen, so extra supply must come from more flow.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #MyocardialIschaemia #Physiology #Haemodynamics #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 69 in this tracked set.

Postiz publish time (27 October 2026, 17:06 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Coronary Blood Flow: LV vs RV Timing

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Coronary Blood Flow: LV vs RV Timing: scoped rendered-panel and claim review; qualifications and unresolved groups remain. Not approved for publication.

Review scope

Every2-second decoded sample contact sheet examined; all distinct recovered main teaching panels also read at full image resolution and compared with recovered exact scripts/specs where available. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Exact original flow-timing and CPP simplification source; transmural/LV-RV/perfusion-pressure exceptions.

Still unreviewed

  • Recordedexactoriginalnotidentified; fullunderlyinghumanstudyconfirmationandclinicalmanagementimplicationsremainopen.
  • Continuous video/audio, transient between-sample overlays and identity with the native Instagram upload remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — LVmostlydiastolic/subendocardialflowstopsinsystole

Source:littleifanyendocardialflowinsystoleandLV≈80%diastolic. NotsystoliccessationinallLVlayers.

qualified — NormalRVflowbothphases;PHreducesperfusion

LowernormalRVcompressivepressureallowsbothphases. ElevatedRVpressurechangesflow;individualpressure/systemicgradient/coronaryreserve matters.

qualified — CPP=aorticDBP−LVEDP

SourceexplicitlyreasonableestimateforinnermostLVsubendocardium,notexactgradientforallcoronarybeds;venous/tissue/zero-flowpressuresmatter.

qualified — Tachycardia/subendocardialvulnerability

Shorterdiastoletimeandgreatercompressiveforces/metabolicrequirementsincreasevulnerability; notuniversalischemiaatanyparticularrate.

Qualifications on the reviewed points

  • WriteCPP≈aorticDBP−LVEDPasateachingsubendocardialestimate,notuniversalidentity.
  • SeparatehealthyRVfromPH/RVpressureoverload; ECG/pressure/rhythm/perfusioncontextneeded.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Regulation of Coronary Blood Flow

Adam G. Goodwill, Gregory M. Dick, Alexander M. Kiel, Johnathan D. Tune

2017

DOI 10.1002/cphy.c160016

Open source at pmc.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Mechanical determinants/extravascular compression: LV flow predominantly diastolic, subendocardial systolic flow minimal; normal RV has systolic and diastolic flow.
  • Diastolic arterial minus intraventricular pressure is a reasonable simplified estimate for innermost LV subendocardium, not an exact universal coronary gradient.
  • Metabolic control: resting LV oxygen extraction≈70–80%, greater demand met chiefly by flow. RV resting extraction≈45% with more extraction reserve.
Limits and what this source leaves unreviewed
  • New authoritative physiology review, NOT a recorded original or primary human trial. Specific experimental findings include animal studies. Do not universalise chamber-specific figures or equate a teaching CPP formula to complete autoregulation physiology.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Coronary Blood Flow: LV vs RV Timing

Left coronary flow is mainly diastolic, because systolic compression stops subendocardial flow. RV flow continues through systole and diastole, since RV pressure is low, unless pulmonary hypertension raises it. LV coronary perfusion pressure is aortic diastolic pressure minus LVEDP, and tachycardia steals diastolic time.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #CoronaryPhysiology #Physiology #Haemodynamics #DMCardiacAnaesthesia #Anaesthesia #ExamPrep #MedEd #Viva #FOAMed #CardiacSurgery

Sequence 70 in this tracked set.

Postiz publish time (27 October 2026, 13:24 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

The β-blocker that wears off in minutes. Here's all of it on one page: mechanism, RBC esterase metabolism, kinetics, lab

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

The β-blocker that wears off in minutes. Here's all of it on one page: mechanism, RBC esterase metabolism, kinetics, lab: scoped rendered-panel and claim review; qualifications and unresolved groups remain. Not approved for publication.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Confirmed error

The independent review confirmed an error against the checked source.

Reviewed wording

Pre-laryngoscopy/sternotomy bolus 0.5–1.5 mg/kg

First-pass proposal

Remove this from the “Dose (label)” box. The US label does not recommend preventive perioperative use; its indicated immediate-treatment regimen is 1 mg/kg over 30 s, then 150 micrograms/kg/min if needed. Any off-label pre-laryngoscopy practice needs separate exact evidence and a specialist protocol.

Independent review wording

Move pre-laryngoscopy bolus out of 'label' box; mark as practice-based.

Evidence already listed on this post

  • BREVIBLOC(esmololhydrochloride)USprescribinginformation — DailyMedcurrentlisting

Missing qualifier

The point needs a qualifier. The independent wording is below.

Reviewed wording

Use 10 mg/mL ready-to-use. >10 mg/mL ↑ phlebitis / extravasation necrosis.

First-pass proposal

The US label includes both 10 and 20 mg/mL ready-to-use products. Verify formulation, concentration, appropriate site and pump calculation; monitor for site injury and extravasation. Do not present >10 mg/mL as a universal contraindication.

Independent review wording

Note 20 mg/mL premixed product exists; use large vein.

Evidence already listed on this post

  • BREVIBLOC(esmololhydrochloride)USprescribinginformation — DailyMedcurrentlisting

Confirmed error

The independent review confirmed an error against the checked source.

Reviewed wording

Hypotension = commonest AE → gone in 10–20 min.

First-pass proposal

Hypotension is common and may be severe. Reduce or stop treatment as appropriate and provide monitored support. The label reports reversal usually within 30 min, not guaranteed within 10–20 min.

Independent review wording

Hypotension usually resolves within ~30 min of stopping (label).

Evidence already listed on this post

  • BREVIBLOC(esmololhydrochloride)USprescribinginformation — DailyMedcurrentlisting

Review scope

Every2-second decoded sample contact sheet examined; all distinct recovered main teaching panels also read at full image resolution and compared with recovered exact scripts/specs where available. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Original label version, off-label pre-laryngoscopy evidence, exact succinylcholine-prolongation numbers and full local aortic-dissection comparison.

Still unreviewed

  • ExactoriginalStoeltingedition/pages; offlabelTOF/LVOTO/ischaemiaandprelaryngoscopyevidence; detailedmechanismdiagram,5→8Suxclaimand2014ESCprimarytable.
  • Continuous video/audio, transient between-sample overlays and identity with the native Instagram upload remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — Mechanism/metabolism/halflives/offset

β1selectivity,RBCesterasesand2/9min,acidmetabolite3.7hmatchlabel. Exactonset1–2anddiagramionic/lusitropy/PBPdetailsnotfullyderivedfromlabel.

supported — Loading/infusion/titration/maxand70kgmath

500µg/kg×70=35mg;50µg/kg/min×70=3.5mg/min=210mg/h÷10mg/mL=21mL/h. Optionalrebolusesand≥4mintitrationrequireBP/ECGresponse.

correction-needed — Prelaryngoscopy/sternotomy0.5–1.5mg/kginlabeldosebox

NotlabelregimenandUSlabeldoesnotrecommendpreventingevents. Differentofflabelanaestheticpracticewouldneeditsownsource/population/route/rate.

correction-needed — Only10mg/mL/greater10riskstatement

20mg/mLready-to-usealsolabelled;siteinjury/extravasationriskmustbeproduct/site-specific,notanuniversalbanabove10.

qualified — Contra/PH,CCB;hypotensiongone10–20min;Sux5→8

PHcontraactuallymatchesUSlabel. Hypotensionnotguaranteedgone10–20;labelusuallywithin30. Suxprolongationyes,exact5→8notverified.

unresolved — Dissection2014targets/LVOTOHOCM/TOF/ischaemia

2022aorticcomparisonisnewsupport,notvalidationofallquoted2014/offlabeluses; age/severity/ventricularfunction/exceptionsnotfullyreviewed.

Qualifications on the reviewed points

  • Verifyproductconcentrationandpumpunits;high-riskµg/kg/minversusmg/kgconfusionmustbeavoided.
  • ProphylacticlaryngoscopybolusmustnotbeprintedasUSlabeldosing. PHcontraisactuallyinUSPI;donotremovebecauseanothercontextusesbetablockade.
  • Hypotension/brady/bronchospasmneedmanagement,notwaitforfixedoffset.

References recorded with the episode

Recorded with the episode

BREVIBLOC(esmololhydrochloride)USprescribinginformation — DailyMedcurrentlisting

Baxter Healthcare Company

2023

DOI not recorded

Open source at dailymed.nlm.nih.gov

Link check recorded

Recorded as supporting
  • §2.1–2.2:optional500µg/kgover1minthen50µg/kg/min,titrate≥4min; generallymax200fortachycardiaand300forhypertension. Immediateperioperativecontrol1mg/kgover30sthen150µg/kg/minifneeded.
  • §1.2:preventiveuseforperioperativeeventsNOTrecommendedbyUSlabel. §3/16:10and20mg/mLready-to-usepresentations. §5.1hypotensionusuallyreverseswithin30minafterdosechange/stop.
  • §4contraindicationsincludePH,severebrady,>firstdegreeblock,shock/decompensatedHF,closeIVcardiodepressantCCB. §12RBCesterases,distribution2min,elimination9min,acidmetabolite3.7h; substantiallyrecoveredbetablockade10–20min.
  • §7prolongssuccinylcholineblock; exact5→8minutesnotstatedinreadlabel.
Limits and what this source leaves unreviewed
  • BreviblocUSPIrecordedbutexacteditionusedunidentified; listingheaderupdated14Mar2025,revised6/2023,archivecurrentversiondatedMay2026. ManufacturerPDFretrievedseparatelywasolder2018;thisDailyMedfulltextactuallyread. Offlabelusesnotvalidatedbylabel.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease

Eric M. Isselbacher, Ourania Preventza, James Hamilton Black III

2022

DOI 10.1016/j.jacc.2022.08.004

Open source at pmc.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Acuteaorticsyndromeanti-impulsetherapyneedsperfusion-safeBPandbetablockerexceptions;2022HR60–80versusquotedhistoricalESC2014≤60notitselfproof2014wrong.
Limits and what this source leaves unreviewed
  • New supporting2022primary guideline, not recorded original. Does not establish that all other societies use identical HR targets; newer ESC/aortic and complete imaging/operative pathways not audited.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

The β-blocker that wears off in minutes. Here's all of it on one page: mechanism, RBC esterase metabolism, kinetics, label dosing with a 70 kg worked example, dilution safety, theatre uses and contraindications.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily high-yield cardiac anaesthesia.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #Esmolol #BetaBlocker #Pharmacology #AorticDissection #HOCM #CardiacSurgery #Anaesthesiology #DMCardiacAnaesthesia #CriticalCare #AnaesthesiaPharmacology #MedEd #FOAMed

Sequence 71 in this tracked set.

Postiz publish time (27 October 2026, 10:17 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Aortic Root Anatomy

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Aortic Root Anatomy: scoped rendered-panel and claim review; qualifications and unresolved groups remain. Not approved for publication.

Review scope

Every2-second decoded sample contact sheet examined; all distinct recovered main teaching panels also read at full image resolution and compared with recovered exact scripts/specs where available. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Exact VARC/device coronary-height risk context, His/conduction anatomy and measurement methods; population means are not intervention cutoffs.

Still unreviewed

  • ExactVARC/TAVIexpertconsensuseditionandfullcoronaryriskalgorithm;operativeHis/anatomicalrenderreview;normalAVAoriginal.
  • Continuous video/audio, transient between-sample overlays and identity with the native Instagram upload remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — All8aorticrootmean±SDnumbers

Readoriginal2015Table14;allcm→mmconversionsandSDsmatch. Thesearemeans/SDs,not95%limitsorindividualdiseasecutoffs.

supported — Annulusmid-systoleinneredge;MELAX120–140

Matches2015/2013primarysections; otherrootdimensionsenddiastolicL-Landnomogramsimportant.

qualified — RCC/NCC/LCC,coaptation/root/curtain/Hisrelationships

Cusps/ostia/basicMEorientationandrootcomponentsprimarymatched; exact3DrenderleaderlocationandHis/membranousseptumoperativeinjuryschematicnotfullyanatomicallysignedoff.

unresolved — Coronaryheight<10mmTAVIobstructionrisk

ArecognisedriskfactorbutexactVARC/expertconsensuseditionabsent;notuniversalcutofforadequateriskmodel. Sinus/STJ/leaflet/device/virtual-valvetocoronaryfeaturesmatter.

unresolved — NormalAVA3–4cm²

Exactoriginalreference/normalpopulationnotindividuallytracedinthiscard.

Qualifications on the reviewed points

  • TTEpopulationmeans/SDsarenotTAVIsizingorindividualnormalupperlimits;useappropriate3D/CTandage/BSAcontext.
  • Lowostialheightisonecoronaryobstructionriskfactor,notasufficientassessment.

References recorded with the episode

Recorded with the episode

Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from ASE and EACVI

Roberto M. Lang, Luigi P. Badano, Victor Mor-Avi

2015

DOI 10.1016/j.echo.2014.10.003

Open source at asecho.org

Link check recorded

Recorded as supporting
  • Table14 all8 sex-specific root means/SDs match rendered millimetres after cm×10: annulus26±3/23±2; sinuses34±3/30±3; STJ29±3/26±3; proximalascending30±4/27±4.
  • §11–13: annulus mid-systolic inner-edge; other root dimensions end-diastolic leading-edge; use age/BSA nomograms, not population mean as individual cutoff.
Limits and what this source leaves unreviewed
  • Exact2015Table14 recorded in index71 footer and actually read. Does not validate all operative anatomy/TAVI risk statements.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Guidelines for Performing a Comprehensive Transesophageal Echocardiographic Examination: Recommendations from ASE and SCA

Rebecca T. Hahn, Theodore Abraham, Mark S. Adams

2013

DOI 10.1016/j.echo.2013.07.009

Open source at asecho.org

Link check recorded

Recorded as supporting
  • Mitral anatomy pp942–943 and Figure7: P1 lateral/P3 medial, aortic valve12o’clock, anterior1/3 annular circumference, posterior2/3; Figure7 says anterior2/3 surface area, whereas adjacent prose says roughly equal leaflet areas. This internal inconsistency is retained, not silently settled.
  • Standard MEcommissural P3–A2–P1 and MELAX P2–A2 sections; scallops vary with probe plane and multiple views are needed.
  • AV/LVOT pp945–946: MEAVSAX for cusp/orifice morphology, MELAX for LVOT size; deepTG/TGLAX align CW Doppler; TEE may underestimate transaortic velocities.
  • AV anatomy and MEAVSAX cusp identification: NCC adjacent IAS, RCC anterior. RootLAX120–140°; angles approximate.
Limits and what this source leaves unreviewed
  • Full original2013PDF retrieved/read in scoped sections. Not complete surgical-neighbour injury, papillary blood-supply, TAVI complication or treatment authority.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Aortic Root Anatomy

Every structure around the aortic valve that can catch you out in theatre 👇 the coronary ostia and the TAVI height cut-off, the non-coronary sinus, Mercedes-Benz coaptation, the RCC–NCC commissure over the His bundle, the aorto-mitral curtain, and normal root sizes from ASE/EACVI for men and women.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily high-yield cardiac anaesthesia.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #AorticValve #AorticRoot #TEE #Echocardiography #TAVI #CardiacSurgery #Anaesthesiology #DMCardiacAnaesthesia #PerioperativeEcho #CardiacAnatomy #MedEd #FOAMed

Sequence 72 in this tracked set.

Postiz publish time (27 October 2026, 07:34 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Partial

Partial review only. This label is not a full sign-off.

Pulmonary Hypertension: Definition, WHO Groups and Haemodynamic Cut-offs

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Pulmonary Hypertension: Definition, WHO Groups and Haemodynamic Cut-offs: scoped rendered-panel and claim review; qualifications and unresolved groups remain. Not approved for publication.

Review scope

Every2-second decoded sample contact sheet examined; all distinct recovered main teaching panels also read at full image resolution and compared with recovered exact scripts/specs where available. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Exact original population claim about preoperative group-2 PH; all group/subgroup and vasoreactivity-testing restrictions.

Still unreviewed

  • Specificcardiac-surgeryepidemiologyoriginal;fullclassification/measurement/vasoreactivitytreatmentexceptionsandnativeversion.
  • Continuous video/audio, transient between-sample overlays and identity with the native Instagram upload remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

supported — PHpre/postcapillarynumericdefinitions

AllthresholdsandunitsmatchTable5whenmPAP>20appliestoallcategories;precapillarynotidenticalPAH.

qualified — WHOgroups

Coregroups1–5match;group4includesotherpulmonaryarteryobstructions,notonlyCTEPH.

unresolved — Group2commonestbeforecardiacsurgery

Noexactpopulation/cohortforbeforecardiacsurgeryfrequencyrecorded. Group2commonoverallnotvalidationofaspecificoperativepopulationclaim.

qualified — iNOpositiveresponse≥10to≤40COmaintained

Exactthresholdmatch;COcanincreaseaswellasunchanged. CCB-respondertestingonlyIPAH/HPAH/DPAH;separatetransplant/CHDquestionsarenotsamegeneralPHtest.

Qualifications on the reviewed points

  • ApplyallhaemodynamicdefinitionswithmPAP>20,andmeasuredPAWP/PVRusingappropriatetechnique.
  • Do nottestallPHpatientsorselectCCBtherapyfromisolatedcutoff;specialistpopulationandpurposematter.

References recorded with the episode

Recorded with the episode

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Marc Humbert, Gabor Kovacs, Marius M. Hoeper

2022

DOI 10.1093/eurheartj/ehac237

Open source at doi.org

Link check recorded

Recorded as supporting
  • Table5: PH mPAP>20mmHg; pre-capillary PAWP≤15,PVR>2WU; isolated post-capillary PAWP>15,PVR≤2; combined post-/pre-capillary PAWP>15,PVR>2, all with mPAP>20.
  • §5.1.12.2: acute positive response mPAP reduction≥10 to≤40mmHg with unchanged/increasedCO; CCB-responder testing only IPAH/HPAH/DPAH, with separate transplant/CHD purposes.
  • §3.1 upper normal PVR around2WU; §5.1.12.1 PVR=(mPAP−PAWP)/CO, directFick/thermodilution selection, indirectFick less reliable; shunts need special measurements.
Limits and what this source leaves unreviewed
  • Exact source explicitly named by PH/iNO posts. In other posts this is newly checked supporting evidence; no full PH diagnostic/therapeutic algorithm endorsement.

Supporting literature checked separately

None recorded in this review.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Pulmonary Hypertension: Definition, WHO Groups and Haemodynamic Cut-offs

A classic viva opener: define pulmonary hypertension with the 2022 numbers, then use PAWP and PVR to say whether it is pre-capillary, post-capillary or combined, and place it in one of the five WHO groups before you plan the anaesthetic.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #PulmonaryHypertension #RightHeart #Haemodynamics #CardiacSurgery #Anaesthesia #DMCardiacAnaesthesia #CriticalCare #MedEd #ExamPrep #Viva

Sequence 73 in this tracked set.

Postiz publish time (26 October 2026, 19:23 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Fick Principle: Calculating Cardiac Output

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Fick Principle: Calculating Cardiac Output: scoped rendered-panel and claim review; qualifications and unresolved groups remain. Not approved for publication.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Missing qualifier

The point needs a qualifier. The independent wording is below.

Reviewed wording

Assumed VO₂ ≈ 125 mL/min/m² (estimate, not measured)

First-pass proposal

If using an assumed VO2 index, identify its validated population and multiply by body-surface area to obtain absolute VO2 in mL/min for cardiac output; otherwise calculate cardiac index. Use appropriately measured VO2 when required and state estimation limitations.

Independent review wording

Assumed VO2I ×BSA gives VO2; result otherwise is cardiac index.

Evidence already listed on this post

  • Edwards Lifesciences: hemodynamic monitoring clinical reference guide
  • 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Missing qualifier

The point needs a qualifier. The independent wording is below.

Reviewed wording

Low SvO₂ = wider a-v gap = lower CO

First-pass proposal

For constant VO2 and arterial oxygen content, a wider arterial–mixed-venous oxygen-content difference implies lower cardiac output; low SvO2 alone is not specific. With content in mL/dL and VO2 in mL/min: CO in L/min = VO2 / [10 × content difference].

Independent review wording

Holds at constant VO2 and Hb/SaO2.

Evidence already listed on this post

  • Edwards Lifesciences: hemodynamic monitoring clinical reference guide
  • Regulation of Coronary Blood Flow

Missing qualifier

The point needs a qualifier. The independent wording is below.

Reviewed wording

Inaccurate with shunts or high FiO₂ error

First-pass proposal

Shunts require site-specific compartmental oximetry and separate systemic/pulmonary flow assessment. Direct Fick can be appropriate and is not intrinsically invalid. At high FiO2, include relevant dissolved oxygen and measurement/VO2 limitations.

Independent review wording

Minor.

Evidence already listed on this post

  • 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Review scope

Every2-second decoded sample contact sheet examined; all distinct recovered main teaching panels also read at full image resolution and compared with recovered exact scripts/specs where available. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Original 125 mL/min/m² estimation formula/population, all Fick/content assumptions and actual complete script; shunts need compartmental oximetry.

Still unreviewed

  • Fulloriginalscriptnotrecovered;release-linked12-secondmediarecoveredandall5teachingsentencesread.
  • Exact125indexestimatepopulation/formulaandhighFiO2quantitativecorrection/1.34coefficientprimarysource.
  • Continuous video/audio, transient between-sample overlays and identity with the native Instagram upload remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — FickCOandCaO2equation

Fickrelationcorrect,butunitsomitted. WithVO2mL/minandcontentmL/dL,CO L/min=VO2/[10×(CaO2−CvO2)]; Hb g/dL,SaO2fraction,PaO2mmHg. Sourceexact1.34coefficient/oxygencontentqualificationneedsadditionaltrace.

correction-needed — AssumedVO2≈125mL/min/m²

IndexrequiresBSAforabsoluteVO2,orresultisCI. EstimatedVO2notmeasured;PHprimaryindirectFicklessreliable. Exact125populationformula notvalidated.

correction-needed — LowSvO2=widera-vgap=lowerCO

OnlyifVO2andarterialoxygencontentstable;changesinHb,SaO2,extraction/metabolismcanalterrelationship. Fickidentitydoesnotpermitunconditionalinference.

correction-needed — Inaccuratewithshunts/highFiO2

Overbroad:PHprimaryprefersdirectFickwithcompartmentaloximetryforCHDshunts;thermodilutionnotforshunts. Differentiatesystemic/pulmonaryflowandaccountforhighFiO2dissolvedO2.

Qualifications on the reviewed points

  • Do notmixindexedVO2withabsoluteCO;explicitlydocumentBSA,units,measured/estimatedVO2,arterialandTRUEmixedvenoussampling.
  • LowSvO2doesnotuniquelydiagnoselowCO;concomitantmetabolic/Hb/arterialsaturationchangesmatter.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Edwards Lifesciences: hemodynamic monitoring clinical reference guide

Edwards Lifesciences

Year not recorded

DOI not recorded

Open source at edwardsprodjp.blob.core.windows.net

Link check recorded

Recorded as supporting
  • Adultresistanceformulasandunits:SVR=80(MAP−RAP)/CO; PVR=80(mPAP−PAWP)/CO; indexusingCI. Sourceadultnormalrangesvarybysection/population.
  • Ficksectionpp182–183:CO=VO2/(CaO2−CvO2),CI=CO/BSA; units/conversionmustmatch; assumednormalVO2mayproduceerrors.
Limits and what this source leaves unreviewed
  • Newmanufacturerauthoritativeeducationalmanual,notrecordedoriginaloramodel-specificIFU.2014edition; notcurrentPHnormaldefinitionauthority.

Supporting literature checked separately. Not the episode’s recorded source.

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Marc Humbert, Gabor Kovacs, Marius M. Hoeper

2022

DOI 10.1093/eurheartj/ehac237

Open source at doi.org

Link check recorded

Recorded as supporting
  • Table5: PH mPAP>20mmHg; pre-capillary PAWP≤15,PVR>2WU; isolated post-capillary PAWP>15,PVR≤2; combined post-/pre-capillary PAWP>15,PVR>2, all with mPAP>20.
  • §5.1.12.2: acute positive response mPAP reduction≥10 to≤40mmHg with unchanged/increasedCO; CCB-responder testing only IPAH/HPAH/DPAH, with separate transplant/CHD purposes.
  • §3.1 upper normal PVR around2WU; §5.1.12.1 PVR=(mPAP−PAWP)/CO, directFick/thermodilution selection, indirectFick less reliable; shunts need special measurements.
Limits and what this source leaves unreviewed
  • Exact source explicitly named by PH/iNO posts. In other posts this is newly checked supporting evidence; no full PH diagnostic/therapeutic algorithm endorsement.

Supporting literature checked separately. Not the episode’s recorded source.

Regulation of Coronary Blood Flow

Adam G. Goodwill, Gregory M. Dick, Alexander M. Kiel, Johnathan D. Tune

2017

DOI 10.1002/cphy.c160016

Open source at pmc.ncbi.nlm.nih.gov

Link check recorded

Recorded as supporting
  • Mechanical determinants/extravascular compression: LV flow predominantly diastolic, subendocardial systolic flow minimal; normal RV has systolic and diastolic flow.
  • Diastolic arterial minus intraventricular pressure is a reasonable simplified estimate for innermost LV subendocardium, not an exact universal coronary gradient.
  • Metabolic control: resting LV oxygen extraction≈70–80%, greater demand met chiefly by flow. RV resting extraction≈45% with more extraction reserve.
Limits and what this source leaves unreviewed
  • New authoritative physiology review, NOT a recorded original or primary human trial. Specific experimental findings include animal studies. Do not universalise chamber-specific figures or equate a teaching CPP formula to complete autoregulation physiology.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Fick Principle: Calculating Cardiac Output

Fick cardiac output: CO = VO₂ ÷ (CaO₂ − CvO₂). A widening arterial–venous O₂ difference means falling cardiac output, a classic viva calculation.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily cardiac anaesthesia exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #FickPrinciple #CardiacOutput #Physiology #Haemodynamics #FRCA #CardiacOR #ExamPrep #MedEd #Anaesthesia #FOAMed #Reels

Sequence 74 in this tracked set.

Postiz publish time (26 October 2026, 14:42 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid

Back to grid

Correction needed

A correction is recorded. Read it before the historical caption.

Severe Chronic AR: Anaesthetic Goals and Bypass Pitfalls

PUBLICATION HOLD. Scoped source/claim review only; no whole-post clinical sign-off, continuous-video/audio review or independently verified native upload identity. Read corrections, source limitations and the per-post readiness record.

Severe Chronic AR: Anaesthetic Goals and Bypass Pitfalls: scoped rendered-panel and claim review; qualifications and unresolved groups remain. Not approved for publication.

Proposed wording

Read this before the historical caption. The caption stays as the audit record. A rejected proposal is not shown as an error.

Rejected proposal

This proposal was rejected. It is not a confirmed error.

Reviewed wording

Antegrade root cardioplegia fails: give it via the coronary ostia or retrograde

First-pass proposal

Severe AR can make aortic-root cardioplegia ineffective and distend the LV. Plan individualised myocardial protection using appropriate ostial and/or retrograde delivery, adequate venting and monitoring. Retrograde delivery alone may not protect the RV adequately.

Independent review wording

Optional: retrograde may under-protect the RV.

Evidence already listed on this post

  • 2024 EACTS/EACTAIC/EBCP Guidelines on cardiopulmonary bypass in adult cardiac surgery

Review scope

Every2-second decoded sample contact sheet examined; all distinct recovered main teaching panels also read at full image resolution and compared with recovered exact scripts/specs where available. No continuous-video/audio review.

  • Clinical evidence complete: no
  • Rendered text review complete: no
  • Native upload identity verified: no

Remaining priority: Primary IABP device IFU, fixed HR/preload exceptions and full cardioplegia/venting/RV-protection protocol; rendered moderate-to-severe scope differs from broad caption.

Still unreviewed

  • ExactIABPmanufacturerIFUandfullchronic/acuteARanaesthesia/ventingalgorithm;originalunrecorded.
  • Continuous video/audio, transient between-sample overlays and identity with the native Instagram upload remain unverified.

Claim audit

An assessment names one claim. It is not a full sign-off of the post.

qualified — SevereARVC/PHT/reversal

ConcordantsevereARmarkers,notsingleparameterdiagnosis;PHTcontext,holodiastolicflowquality/locationandquantitativeintegrationneeded.

unresolved — FullfastforwardHR80–100/preloadlowerSVR/avoidbrady

ReasonablebroadchronicARteaching,butexactfixedrate/volume/afterloadexceptionsandacuteAR/ischemia/sourceunresolved.

qualified — IABPmoderate-to-severeARinrender;neverIABPincaption

Renderalreadyappropriatelyscopedtomoderate-to-severeAR;captionbroader. PrimarydeviceIFUnotyetretrieved,sodonotmarkentireIABPclaimverifiedordilutethecontrasafeguard.

correction-needed — Rootcardioplegiafails;ostialorretrograde/earlyvent

SevereARmaydivertrootcardioplegiaanddistendLVbutabsolutealwaysfailsisunhelpful;guidelinecallsadaptedprotectionandretrogradeRVlimitations. Specificventtimingnotfullysourced.

Qualifications on the reviewed points

  • SeverechronicARcontextdoesnotautomaticallytransferallgoalstoacuteARorotherhemodynamicstates.
  • RetrogradecardioplegiaalonemayinadequatelyprotectRV;team-specificdelivery/ventingmustbeplanned.
  • CaptionmustnotextendanIABPcontraindicationbeyondvalidateddevice/diseaseseveritycontext.

References recorded with the episode

None recorded in this review.

Supporting literature checked separately

Supporting literature checked separately. Not the episode’s recorded source.

Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the ASE Developed in Collaboration with the SCMR

William A. Zoghbi, David Adams, Robert O. Bonow

2017

DOI 10.1016/j.echo.2017.01.007

Open source at asecho.org

Link check recorded

Recorded as supporting
  • SevereARmultiparametricassessment:vena-contracta>0.6cm,PHT<200ms,holodiastolicdescendingaorticflowreversalareconsistentmarkerswithsubstantialcontext/limitations. PHTaloneaffectedbyloading/relaxation.
Limits and what this source leaves unreviewed
  • New supporting source, not proven exact original from the generic ASE/EACVI series attribution. AR section Tables9/11 and relevant Doppler caveats read. Not a perioperative drug/repair-threshold guideline.

Supporting literature checked separately. Not the episode’s recorded source.

2024 EACTS/EACTAIC/EBCP Guidelines on cardiopulmonary bypass in adult cardiac surgery

Alexander Wahba, Gudrun Kunst, Filip De Somer

2025

DOI 10.1093/ejcts/ezae354

Open source at iperfusion.org

Link check recorded

Recorded as supporting
  • Myocardial protection section: severe aortic insufficiency complicates root cardioplegia; direct ostial and/or retrograde delivery may be needed; retrograde alone may inadequately protect RV and requires appropriate delivery/monitoring.
Limits and what this source leaves unreviewed
  • New supporting source, not recorded original. Relevant myocardial-protection section pp26–27 read; does not establish every proposed vent/clamp action, anaesthetic target or repair metric.

Historical caption

Audit record of the caption stored with this release. It is not a new endorsement.

Severe Chronic AR: Anaesthetic Goals and Bypass Pitfalls

Chronic AR is an exam favourite: keep the heart full, fast and forward, never give IABP, and remember that root cardioplegia will not reach the coronaries through an incompetent valve.

Save this for your exam 📌

Follow @cardiac.anaesthesia.podcast for daily exam pearls.

#CardiacAnaesthesia #CardiacAnaesthesiaPodcast #AorticRegurgitation #ValvularHeartDisease #CardiacSurgery #Cardioplegia #CardiopulmonaryBypass #TEE #Anaesthesia #DMCardiacAnaesthesia #MedEd #ExamPrep

Sequence 75 in this tracked set.

Postiz publish time (25 October 2026, 20:17 IST).

Postiz publishDate (scheduled publishing time; actual Instagram timestamp not independently fetched)

Postiz recorded publishDate descending; stable ID descending tie-break. Native Instagram feed order not independently verified.

Open the Instagram post

Last reviewed:

Back to grid